Abstract
Objective:
The emergence of resistance to colistin, the last resort for treating severe infections caused by Pseudomonas aeruginosa, poses a significant threat to public health. This meta-analysis aimed to investigate the prevalence of colistin resistance in clinical isolates of P. aeruginosa.
Method:
A comprehensive search of MEDLINE (PubMed), Web of Science, and Scopus databases was conducted to identify relevant articles published until December 2023. Subsequently, a meta-analysis was performed using Stata software to examine the pooled prevalence of colistin resistance and to conduct subgroup analyses.
Results:
A total of 619 studies were included in the meta-analysis, revealing a global prevalence of colistin resistance of 1% among all P. aeruginosa isolates. Furthermore, cystic fibrosis patients exhibited the highest resistance to colistin, with a prevalence of 7% among the examined diseases.
Conclusion:
The increase in colistin resistance in P. aeruginosa in recent years from 2% (in the period of 2006–2010) to 5% (in the period of 2020–2023) underscores the need for implementing infection prevention programs, using appropriate treatment regimens, and disseminating comprehensive information on antimicrobial resistance patterns. These measures are crucial for addressing this growing public health concern.
Introduction
Pseudomonas aeruginosa is recognized as an opportunistic pathogen and a major causative agent of hospital-acquired infections, including urinary tract infections, pneumonia, bloodstream infections, and surgical site infections (Pang et al., 2019; Sadikot et al., 2005). The development of intrinsic and acquired resistance in P. aeruginosa is attributed to the inappropriate and excessive use of antibiotics, leading to the emergence of antibiotic resistance (El-Mokhtar and Hetta, 2018).
The management of P. aeruginosa infections has always presented challenges. Carbapenems such as imipenem and meropenem were introduced as effective treatments for severe multidrug-resistant (MDR) P. aeruginosa infections. However, the overuse of antibiotics has resulted in the emergence of carbapenem-resistant isolates, posing a significant concern (Wi et al., 2017; Bonyadi et al., 2022). In 2017, the World Health Organization (WHO) identified carbapenem-resistant P. aeruginosa as a priority pathogen necessitating the development of new antibiotics for treatment (Tacconelli et al., 2018).
The increasing rate of infections caused by multidrug-resistant (MDR), extensively drug-resistant (XDR), and particularly carbapenem-resistant P. aeruginosa has led to the resurgence of colistin as a critical last-resort therapeutic option (Wi et al., 2017; Biswas et al., 2012; Al-Orphaly et al., 2021). Despite its potent antimicrobial activity against P. aeruginosa and its designation as a potentially effective drug, the increased utilization of colistin has resulted in the emergence of bacterial strains with reduced susceptibility to this antibiotic class worldwide (Pechorsky et al., 2009; Lee et al., 2012).
Colistin resistance primarily arises through various mechanisms, including enzymatic modification of lipid A, leading to a decrease in the outer membrane’s negative charge and reduced colistin affinity. Resistance to colistin may also stem from chromosomally encoded mutations or plasmid-mediated colistin resistance gene mcr, facilitating horizontal dissemination of resistance (Cannatelli et al., 2013; Paterson and Harris, 2016; Hasman et al., 2015; Arcilla et al., 2016). The prevalence of colistin resistance is typically below 10%, but this rate is steadily increasing in the Mediterranean, Southeast Asia, and certain African countries (Bialvaei and Samadi, 2015). Recent observations indicate that resistance to colistin has emerged in several Enterobacteriaceae species, including Klebsiella pneumoniae, Escherichia coli, and Enterobacter aerogenes. This resistance has been linked to the extensive use of polymyxins for infection control in veterinary medicine (Baron et al., 2016; Al-Kadmy et al., 2020). Given the potential for both horizontal transfer of resistance genes through conjugative plasmids and vertical transfer through chromosomal mutation, the emergence of colistin-resistant isolates poses a significant global health threat, especially considering the importance of colistin as a last-resort treatment option (Liu et al., 2016; Abd El-Baky et al., 2020).
The rise of MDR, XDR, and pan drug-resistant (PDR) P. aeruginosa poses a significant public health challenge, leading to delays in antimicrobial therapy, treatment failures, and increased mortality rates (Abd El-Baky et al., 2020). This situation necessitates urgent attention, as these resistant strains may exhibit resistance to all available antimicrobials or show susceptibility only to colistin or polymyxins, severely limiting treatment options for healthcare providers managing severe infections associated with MDR P. aeruginosa. The emergence of colistin-resistant strains is particularly concerning for patients with critical infections. Consequently, this systematic review and meta-analysis aims to investigate the global prevalence of colistin resistance in P. aeruginosa, thereby enhancing our understanding of antibiotic resistance in this pathogen.
Methods
Search strategy
We conducted a comprehensive search for eligible studies published from 1990 to December 2023 using MEDLINE (PubMed), Web of Science, and Scopus. The search terms included (“Pseudomonas aeruginosa” OR P. aeruginosa) AND (Colisticin OR “Polymyxin E” OR Colimycin OR colistin OR colistimethate). This review was carried out and reported in accordance with current guidelines, and the results were reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (Moher et al., 2009).
Inclusion and exclusion criteria
All original articles that provided data on the total number of clinical P. aeruginosa isolates and the number of colistin-resistant P. aeruginosa isolates were included. Studies were excluded if they met the following criteria: (Pang et al., 2019) did not present P. aeruginosa colistin resistance; (Sadikot et al., 2005) did not clearly report resistance rates (the exact number of primary isolates and the number of resistant isolates are not provided); (El-Mokhtar and Hetta, 2018) conducted antimicrobial susceptibility tests for colistin without specifying the method; (Wi et al., 2017) were written in languages other than English; and (Bonyadi et al., 2022) sourced data from conference abstracts, editorials, case reports, meta-analyses, systematic reviews, narrative reviews, experimental studies on animal models, and articles without full text after contacting the corresponding author.
Data extraction
After consolidating the articles using EndNote X20 Citation Manager Software, duplicate articles were removed before review. The citations were then imported into Rayyan, a citation classification application (Ouzzani et al., 2016). Three reviewers independently screened all titles and abstracts to exclude irrelevant topics. In the subsequent assessment stage, qualified studies were downloaded, and the full text of selected articles was retrieved based on the inclusion and exclusion criteria.
Three reviewers developed a data extraction form and collected data from all qualified studies. The extracted data included the first author’s name, year of publication, year of collection, continent and countries where the study was conducted, sample size (number of P. aeruginosa isolates and number of colistin-resistant isolates), origin of isolates, drug resistance categories, disease, guideline, and susceptibility test methodology (agar dilution, broth microdilution, disk elution, E-test, and disk diffusion).
Quality assessment
The quality of the included studies was evaluated independently by three reviewers using a modified version of the Joanna Briggs Institute (JBI) assessment tool for prevalence studies (Munn et al., 2014). The checklist includes the following questions: Was the sample frame appropriate to address the target population? Were study participants sampled appropriately? Was the sample size adequate? Were the study subjects and the setting described in detail? Was the data analysis conducted with sufficient coverage of the identified sample? Were valid methods used for the identification of the condition? Was the condition measured in a standard, reliable way for all participants? Was there an appropriate statistical analysis? Was the response rate adequate, and if not, was the low response rate managed appropriately? Each item is evaluated as “yes,” “no,” or “unclear.” A “yes” response is assigned a score of 1 point, while responses categorized as “no” or “unclear” receive 0 points. Studies that score 7 or higher are classified as high quality, those with scores between 5 and 6 are considered medium quality, and studies scoring 4 or lower are designated as low quality. In cases of disagreement, a fourth reviewer provided adjudication.
Statistical analysis
We conducted a prevalence meta-analysis using the metaprop package in Stata 17 software. We calculated the pooled prevalence of colistin-resistant P. aeruginosa, along with the associated 95% confidence intervals (CIs), utilizing the Freeman-Tukey double arcsine transformation within a random-effects model.
To identify publication bias, we employed Egger’s test, with a significance threshold set at p < 0.05, indicating the presence of statistically significant bias. Additionally, a trim-and-fill analysis was conducted to address potential bias. Funnel plots were also utilized for a visual assessment of publication bias.
Heterogeneity among studies was measured using the I2 statistic. Specifically, I2 ≤ 25% indicated low heterogeneity, 25% < I2 ≤ 75% indicated moderate heterogeneity, and I2 > 75% indicated high heterogeneity.
Subgroup analyses were conducted based on various factors, including publication year (from 2009 to 2023), collection period (five distinct periods), continent (five continents), country (thirty-two countries), guidelines followed (CLSI and EUCAST), disease type (including Urinary Tract Infections, Pneumonia, Lower Respiratory Tract Infections, Intra-abdominal Infection, COVID-19, cancer, Cystic Fibrosis, Bacteremia, and Bloodstream Infection), method of colistin resistance detection (agar dilution, E-test, disk diffusion, and broth microdilution), different resistance categories (Multidrug Resistance, Extensively Drug Resistant, and Carbapenem Resistance), and sample origin (urine, sputum, endotracheal aspirate, burn wounds, and blood).
Results
Studies selection
Our initial search yielded a total of 9,378 articles. After removing duplicates, we screened the titles and abstracts of 7,561 articles. From this screening process, 1,076 articles met the inclusion criteria and were selected for a full-text review. After the full-text review, we identified 619 articles that were suitable for analysis (Abavisani et al., 2021; Abd El-Baky et al., 2020; Abdelatti et al., 2023; Abed and Kareem, 2021; Abubakar et al., 2022; Abulzahra and Ismail, 2020; Addis et al., 2021; Agrawal et al., 2013; Aguilar-Rodea et al., 2017; Ahani Azari and Fozouni, 2020; Ahmed et al., 2022; Ahmed et al., 2019; Aiyegoro et al., 2007; Akgül et al., 2021; Akhi et al., 2015; Akram et al., 2022; Al Dawodeyah et al., 2018; Al-Agamy et al., 2012; Al-Bayssari et al., 2021; Al-Kabsi et al., 2011; Al-kaffas et al., 2022; Al-Khudhairy and Al-Shammari, 2020; Al-shimmary, 2018; Al-Zahrani and Al-Ahmadi, 2021; Alam et al., 2021; Alcántar-Curiel et al., 2023; Alexopoulou et al., 2016; Alfouzan et al., 2022; Alfouzan et al., 2018; Alhanout et al., 2009; Ali et al., 2021; Ali et al., 2015; Alkhulaifi and Mohammed, 2023; Alotaibi et al., 2023; Alruways, 2023; Amabile-Cuevas, 2017; Appalaraju et al., 2020; Aprile et al., 2019; Arab et al., 2023; Araújo Lima et al., 2020; Arca-Suárez et al., 2021; Arici et al., 2023; Arif et al., 2022; Armengol et al., 2020; Armengol et al., 2019; Aruhomukama et al., 2019; Asar et al., 2019; Aydemir et al., 2022; Aydın et al., 2018; Azimi et al., 2012; Azimi L. et al., 2016; Azimi S. et al., 2016; Babu and Menon, 2018; Badawy et al., 2023; Badierah et al., 2019; Bae and Stone, 2022; Baek et al., 2020; Bagheri-Nesami et al., 2017; Bahabri et al., 2022; Bahador et al., 2019; Bahçe et al., 2022; Baiomy et al., 2023; Bakht et al., 2022; Balkhair et al., 2023; Bandic-Pavlovic et al., 2020; Banerjee et al., 2024; Bangera et al., 2016; Basu et al., 2013; Bayram et al., 2013; Bazgir et al., 2021; Beirao et al., 2020; Ben Nejma et al., 2018; Berwal et al., 2020; Bian et al., 2022; Blondeau et al., 2023; Bogiel et al., 2022; Bono et al., 2015; Bourgi et al., 2020; Boustanshenas et al., 2023; Brauncajs et al., 2022; Brzozowski et al., 2020; Bunsow et al., 2020; Buzilă et al., 2021; Cabot et al., 2011; Camargo et al., 2023; Candel et al., 2022; Canton et al., 2022; Carvalhaes et al., 2020; Castanheira et al., 2018; Cavallo et al., 2022; Cesur et al., 2012; Çetin et al., 2022; Chang et al., 2023; Chaturvedi et al., 2021; Chaudhary et al., 2020; Chauhan et al., 2022; Chen et al., 2022; Chen et al., 2015; Chen et al., 2023; Chen Q. et al., 2020; Chen X. et al., 2020; Chen et al., 2014; Chew et al., 2019; Chittawatanarat et al., 2014; Chukamnerd et al., 2023; Cillóniz et al., 2016; Cipriano et al., 2007; Çopur Çiçek et al., 2021; Czekajło-Kołodziej et al., 2006; da Costa Júnior et al., 2020; Dadmanesh et al., 2014; Darji and Patel, 2023; Dassner et al., 2017; Datar et al., 2021; de Dios et al., 2016; De Francesco et al., 2013; de Oliveira Santos et al., 2019; De Vecchi et al., 2013; Dehbashi et al., 2018; Del Barrio-Tofino et al., 2017; Del Giacomo et al., 2022; Delgado-Valverde et al., 2020; Delroshan et al., 2023; Depka et al., 2020; Descours et al., 2018; Dharati et al., 2021; Di Carlo et al., 2021; Di Domenico et al., 2017; Dias et al., 2017; Díaz-Cañestro et al., 2018; Diekema et al., 2019; Din et al., 2023; Do Tran et al., 2022; Dogonchi et al., 2018; Dong et al., 2012; Doumith et al., 2022; Durdu et al., 2018; Ebadati et al., 2023; Ece et al., 2014; Eftekhar et al., 2009; Eid et al., 2020; Ejaz, 2022; Ekkelenkamp et al., 2020; El Mekes et al., 2020; El-Sokkary et al., 2021; Eladawy et al., 2021; Elshafie et al., 2007; Emami et al., 2017; Emami et al., 2019; Emami et al., 2020; Ergul et al., 2017a; Ergul et al., 2017b; Escolà-Vergé et al., 2018; Evans et al., 2019; Fakhkhari et al., 2022; Falagas et al., 2017; Fang et al., 2023; Farag et al., 2020; Farhan et al., 2019; Farrell et al., 2013; Farrell et al., 2014a; Farrell et al., 2014b; Fekri Kohan et al., 2020; Feretzakis et al., 2019; Ferjani et al., 2022; Fernández-Olmos et al., 2013; Flamm et al., 2014; Flores-Paredes et al., 2021; Fluge et al., 2001; Ford et al., 2022; Fournier et al., 2021; Fournier et al., 2013; Fraenkel et al., 2023; Franco et al., 2010; Franco et al., 2023; Gaber et al., 2020; Gahlot and Kasana, 2021; Gajdács et al., 2021a; Gajdács et al., 2019; Gajdács et al., 2021b; Galani et al., 2008; Galani et al., 2020; Gales et al., 2012; Gales et al., 2011; Gales et al., 2003; Galindo-Mendez et al., 2023; Gangwar et al., 2021; Gant et al., 2021; García-Castillo et al., 2011; Garcia-Fernandez et al., 2019; Garg et al., 2019; Gaudereto et al., 2020; Ghanem et al., 2023; Ghasemian et al., 2023; Ghasemshahi et al., 2022; Gherardi et al., 2019; Giani et al., 2018; Gilani et al., 2015; Goli et al., 2017; Goli et al., 2016; Golli et al., 2022; Gomez et al., 2023; Gómez-Garcés et al., 2009; Gomila et al., 2013; Gunalan et al., 2021; Guo et al., 2023; Gutierrez-Santana et al., 2022; Guzek et al., 2017; Guzek et al., 2015; Güzel and Gerçeker, 2008; Hackel et al., 2018; Hakeam et al., 2022; Hallit et al., 2020; Hansen et al., 2008; Hao et al., 2023; Hawser et al., 2021; Heidari et al., 2022; Henderson et al., 2018; Herrera-Espejo et al., 2020; Hindler and Humphries, 2013; Hishinuma et al., 2018; Hishinuma et al., 2020; Holger et al., 2023; Holger et al., 2022a; Hong et al., 2015; Hoşbul et al., 2022; Hosseininassab Nodoushan et al., 2017; Howard-Anderson et al., 2022; Hrbacek et al., 2020; Hsueh et al., 2019; Hu et al., 2022; Hu et al., 2023; Hu et al., 2021a; Hu et al., 2021b; Huang et al., 2022; Huband et al., 2016; Huband et al., 2020; Humphries et al., 2023; Ibrahim, 2018; Ioannou et al., 2023; Ismail and Mahmoud, 2018; Izadi Pour Jahromi et al., 2018; Jalali et al., 2021; Jamalifar et al., 2019; Jansen et al., 2016; Japoni et al., 2011; Jauhari et al., 2020; Jayarani et al., 2020; Jazani et al., 2012; Jean et al., 2009; Jean et al., 2016; Jean et al., 2022; Jeong et al., 2024; Jimenez-Guerra et al., 2018; Jones et al., 2013a; Jones et al., 2014; Jones et al., 2013b; Juhász et al., 2017a; Juhasz et al., 2017b; Jung et al., 2019; Kabic et al., 2023; Kakhandki et al., 2020; Kanwar et al., 2023; Karami et al., 2020; Karimzadeh et al., 2017; Karlowsky et al., 2013; Karlowsky et al., 2022; Karlowsky et al., 2019a; Karlowsky et al., 2019b; Karlowsky et al., 2023; Karlowsky et al., 2018a; Karlowsky et al., 2018b; Karlowsky et al., 2021; Karruli et al., 2022; Kashfi et al., 2017; Katchanov et al., 2018; Kaur et al., 2022; Kazmierczak et al., 2018; Kazmierczak et al., 2016; Kc et al., 2019; Keepers et al., 2014; Khajuria et al., 2013; Khan et al., 2017; Khan et al., 2023; Khater, 2022; Khater and AlFaki, 2022; Khorvash et al., 2017; Khoshnood et al., 2019; Khosravi et al., 2017; Khosravi et al., 2016; Kidd et al., 2009; Kim et al., 2022; Kim et al., 2017; Kiratisin et al., 2021; Kiratisin et al., 2023; Kırac et al., 2018; Ko and Stone, 2020; Ko and Stone, 2020; Kohira et al., 2023; Kokkayil et al., 2018; Kombade et al., 2021; Korzekwa et al., 2021; Kothari et al., 2022; Kovacevic et al., 2019; Kragh et al., 2021; Krause et al., 2019; Kresken et al., 2020a; Kresken et al., 2020b; Kristof et al., 2021; Kuo et al., 2021; Kurihara et al., 2022; Lai et al., 2019; Laurentiu et al., 2017; Lee J.-Y. et al., 2011; Lee S.-C. et al., 2011; Lee et al., 2023; Lee et al., 2019; Li et al., 2021; Li et al., 2022; Li et al., 2023; Licata et al., 2020; Lin J. et al., 2019; Lin et al., 2016; Lin Z. et al., 2019; Liu et al., 2018; Liu et al., 2020; Livermore et al., 2017; Llanes et al., 2013; Lob et al., 2023; Lockwood and Lawson, 1973; Longshaw et al., 2020; López Montesinos et al., 2022; Lopez-Causape et al., 2017; Lopez-Causape et al., 2013; Macin and Akyon, 2017; MacKenzie et al., 2004; Mahar et al., 2020; Mahdy, 2022; Mahmoud et al., 2021; Maina et al., 2023; Makharita et al., 2020; Malekzadegan et al., 2019; Mallikarjuna and Dhanashree, 2023; Manno et al., 2005; Mansour et al., 2013; Maraki et al., 2015; Maraki et al., 2012; Marteva-Proevska et al., 2021; Martínez et al., 2012; Mataraci Kara et al., 2020; Matuschek et al., 2018; McCracken et al., 2019; McCracken et al., 2019; Medell et al., 2013; Medell et al., 2012; Mellouli et al., 2021; Memar et al., 2016; Mendes et al., 2013; Meradji et al., 2016; Meradji et al., 2015; Meschiari et al., 2021; Mickymaray, 2019; Mikucionyte et al., 2016; Milczewska et al., 2020; Milojković et al., 2020; Mirbagheri et al., 2015; Mishra et al., 2020; Mobaraki et al., 2018; Mohamed et al., 2021; Mohamed et al., 2022; Mohamed and Youssef, 2011; Mohammadi Barzelighi et al., 2020; Mohammadzadeh et al., 2017; Mohammadzamani et al., 2020; Mohanty et al., 2013; Momenah et al., 2023; Monogue and Nicolau, 2018; Montero M. et al., 2020; Montero et al., 2019; Montero M. M. et al., 2020; Moradi et al., 2021; Morata et al., 2012; Mordi and Erah, 2006; MaI et al., 2005; Morrow et al., 2013; Morteza et al., 2019; Mostafa et al., 2022; Moubareck et al., 2019; Mulet et al., 2021; Mustafa et al., 2016; Naas et al., 2021; Nair et al., 2020; Najafi et al., 2015; Nedeljković et al., 2015; Negm et al., 2023; Negm et al., 2021; Nelson and Rosowsky, 2002; Nguyen et al., 2021; Nichols et al., 2016; Nitescu et al., 2023; Nitz et al., 2021; Nojookambari et al., 2019; Nolan et al., 2021; Nwabuisi and Ologe, 2002; O'Carroll et al., 2004; Odumosu et al., 2012; Olowo-okere et al., 2020; Öncül et al., 2014; Ozumba, 2005; Pani et al., 2022; Papagiannitsis et al., 2017; Paprocka et al., 2021; Park et al., 2017; Parsa et al., 2020; Pasca et al., 2012; Peña et al., 2012; Pérez et al., 2019; Perez et al., 2014; Pérez-Vázquez et al., 2020; Perovic et al., 2023; Petca, 2021; Petca, 2021; Petrova et al., 2016; Peymani et al., 2015; Pfaller et al., 2022; Pfaller et al., 2017; Pfaller et al., 2018; Picão Renata et al., 2009; Pierard and Stone, 2021; Pitt et al., 2003; Pourakbari et al., 2016; Pragsam et al., 2018; Prasanth Manohar et al., 2017; Kokkayil et al., 2018; Priyadarshi et al., 2023; Pujji et al., 2019; Qadeer et al., 2016; Radan et al., 2016; Rafalskiy et al., 2020; Rahimi et al., 2021; Rajenderan et al., 2014; Ramadan et al., 2018; Ramanathan et al., 2017; Rashid et al., 2014; Rattanaumpawan et al., 2013; Raza et al., 2019; Reddy et al., 2014; Rizek et al., 2014; Rodulfo et al., 2019; Rolston et al., 2020; Rosales-Reyes et al., 2020; Rossolini et al., 2008; Rout et al., 2023; Roy Chowdhury et al., 2016; Ruekit et al., 2022; Ruh et al., 2016; Ruiz-Roldan et al., 2018; Sacha et al., 2015; Sader et al., 2020a; Sader et al., 2020b; Sader et al., 2019; Sader et al., 2018a; Sader et al., 2015a; Sader et al., 2017a; Sader et al., 2016; Sader et al., 2017b; Sader et al., 2017c; Sader et al., 2018b; Sader et al., 2017d; Sader et al., 2021a; Sader et al., 2014a; Sader et al., 2014b; Sader et al., 2014c; Sader et al., 2018c; Sader et al., 2018d; Sader et al., 2018e; Sader et al., 2017e; Sader et al., 2015b; Sader et al., 2021b; Saderi et al., 2015; Saffari et al., 2017; Saleem M. et al., 2023; Saleem et al., 2022; Saleem and Bokhari, 2020; Saleem Z. et al., 2023; Salimizand et al., 2023; Samonis et al., 2012; Samonis et al., 2010; Samonis et al., 2012; Sanchez-Lopez et al., 2021; Santella et al., 2021; Santimaleeworagun et al., 2020; Sarwat et al., 2021; Schaumburg et al., 2022; Schechner et al., 2011; Schülin, 2002; Seale et al., 1979; Sefraoui et al., 2014; Seifert et al., 2018; Şen et al., 2016; Sendra et al., 2022; Shahri et al., 2022; Sharan et al., 2016; Shariati et al., 2018; Sharifi et al., 2019; Sharma et al., 2023; Sherchan et al., 2022; Sherchan and Humagain, 2020; Sheth et al., 2012a; Sheth et al., 2012b; Shiralizadeh et al., 2023; Shivshetty et al., 2020; Shortridge et al., 2021a; Shortridge et al., 2021b; Shortridge et al., 2017; Shortridge et al., 2019a; Shortridge et al., 2019b; Shortridge et al., 2019c; Shortridge et al., 2018; Shortridge et al., 2020; Shortridge et al., 2022; Shravani et al., 2023; Sid Ahmed et al., 2020; Sid Ahmed et al., 2019; Sid Ahmed et al., 2021; Sid Ahmed et al., 2021; Sid Ahmed et al., 2023; Simar et al., 2017; Singh-Moodley et al., 2018; Singhal et al., 2019; Sleiman et al., 2023; Soliman et al., 2020; Soni et al., 2023; Stone and Ponce-de-Leon, 2020; Stone et al., 2020; Stracquadanio et al., 2021; Tada et al., 2019; Tada et al., 2013; Tahmasebi et al., 2020a; Tahmasebi et al., 2020b; Tahmasebi et al., 2020c; Takahashi et al., 2021; Taleb et al., 2023; Talebi and Hakemi-Vala, 2019; Tan and Ng, 2006; Tantisiriwat et al., 2022; Tarashi et al., 2016; Taylor et al., 2021; Tchakal-Mesbahi et al., 2021; Tekin et al., 2013; Tenover et al., 2022; Thabet et al., 2022; Thapa et al., 2023; Thelen et al., 2022; Tiengrim et al., 2017; Tohamy et al., 2018; Tsitsopoulos et al., 2016; Tumbarello et al., 2013; Tumbarello et al., 2011; Tuon et al., 2020; Khudair and Mahmood, 2021; Ullah et al., 2019; Ullah et al., 2023; Uskudar Guclu et al., 2021; Uzun et al., 2014; Valenza et al., 2010; Valenza et al., 2008; Valenza et al., 2015; Vamsi et al., 2023; Van An et al., 2023; Van An et al., 2023; van Burgh et al., 2019; van der Heijden et al., 2007; Vasudeva et al., 2016; Vata et al., 2018; Vata et al., 2018; Veeraraghavan et al., 2018; Viasus et al., 2020; Viedma et al., 2012; Vosahlikova et al., 2007; Wadhwa et al., 2016; Walkty et al., 2012; Walkty et al., 2011; Walkty et al., 2009; Walkty et al., 2013; Walkty et al., 2022; Walkty et al., 2017; Walters et al., 2019; Wang et al., 2020; Wang and Wang, 2020; Wattal et al., 2019; Wattal et al., 2014; Wemambu and Joshi, 1983; Wendel et al., 2022; Wi et al., 2017; Wi et al., 2018; Willmann et al., 2013; Wise et al., 2023a; Wise et al., 2023b; Wu et al., 2022; Xi et al., 2022; Yadav et al., 2020; Yayan et al., 2015; Yilmaz et al., 2023; Yilmaz et al., 2017; Yousefi et al., 2013; Zerouali et al., 2016; Zhanel et al., 2019; Zhanel et al., 2013; Zhanel et al., 2011; Zhanel et al., 2010; Zhang et al., 2021; Zhao et al., 2023; Zhu et al., 2021; Zhu et al., 2023; Zorgani et al., 2015; Zubair and Iregbu, 2018; Farzana et al., 2013).
A total of 262 articles investigated colistin resistance in P. aeruginosa using the microbroth dilution method, while 242 articles employed methods other than microbroth dilution. Additionally, 115 articles examined colistin resistance in multidrug-resistant (MDR), extensively drug-resistant (XDR), and carbapenem-resistant (CR) bacteria.
We followed the PRISMA guidelines and presented the article selection process in a flow diagram (Figure 1). Supplementary Table S1 provides a summary of the characteristics and quality assessment of all included studies. Additionally, references to the included studies can be found in Supplementary File 2.
Figure 1
Meta-analysis results
For our meta-analysis, we focused on studies that utilized standard methods such as the broth microdilution and disk elution, which is recommended by the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines for evaluating resistance rates. Out of the total articles reviewed, 262 articles investigated colistin resistance in P. aeruginosa isolates using the microbroth dilution method. The pooled prevalence of colistin resistance among clinical P. aeruginosa isolates was estimated to be 1% (95% CI: 1–2%; I2 = 97.47%; p < 0.001).
To assess publication bias, we examined a funnel plot (Figure 2) and conducted Egger’s tests, which yielded a p-value of 0.053, indicating no evidence of publication bias. Additionally, the results following the Trim-and-Fill adjustment indicated that the prevalence of colistin resistance remained unchanged.
Figure 2
Subgroup meta-analysis
Subgroup meta-analyses were conducted based on various factors, including the year of publication, period of sample collection, continent, country, guideline used, disease assessed, origin of samples, different resistance categories, and methods.
Subgroup meta-analyses based on continents indicated that Africa exhibited the highest resistance rate at 4% (95% CI: 0–13%) (p < 0.001) (Figure 3). The studies encompassed 32 countries, with Egypt 15% (95% CI: 5–29%), and Pakistan 13% (95% CI: 9–17%) had the highest resistance (p < 0.001) (Figure 4).
Figure 3
Figure 4
Regarding the subgroup meta-analyses based on the year of article publication, the rate of P. aeruginosa resistance to colistin has increased from 2% (95% CI: 0–11%) in 2009 to 3% (95% CI: 2–5%) in 2023, representing a 1% increase (p < 0.001) (Figure 5).
Figure 5
When the sample collection time was divided into five periods, the subgroup meta-analyses revealed an increase in resistance over time from 2% (95% CI: 0–5%) to 5% (95% CI: 0–10%), from 2010–2006 to 2020–2023 (p = 0.005) (Figure 6).
Figure 6
Subgroup analysis based on guidelines demonstrated that the CLSI group had a higher resistance level at 2% (95% CI: 1–2%) compared to 1% (95% CI: 1–2%) in the EUCAST group (p = 0.280) (Figure 7).
Figure 7
Regarding the origin of samples, sputum samples exhibited the highest resistance at 4% (95% CI: 0–15%), whereas burn wound samples showed the lowest at 0% (95% CI: 0–1%) (p = 0.036) (Figure 8).
Figure 8
Subgroup analysis based on disease type showed that patients with cystic fibrosis and lower respiratory infection had the highest resistance with rates of 7% (95% CI: 13–3%) and 5% (95% CI: 1–12%) respectively (p < 0.001) (Figure 9).
Figure 9
Among the methodologies used, 22 articles employed the agar dilution method, 28 used the E-test method, 192 utilized the disk diffusion method, and 262 opted for the broth microdilution method. The analysis indicated the highest resistance level with the agar dilution method at 6% (95% CI: 2–12%), while the broth microdilution method showed the lowest at 1% (95% CI: 1–2%) (p < 0.001) (Figure 10).
Figure 10
When exploring colistin resistance in isolates with different resistance categories, findings based on the broth microdilution and disk elution method revealed that Extensively Drug-Resistant (XDR) isolates displayed a resistance rate of 11% (95% CI: 0–35%), Multidrug-resistant (MDR) isolates displayed a resistance rate of 8% (95% CI: 3–5%), and Carbapenem-Resistant (CR) isolates displayed a resistance rate of 4% (95% CI: 2–6%) (p = 0.068) (Figure 11).
Figure 11
Discussion
Antimicrobial resistance poses a significant threat to public health, leading to increased treatment expenses, prolonged hospital stays, and higher mortality rates. Currently, the rise in antibiotic resistance is particularly concerning in Enterobacteriaceae family members and the hospital bacterium P. aeruginosa (Talebi Bezmin Abadi et al., 2019). Additionally, the inappropriate and excessive use of antibiotics in medical and veterinary settings has contributed to the emergence of resistant strains.
P. aeruginosa exhibits various intrinsic and acquired antimicrobial resistance mechanisms, including AmpC cephalosporinases, diverse carbapenemases, and multidrug efflux pumps, resulting in resistance to a wide range of antimicrobial agents (Pang et al., 2019). The emergence and dissemination of MDR and XDR strains of P. aeruginosa, coupled with the limited availability of effective antimicrobial agents against these bacteria, have severely restricted treatment options (del Barrio-Tofiño et al., 2020; Willmann et al., 2015). Numerous studies have indicated that P. aeruginosa is resistant to most beta-lactam antibiotics, quinolones, and aminoglycosides (Pachori et al., 2019). Although carbapenems have been considered one of the primary treatment choices for P. aeruginosa infections, increasing resistance to this antibiotic has imposed limitations on its use (Pang et al., 2019; Balkhair et al., 2019). Despite colistin and tigecycline being commonly viewed as the only available antimicrobial agents for treating XDR P. aeruginosa infections, some strains have developed resistance to these last-line treatment options (Pang et al., 2019; Ibrahim et al., 2021; Cai et al., 2012). The widespread use of colistin has created conditions conducive to the emergence of resistant strains (Bialvaei and Samadi, 2015). The objective of this meta-analysis was to investigate the global prevalence of colistin resistance in P. aeruginosa isolates.
Our findings revealed that the estimated overall prevalence of colistin resistance in clinical isolates of P. aeruginosa was 1%. Several other meta-analyses have examined colistin resistance in different Gram-negative bacteria, finding rates of 6.9% in Iran for Klebsiella pneumoniae (Narimisa et al., 2022) and 4% in Acinetobacter baumannii (Bostanghadiri et al., 2024). While the level of colistin resistance in P. aeruginosa has been lower than in other Gram-negative bacteria, our analysis indicates that this resistance has been increasing in recent years. The recent rise in colistin resistance among P. aeruginosa can be attributed to multiple factors, particularly the overuse and misuse of antibiotics in both clinical and agricultural contexts, which have intensified selective pressure on bacterial populations (Hassen et al., 2022). Colistin, recognized as a last-resort antibiotic for multidrug-resistant infections, has seen increased utilization due to the emergence of resistant pathogens (Sharma et al., 2022), especially during the COVID-19 pandemic. As healthcare systems faced a surge in respiratory infections, colistin was often employed as a last-resort treatment, further heightening selective pressure on bacteria (de Blasio, 2021). This surge in usage, frequently driven by empirical treatment strategies amid uncertainty, has facilitated the emergence and spread of resistant strains (Ghosh et al., 2021). Additionally, the pandemic disrupted routine healthcare practices and antibiotic stewardship programs, creating an environment conducive to the development of resistance (Campbell et al., 2023). The implications of this growing resistance are significant, complicating treatment options for infections caused by multidrug-resistant organisms and presenting considerable challenges for public health.
Our analysis revealed that the highest rates of colistin resistance were observed in Egypt (15%) and Pakistan (13%). The implementation of effective management strategies is essential for the appropriate use of this antibiotic in these regions. This issue may be attributed to the lack of adequate diagnostic tools, as patient management often relies heavily on drug prescriptions, particularly antibiotics, in developing countries. Additionally, the availability of substandard antibiotics sold over the counter further exacerbates the problem, contributing to the rising rates of antimicrobial resistance in these areas (Dadgostar, 2019; Chaw et al., 2018; Chokshi et al., 2019).
Having a comprehensive standard protocol for determining antibiotic sensitivity is critical for several antibiotics. The CLSI recommends utilizing broth microdilution, colistin broth disc elution (CBDE), and the colistin agar test (CAT) for antimicrobial susceptibility testing against colistin. Additionally, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) also advocates for broth microdilution as the preferred method for evaluating susceptibility to colistin (Pancholi et al., 2018; Özhak et al., 2019). The disk diffusion method, a widely employed and cost-effective approach in clinical microbiology laboratories, particularly in developing countries, lacks a standardized protocol for colistin sensitivity testing (Waites et al., 2011). In a study by Irene Galani and colleagues in Greece, two phenotypic methods, E-test and disk diffusion, were compared for measuring colistin resistance in Gram-negative bacilli. The researchers concluded that the disk diffusion method is not suitable or reliable for assessing antimicrobial sensitivity to colistin (Galani et al., 2008). Despite this, numerous articles have utilized non-endorsed methods, such as disk diffusion, to assess resistance. A subgroup meta-analysis focusing on measurement methods consistently found higher resistance rates when alternative methods were used, compared to the standard method. This discrepancy may be attributed to the lack of sensitivity in other methods for detecting and distinguishing resistant strains. Therefore, adherence to established standard guidelines for measurement methods is imperative.
The findings of our study revealed that P. aeruginosa isolated from respiratory samples, particularly in patients with respiratory infections such as cystic fibrosis, exhibited the highest level of resistance to colistin. In a meta-analysis conducted by Bonyadi et al. (2022), the resistance rate of P. aeruginosa isolates from cystic fibrosis patients to colistin was reported as 5%. However, our study demonstrated a resistance rate of 7%, suggesting a potential increase in resistance over the past two years. Notably, our subgroup meta-analysis focused solely on studies where resistance rates were confirmed by established guidelines, which may account for the variance in resistance percentages among cystic fibrosis patients.
Given the challenges in discovering new antibiotics, optimizing the use of existing treatments is crucial. Colistin is considered the last resort for treating extensively drug-resistant (XDR) Gram-negative bacteria (Ozsurekci et al., 2016). To address the increasing rates of antibiotic resistance, it is vital to implement innovative strategies. For instance, the combination of colistin and other antibiotics has demonstrated a synergistic effect against antibiotic-resistant Gram-negative pathogens, potentially curtailing the development of resistance (Ly et al., 2015). Other approaches may include combination therapies utilizing nanoparticles, natural components, and phage-based strategies (Holger et al., 2022b; Yassin et al., 2022; Wang et al., 2022). Additionally, promoting antibiotic stewardship and preventing the misuse and overprescription of colistin, particularly among physicians in developing countries, is essential for maintaining its effectiveness.
The considerable heterogeneity among the studies represents a primary limitation of this research. Nonetheless, through the use of subgroup analysis, we were able to identify sources of heterogeneity and mitigate its impact on the outcomes. Another limitation of this article is the exclusion of non-English studies, which may contain valuable data. The decision to focus solely on English-language research aimed to ensure accurate comprehension of the studies and maintain consistency in data quality and reporting. However, we recognize that this exclusion may compromise the comprehensiveness of our analysis. We encourage future research to incorporate studies in other languages to provide a more comprehensive view of the topic.
Conclusion
Our study indicates that while the overall rate of resistance to colistin in P. aeruginosa is relatively low, there has been a recent upward trend in resistance levels. This underscores the importance of accurate surveillance of resistance rates, particularly in regions with higher prevalence, and the judicious prescription of antibiotics for patients with P. aeruginosa infection. Promoting antibiotic stewardship and preventing the misuse and overprescription of colistin, especially among healthcare professionals in developing countries, is crucial for preserving its efficacy.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.
Author contributions
NN: Data curation, Formal analysis, Software, Writing – original draft, Writing – review & editing. AK: Software, Validation, Writing – review & editing. LD-Z: Data curation, Methodology, Writing – review & editing. NB: Data curation, Methodology, Writing – original draft, Writing – review & editing. YF: Data curation, Methodology, Writing – review & editing. SS: Data curation, Methodology, Writing – review & editing. AZ: Supervision, Validation, Writing – review & editing. SR: Conceptualization, Supervision, Validation, Writing – review & editing.
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This study was funded by Microbial Biotechnology Research Center (Iran University of Medical Sciences) by a research grant (No. 18205).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2024.1477836/full#supplementary-material
Abbreviations
P. aeruginosa, Pseudomonas aeruginosa; PRISMA, Preferred reporting items for systematic reviews and meta-analyses guidelines; CI, Confidence interval; CLSI, The Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing.
References
1
AbavisaniM.GoudarziM.GhalavandZ.HajikhaniB.RadZ. R.RadZ. R.et al. (2021). Evaluation of efflux pumps overexpression and β-lactamase genes among colistin resistant Pseudomonas aeruginosa. Gene Rep.24:101301. doi: 10.1016/j.genrep.2021.101301
2
Abd El-BakyR. M.MasoudS. M.MohamedD. S.WalyN. G.ShafikE. A.MoharebD. A.et al. (2020). Prevalence and some possible mechanisms of colistin resistance among multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa. Infect. Drug Resist.13, 323–332. doi: 10.2147/IDR.S238811
3
AbdelattiM. A.Abd El-AzizN. K.El-NaenaeeyE.-s. Y.AmmarA. M.AlharbiN. K.AlharthiA.et al. (2023). Antibacterial and anti-efflux activities of cinnamon essential oil against pan and extensive drug-resistant Pseudomonas aeruginosa isolated from human and animal sources. Antibiotics12:514. doi: 10.3390/antibiotics12101514
4
AbedW. H.KareemS. M. (2021). Molecular detection of gyrA and mexA genes in Pseudomonas aeruginosa. Mol. Biol. Rep.48, 7907–7912. doi: 10.1007/s11033-021-06820-0
5
AbubakarU.ZulkarnainA. I.Rodríguez-BañoJ.KamarudinN.ElrggalM. E.ElnaemM. H.et al. (2022). Treatments and predictors of mortality for carbapenem-resistant gram-negative bacilli infections in Malaysia: a retrospective cohort study. Trop. Med. Infect. Dis.7:415. doi: 10.3390/tropicalmed7120415
6
AbulzahraA. N.IsmailM. I. (2020). Antimicrobial resistance patterns and phenotypic-βlactamases detection of MDR Pseudomonas aeruginosa isolates from wounds and burns of Iraqi patients. Biochem. Cell. Arch.20.
7
AddisT.ArayaS.DestaK. (2021). Occurrence of multiple, extensive and Pan drug-resistant Pseudomonas aeruginosa and Carbapenemase production from presumptive isolates stored in a biobank at Ethiopian Public Health Institute. Infect. Drug Resist.14, 3609–3618. doi: 10.2147/IDR.S327652
8
AgrawalA.KumarD.GoyalA.GoyalS.SinghN.KhandelwalG. (2013). Microbiological profile and their antimicrobial sensitivity pattern in patients of otitis media with ear discharge. Indian J. Otol.19, 5–8. doi: 10.4103/0971-7749.108149
9
Aguilar-RodeaP.ZunigaG.Rodríguez-EspinoB. A.Olivares CervantesA. L.Gamiño ArroyoA. E.Moreno-EspinosaS.et al. (2017). Identification of extensive drug resistant Pseudomonas aeruginosa strains: new clone ST1725 and high-risk clone ST233. PLoS One12:e0172882. doi: 10.1371/journal.pone.0172882
10
Ahani AzariA.FozouniL. (2020). Incidence of multidrug-resistant, extensively drug-resistant, and Pandrug-resistant Pseudomonas aeruginosa strains isolated from clinical specimens. Infect. Epidemiol. Microbiol.6, 211–217. doi: 10.29252/iem.6.3.211
11
AhmedM. A. S.HadiH. A.JarirS. A.KhanF. A.ArbabM. A.HamidJ. M.et al. (2022). Prevalence and microbiological and genetic characteristics of multidrug-resistant Pseudomonas aeruginosa over three years in Qatar. Antimicrobial Stewardship Healthcare Epidemiol.2:e96. doi: 10.1017/ash.2022.226
12
AhmedM. S.HassanA.JarirS. A.HadiH. A.BansalD.WahabA. A.et al. (2019). Emergence of multidrug-and pandrug-resistant Pseudomonas aeruginosa from five hospitals in Qatar. Infect. Prevent. Pract.1:100027. doi: 10.1016/j.infpip.2019.100027
13
AiyegoroO.IgbinosaO.OgunmwonyiI.OdjadjareE.IgbinosaO.OkohA. (2007). Incidence of urinary tract infections (UTI) among children and adolescents in Ile-Ife, Nigeria. Afr. J. Microbiol. Res.1, 13–19.
14
AkgülÖ.ArvasG.KuŞTanA. (2021). Phenotypic and genotypic analysis of the antibiotic resistance profiles of gram negative Bacteria isolated from the blood culture samples. Eastern J. Med.26, 299–307. doi: 10.5505/ejm.2021.03880
15
AkhiM. T.GhotaslouR.BeheshtirouyS.AsgharzadehM.PirzadehT.AsghariB.et al. (2015). Antibiotic susceptibility pattern of aerobic and anaerobic Bacteria isolated from surgical site infection of hospitalized patients. Jundishapur J. Microbiol.8:e20309. doi: 10.5812/jjm.20309v2
16
AkramW.RazaA.MunirS.WaqasK.MuddassirM.IslamM.et al. (2022). Incidence, characterization and anti-microbial susceptibility pattern of Pseudomonas aeruginosa isolated from clinical subjects. Bacteriology13, 962–965.
17
Al DawodeyahH. Y.ObeidatN.Abu-QatousehL. F.ShehabiA. A. (2018). Antimicrobial resistance and putative virulence genes of Pseudomonas aeruginosa isolates from patients with respiratory tract infection. Germs8, 31–40. doi: 10.18683/germs.2018.1130
18
Al-AgamyM. H.ShiblA. M.TawfikA. F.ElkhizziN. A.LivermoreD. M. (2012). Extended-spectrum and metallo-beta-lactamases among ceftazidime-resistant Pseudomonas aeruginosa in Riyadh, Saudi Arabia. J. Chemother.24, 97–100. doi: 10.1179/1120009X12Z.00000000015
19
AlamM. M.IslamM. N.Hossain HawladerM. D.AhmedS.WahabA.IslamM.et al. (2021). Prevalence of multidrug resistance bacterial isolates from infected wound patients in Dhaka, Bangladesh: a cross-sectional study. Int. J. Surg. Open28, 56–62. doi: 10.1016/j.ijso.2020.12.010
20
Al-BayssariC.DagherT. N.El HamouiS.FenianosF.MakdissyN.RolainJ.-M.et al. (2021). Carbapenem and colistin-resistant bacteria in North Lebanon: coexistence of mcr-1 and NDM-4 genes in Escherichia coli. J. Infect. Dev. Countries15, 934–342. doi: 10.3855/jidc.14176
21
Alcántar-CurielM. D.Huerta-CedeñoM.Jarillo-QuijadaM. D.Gayosso-VázquezC.Fernández-VázquezJ. L.Hernández-MedelM. L.et al. (2023). Gram-negative ESKAPE bacteria bloodstream infections in patients during the COVID-19 pandemic. PeerJ11:e15007. doi: 10.7717/peerj.15007
22
AlexopoulouA.VasilievaL.AgiasotelliD.SiranidiK.PourikiS.TsirigaA.et al. (2016). Extensively drug-resistant bacteria are an independent predictive factor of mortality in 130 patients with spontaneous bacterial peritonitis or spontaneous bacteremia. World J. Gastroenterol.22, 4049–4056. doi: 10.3748/wjg.v22.i15.4049
23
AlfouzanW.DharR.MohsinJ.KhamisF.MokaddasE.AbdullahA.et al. (2022). Evaluation of in vitro activity of ceftolozane/tazobactam and comparators against recent clinical bacterial isolates, and genomics of Pseudomonas aeruginosa, Klebsiella pneumoniae and Escherichia coli isolates that demonstrated resistance to ceftolozane/tazobactam: data from Kuwait and Oman. JAC-Antimicrob. Resist.4:35. doi: 10.1093/jacamr/dlac035
24
AlfouzanW.DharR.NicolauD. P. (2018). In vitro activity of newer and conventional antimicrobial agents, including Fosfomycin and Colistin, against selected gram-negative Bacilli in Kuwait. Pathogens7:75. doi: 10.3390/pathogens7030075
25
AlhanoutK.BrunelJ.-M.RaoultD.RolainJ.-M. (2009). In vitro antibacterial activity of aminosterols against multidrug-resistant bacteria from patients with cystic fibrosis. J. Antimicrob. Chemother.64, 810–814. doi: 10.1093/jac/dkp281
26
AliA.AhmadK.RahatS. (2021). Diversity of extended Spectrum β-lactamases among multi drug resistant clinical isolates of Pseudomonas aeruginosa collected fromTertiary care hospitals of Peshawar, Pakistan. Pakistan J. Zool.53:705. doi: 10.17582/journal.pjz/20190712160705
27
AliZ.MumtazN.NazS. A.JabeenN.ShafiqueM. (2015). Multi-drug resistant pseudomonas aeruginosa: a threat of nosocomial infections in tertiary care hospitals. J. Pak. Med. Assoc.65, 12–16
28
Al-KabsiA. M.YusofM.SekaranS. D. (2011). Antimicrobial resistance pattern of clinical isolates of Pseudomonas aeruginosa in the University of Malaya Medical Center, Malaysia. Afr. J. Microbiol. Res.5, 5266–5272. doi: 10.5897/AJMR11.284
29
Al-KadmyI. M.IbrahimS. A.Al-SaryiN.AzizS. N.BesinisA.HettaH. F. (2020). Prevalence of genes involved in colistin resistance in Acinetobacter baumannii: first report from Iraq. Microb. Drug Resist.26, 616–622. doi: 10.1089/mdr.2019.0243
30
Al-kaffasM.HaggagM. G.SolimanS. M.GhalwashA. A.AlkaffasM. (2022). Genetic identification of Pseudomonas aeruginosa virulence genes associated with keratitis in Egyptian population. J. Pure Appl. Microbiol.16, 1714–1721. doi: 10.22207/JPAM.16.3.12
31
Al-KhudhairyM. K.Al-ShammariM. M. M. (2020). Prevalence of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolated from diabetic foot infections in Iraq. New Microbes New Infect.35:100661. doi: 10.1016/j.nmni.2020.100661
32
AlkhulaifiZ. M.MohammedK. A. (2023). Prevalence and molecular analysis of antibiotic resistance of Pseudomonas aeruginosa isolated from clinical and environmental specimens in Basra, Iraq. Iranian J. Microbiol.15, 45–54. doi: 10.18502/ijm.v15i1.11917
33
Al-OrphalyM.HadiH. A.EltayebF. K.Al-HailH.SamuelB. G.SultanA. A.et al. (2021). Epidemiology of multidrug-resistant Pseudomonas aeruginosa in the Middle East and North Africa region. Msphere6, e00202–e00221. doi: 10.1128/mSphere.00202-21
34
AlotaibiB. S.TantryB. A.FarhanaA.AlammarM. A.ShahN. N.MohammedA. H.et al. (2023). Resistance pattern in mostly gram-negative Bacteria causing urinary tract infections. Infect. Disord. Drug Targets23:e280922209238. doi: 10.2174/1871526522666220928115043
35
AlruwaysM. W. (2023). Phenotypic and molecular characterization of Carbapenemase-producing gram-negative isolates detected from wound infections. Medical Forum Monthly.
36
Al-shimmaryS. (2018). Improvement rapid molecular detection of Pseudomonas aeruginosa infected some Iraqi patients and It's antimicrobial susceptibility. Res. J. Pharm., Biol. Chem. Sci.7, 1256–1264.
37
Al-ZahraniI. A.Al-AhmadiB. M. (2021). Dissemination of VIM-producing Pseudomonas aeruginosa associated with high-risk clone ST654 in a tertiary and quaternary hospital in Makkah, Saudi Arabia. J. Chemother.33, 12–20. doi: 10.1080/1120009X.2020.1785741
38
Amabile-CuevasC. F. (2017). Selection of amikacin hyper-resistant Pseudomonas aeruginosa after stepwise exposure to high amikacin concentrations. Microb. Drug Resist.23, 32–36. doi: 10.1089/mdr.2015.0218
39
AppalarajuB.BavejaS.BaligaS.ShenoyS.BhardwajR.KongreV.et al. (2020). In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016-18. J. Antimicrob. Chemother.75, 600–608. doi: 10.1093/jac/dkz493
40
AprileA.CaioC.GonaF.StefaniS.MezzatestaM. L. (2019). In vitro evidence of the synergistic interaction of ceftopibrole and other antibiotics against multidrug-resistant gram-negative isolates. Diagn. Microbiol. Infect. Dis.95:114884. doi: 10.1016/j.diagmicrobio.2019.114884
41
ArabO.Al-KayaliR.KhouriA.HajK. S. (2023). Resistance patterns of bacterial pathogens causing lower respiratory tract infections: Aleppo-Syria. Ann. Med. Surg.85, 2655–2661. doi: 10.1097/MS9.0000000000000778
42
Araújo LimaA. V.da SilvaS. M.do Nascimento JúniorJ. A. A.CorreiaM. T. S.LuzA. C.Leal-BalbinoT. C.et al. (2020). Occurrence and diversity of intra-and Interhospital drug-resistant and biofilm-forming Acinetobacter baumannii and Pseudomonas aeruginosa. Microb. Drug Resist.26, 802–814. doi: 10.1089/mdr.2019.0214
43
Arca-SuárezJ.Lasarte-MonterrubioC.Rodiño-JaneiroB.-K.CabotG.Vázquez-UchaJ. C.Rodríguez-IglesiasM.et al. (2021). Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections. J. Antimicrob. Chemother.76, 91–100. doi: 10.1093/jac/dkaa396
44
ArcillaM. S.van HattemJ. M.MatamorosS.MellesD. C.PendersJ.de JongM. D.et al. (2016). Dissemination of the mcr-1 colistin resistance gene. Lancet Infect. Dis.16, 147–149. doi: 10.1016/S1473-3099(15)00541-1
45
AriciN.KansakN.AdaletiR.AksarayS. (2023). Comparison of broth microdilution and Colistin disk elution methods for the determination of Colistin susceptibility in multidrug resistant Pseudomonas aeruginosa isolates. Mediterr J Infect Microb Antimicrob:2023. doi: 10.4274/mjima.galenos.2023.2023.14
46
ArifA.UllahI.UllahO.ZamanR. (2022). Identification of colistin resistance and its bactericidal activity against uropathogenic gram negative bacteria from Hayatabad medical complex Peshawar. Pakistan J. Med. Sci.38:5221. doi: 10.12669/pjms.38.4.5221
47
ArmengolE.AsuncionT.VinasM.SierraJ. M. (2020). When combined with Colistin, an otherwise ineffective rifampicin-linezolid combination becomes Active in Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii. Microorganisms8:86. doi: 10.3390/microorganisms8010086
48
ArmengolE.DomenechO.FusteE.Perez-GuillenI.BorrellJ. H.SierraJ. M.et al. (2019). Efficacy of combinations of colistin with other antimicrobials involves membrane fluidity and efflux machinery. Infect Drug Resist.12, 2031–2038. doi: 10.2147/IDR.S207844
49
AruhomukamaD.NajjukaC. F.KajumbulaH.OkeeM.MboowaG.SserwaddaI.et al. (2019). Bla VIM-and Bla OXA-mediated carbapenem resistance among Acinetobacter baumannii and Pseudomonas aeruginosa isolates from the Mulago hospital intensive care unit in Kampala, Uganda. BMC Infect. Dis.19, 1–8. doi: 10.1186/s12879-019-4510-5
50
AsarL.PfefferleS.LutgehetmannM.HoffmannA.KatchanovJ.AepfelbacherM.et al. (2019). Influence of local epidemiology on the performance of common colistin drug susceptibility testing methods. PLoS One14:e0217468. doi: 10.1371/journal.pone.0217468
51
AydemirO.AydemirY.ŞahinE. Ö.ŞahinF.KorogluM.ErdemA. F. (2022). Secondary bacterial infections in patients with coronavirus disease 2019-associated pneumonia. Rev. Assoc. Med. Bras.68, 142–146. doi: 10.1590/1806-9282.20210745
52
AydınM.ErgönülÖ.AzapA.BilginH.AydınG.ÇavuşS.et al. (2018). Rapid emergence of colistin resistance and its impact on fatality among healthcare-associated infections. J. Hosp. Infect.98, 260–263. doi: 10.1016/j.jhin.2017.11.014
53
AzimiS.KafilH. S.BaghiH. B.ShokrianS.NajafK.AsgharzadehM.et al. (2016). Presence of exoY, exoS, exoU and exoT genes, antibiotic resistance and biofilm production among Pseudomonas aeruginosa isolates in Northwest Iran. GMS Hyg Infect. Control.11:Doc04. doi: 10.3205/dgkh000264
54
AzimiL.LariA. R.AlaghehbandanR.AlinejadF.MohammadpoorM.RahbarM. (2012). KPC-producer gram negative bacteria among burned infants in Motahari hospital, Tehran: first report from Iran. Ann. Burns Fire Disasters25, 74–77
55
AzimiL.NamvarA. E.LariA. R.JamaliS.LariA. R. (2016). Comparison of efflux pump involvement in antibiotic resistance among Pseudomonas aeruginosa isolates of burn and non-burn patients. Arch. Pediatric Infect. Dis.4:e36160. doi: 10.5812/pedinfect.36160
56
BabuM.MenonV. P. (2018). Prevalence of antimicrobial resistant pathogens in severe sepsis and septic shock patients. J. Young Pharm.10, 358–361. doi: 10.5530/jyp.2018.10.79
57
BadawyM. S. E.ElkhatibW. F.SheblR. I. (2023). Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm. Ann. Clin. Microbiol. Antimicrob.22:53. doi: 10.1186/s12941-023-00597-9
58
BadierahR. A.NattoZ. S.NassarM. S.Al-GhamdiA. A.Jiman-FataniA. A.BakhrebahM. A. (2019). The prevalence of antibiotic-resistant bacterial nasal carriage at a Saudi university hospital. Acta Microbiologica Hellenica.
59
BaeI. G.StoneG. G. (2022). In vitro activity of ceftazidime-avibactam and comparators against bacterial isolates collected in South Korea as part of the ATLAS global surveillance program (2016-2018). Diagn. Microbiol. Infect. Dis.102:115553. doi: 10.1016/j.diagmicrobio.2021.115553
60
BaekM. S.ChungE. S.JungD. S.KoK. S. (2020). Effect of colistin-based antibiotic combinations on the eradication of persister cells in Pseudomonas aeruginosa. J. Antimicrob. Chemother.75, 917–924. doi: 10.1093/jac/dkz552
61
Bagheri-NesamiM.RezaiM. S.AhangarkaniF.RafieiA.NikkhahA.EslamiG.et al. (2017). Multidrug and co-resistance patterns of non-fermenting gram-negative bacilli involved in ventilator-associated pneumonia carrying class 1 integron in the north of Iran. Germs7, 123–131. doi: 10.18683/germs.2017.1117
62
BahabriN. M.Al-AlawiM. M.QutubM. O.TashkandiW. A.AlTurkiR.JanahS. S.et al. (2022). In-vitro activity of ceftolozane/tazobactam against recent clinical bacterial isolates from two Saudi Arabian hospitals. J. Infect. Public Health15, 486–490. doi: 10.1016/j.jiph.2022.02.009
63
BahadorN.ShojaS.FaridiF.Dozandeh-MobarrezB.QeshmiF. I.JavadpourS.et al. (2019). Molecular detection of virulence factors and biofilm formation in Pseudomonas aeruginosa obtained from different clinical specimens in Bandar Abbas. Iranian J. Microbiol.11, 25–30. doi: 10.18502/ijm.v11i1.701
64
BahçeY. G.AcerÖ.ÖzüdoğruO. (2022). Evaluation of bacterial agents isolated from endotracheal aspirate cultures of Covid-19 general intensive care patients and their antibiotic resistance profiles compared to pre-pandemic conditions. Microb. Pathog.164:105409. doi: 10.1016/j.micpath.2022.105409
65
BaiomyA. A.SerryF. E.KadryA. A.YahyaG.DoijadS.MostafaA.et al. (2023). Genome analysis of Pseudomonas aeruginosa strains from chronically infected patients with high levels of persister formation. Pathogens12:426. doi: 10.3390/pathogens12030426
66
BakhtM.AlizadehS. A.RahimiS.Kazemzadeh AnariR.RostamaniM.JavadiA.et al. (2022). Phenotype and genetic determination of resistance to common disinfectants among biofilm-producing and non-producing Pseudomonas aeruginosa strains from clinical specimens in Iran. BMC Microbiol.22:124. doi: 10.1186/s12866-022-02524-y
67
BalkhairA.Al SaadiK.AlA. B. (2023). Epidemiology and mortality outcome of carbapenem-and colistin-resistant Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa bloodstream infections. IJID Regions7, 1–5. doi: 10.1016/j.ijregi.2023.01.002
68
BalkhairA.Al-MuharrmiZ.Al’adawiB.Al BusaidiI.TaherH.Al-SiyabiT.et al. (2019). Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: description of a decade-long trend. Int. J. Infect. Dis.85, 10–15. doi: 10.1016/j.ijid.2019.05.004
69
Bandic-PavlovicD.Zah-BogovicT.ZizekM.BielenL.BraticV.HrabacP.et al. (2020). Gram-negative bacteria as causative agents of ventilator-associated pneumonia and their respective resistance mechanisms. J. Chemother.32, 344–358. doi: 10.1080/1120009X.2020.1793594
70
BanerjeeT.AdwityamaA.SharmaS.MishraK.PrustiP.MaitraU. (2024). Comparative evaluation of colistin broth disc elution (CBDE) and broth microdilution (BMD) in clinical isolates of Pseudomonas aeruginosa with special reference to heteroresistance. Indian J. Med. Microbiol.47:100494. doi: 10.1016/j.ijmmb.2023.100494
71
BangeraD.ShenoyS. M.SaldanhaD. R. (2016). Clinico-microbiological study of Pseudomonas aeruginosa in wound infections and the detection of metallo-beta-lactamase production. Int. Wound J.13, 1299–1302. doi: 10.1111/iwj.12519
72
BaronS.HadjadjL.RolainJ.-M.OlaitanA. O. (2016). Molecular mechanisms of polymyxin resistance: knowns and unknowns. Int. J. Antimicrob. Agents48, 583–591. doi: 10.1016/j.ijantimicag.2016.06.023
73
BasuS.MukherjeeS.SamantaA. (2013). Epidemiological study of bacterial microbiology in AECOPD patients of Kolkata, India. Asian J. Pharm. Clin. Res.6, 112–116.
74
BayramY.ParlakM.AypakC.Bayramİ. (2013). Three-year review of bacteriological profile and antibiogram of burn wound isolates in Van, Turkey. Int. J. Med. Sci.10, 19–23. doi: 10.7150/ijms.4723
75
BazgirZ. N.AhanjanM.GoliH. R.GholamiM.GhasemianR.Hashemi-SotehM. B. (2021). Frequency of blaIMP and blaSPM metallo-β-lactamase genes among carbapenem-resistant pseudomonas aeruginosa clinical isolates in Sari, North of Iran. Recent Advances in Anti-Infective Drug Discovery Formerly Recent Patents on Anti-Infective Drug Discovery16, 148–156.
76
BeiraoE. M.RodriguesS. D. S.AndradeT. K.SerraF. B.PaulaM. D. N.PolisT. J. B.et al. (2020). Activity of ceftolozane-tazobactam and comparators against gram-negative bacilli: results from the study for monitoring antimicrobial resistance trends (SMART – Brazil; 2016-2017). Braz. J. Infect. Dis.24, 310–321. doi: 10.1016/j.bjid.2020.05.010
77
Ben NejmaM.SioudO.MastouriM. (2018). Quinolone-resistant clinical strains of Pseudomonas aeruginosa isolated from University Hospital in Tunisia. 3 Biotech8:1019. doi: 10.1007/s13205-017-1019-8
78
BerwalA.ShobhaK. L.GuptaR.GuptaK.AshrafA. A. (2020). Non-fermenting gram negative Bacteria as Uropathogens in causing urinary tract infection and its antimicrobial susceptibility pattern at a tertiary Care Centre of South India. J. Pure Appl. Microbiol.14, 2033–2038. doi: 10.22207/JPAM.14.3.43
79
BialvaeiA. Z.SamadiK. H. (2015). Colistin, mechanisms and prevalence of resistance. Curr. Med. Res. Opin.31, 707–721. doi: 10.1185/03007995.2015.1018989
80
BianX.LiuX.HuF.FengM.ChenY.BergenP. J.et al. (2022). Pharmacokinetic/pharmacodynamic based breakpoints of polymyxin B for bloodstream infections caused by multidrug-resistant gram-negative pathogens. Front. Pharmacol.12:785893. doi: 10.3389/fphar.2021.785893
81
BiswasS.BrunelJ.-M.DubusJ.-C.Reynaud-GaubertM.RolainJ.-M. (2012). Colistin: an update on the antibiotic of the 21st century. Expert Rev. Anti-Infect. Ther.10, 917–934. doi: 10.1586/eri.12.78
82
BlondeauJ.CharlesM. K.LooV.AdamH.Gonzalez Del VecchioM.GhakisC.et al. (2023). A nested cohort 5-year Canadian surveillance of gram-negative antimicrobial resistance for optimized antimicrobial therapy. Sci. Rep.13:14142. doi: 10.1038/s41598-023-40012-z
83
BogielT.DepkaD.RzepkaM.MikuckaA. (2022). Decoding genetic features and antimicrobial susceptibility of Pseudomonas aeruginosa strains isolated from bloodstream infections. Int. J. Mol. Sci.23:9208. doi: 10.3390/ijms23169208
84
BonoL.CavoliG. L.VerdeM. S.SodanoC.TortoriciC.FerrantelliA.et al. (2015). Prevalence of bacterial pathogens and their emerging resistance patterns in patients with renal diseases. Diálisis y Trasplante.36, 78–82. doi: 10.1016/j.dialis.2015.02.006
85
BonyadiP.SalehN. T.YaminiM.DehghaniM.AminiK. (2022). Prevalence of antibiotic resistance of Pseudomonas aeruginosa in cystic fibrosis infection: a systematic review and meta-analysis. Microb. Pathog.165:105461. doi: 10.1016/j.micpath.2022.105461
86
BostanghadiriN.NarimisaN.MirshekarM.Dadgar-ZankbarL.TakiE.NavidifarT.et al. (2024). Prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis. Antimicrob. Resist. Infect. Control13:24. doi: 10.1186/s13756-024-01376-7
87
BourgiJ.SaidJ. M.YaakoubC.AtallahB.Al AkkaryN.SleimanZ.et al. (2020). Bacterial infection profile and predictors among patients admitted to a burn care center: a retrospective study. Burns46, 1968–1976. doi: 10.1016/j.burns.2020.05.004
88
BoustanshenasM.BakhshiB.MobasseriP.KianiP.AbadiF. H. H.SeyfiE.et al. (2023). Genetically diverse, extremely resistant, and Pan-drug resistant Pseudomonas aeruginosa as the Main cause of nosocomial infection among hospitalized patients. Arch. Clin. Infect. Dis.18:136338. doi: 10.5812/archcid-136338
89
BrauncajsM.BielecF.MaciejaA.Pastuszak-LewandoskaD. (2022). Carbapenem-resistant gram-negative fermenting and non-fermenting rods isolated from hospital patients in Poland—what are they susceptible to?Biomedicines10:3049. doi: 10.3390/biomedicines10123049
90
BrzozowskiM.KrukowskaŻ.GalantK.Jursa-KuleszaJ.Kosik-BogackaD. (2020). Genotypic characterisation and antimicrobial resistance of Pseudomonas aeruginosa strains isolated from patients of different hospitals and medical centres in Poland. BMC Infect. Dis.20:693. doi: 10.1186/s12879-020-05404-w
91
BunsowE.Los-ArcosI.Martin-GómezM. T.BelloI.PontT.BerasteguiC.et al. (2020). Donor-derived bacterial infections in lung transplant recipients in the era of multidrug resistance. J. Infect.80, 190–196. doi: 10.1016/j.jinf.2019.12.006
92
BuzilăE. R.NăstaseE. V.LuncăC.BădescuA.MiftodeE.IancuL. S. (2021). Antibiotic resistance of non-fermenting gram-negative bacilli isolated at a large infectious diseases Hospital in North-Eastern Romania, during an 11-year period. Germs11, 354–362. doi: 10.18683/germs.2021.1272
93
CabotG.Ocampo-SosaA. A.TubauF.MaciaM. D.RodríguezC.MoyaB.et al. (2011). Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob. Agents Chemother.55, 1906–1911. doi: 10.1128/AAC.01645-10
94
CaiY.ChaiD.WangR.LiangB.BaiN. (2012). Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J. Antimicrob. Chemother.67, 1607–1615. doi: 10.1093/jac/dks084
95
CamargoC. H.YamadaA. Y.SouzaA. R.LimaM. J. C.CunhaM. P. V.FerraroP. S. P.et al. (2023). Genomics and antimicrobial susceptibility of clinical Pseudomonas aeruginosa isolates from hospitals in Brazil. Pathogens12:918. doi: 10.3390/pathogens12070918
96
CampbellA.BorekA. J.McLeodM.Tonkin-CrineS.PouwelsK. B.RoopeL. S.et al. (2023). Impact of the COVID-19 pandemic on antimicrobial stewardship support for general practices in England: a qualitative interview study. BJGP Open7:193. doi: 10.3399/BJGPO.2022.0193
97
CandelF. J.HenriksenA. S.LongshawC.YamanoY.OliverA. (2022). In vitro activity of the novel siderophore cephalosporin, cefiderocol, in gram-negative pathogens in Europe by site of infection. Clin. Microbiol. Infect.28, 447.e1. e6–447.e6. doi: 10.1016/j.cmi.2021.07.018
98
CannatelliA.D'AndreaM. M.GianiT.Di PilatoV.ArenaF.AmbrettiS.et al. (2013). In vivo emergence of colistin resistance in Klebsiella pneumoniae producing KPC-type carbapenemases mediated by insertional inactivation of the PhoQ/PhoP mgrB regulator. Antimicrob. Agents Chemother.57, 5521–5526. doi: 10.1128/AAC.01480-13
99
CantonR.HamedK.WiktorowiczT.RedderN.JemmelyN.QuevedoJ.et al. (2022). In vitro activity of ceftobiprole and comparator antibiotics against contemporary European isolates (2016–19). JAC-Antimicrobial Resistance4:dlac030. doi: 10.1093/jacamr/dlac030
100
CarvalhaesC. G.ShortridgeD.SaderH. S.CastanheiraM. (2020). Activity of Meropenem-Vaborbactam against bacterial isolates causing pneumonia in patients in U.S. hospitals during 2014 to 2018. ASM J CD64:e02177. doi: 10.1128/AAC.02177-19
101
CastanheiraM.DavisA. P.MendesR. E.SerioA. W.KrauseK. M.FlammR. K. (2018). In vitro activity of plazomicin against gram-negative and gram-positive isolates collected from US hospitals and comparative activities of aminoglycosides against carbapenem-resistant Enterobacteriaceae and isolates carrying carbapenemase genes. Antimicrob. Agents Chemother.62, 313–318. doi: 10.1128/AAC.00313-18
102
CavalloI.Lesnoni La ParolaI.SivoriF.TomaL.KoudriavtsevaT.SperdutiI.et al. (2022). Homocysteine and inflammatory cytokines in the clinical assessment of infection in venous leg ulcers. Antibiotics.11:1268. doi: 10.3390/antibiotics11091268
103
CesurS.YıldızE.IrmakH.GülayZ.ArslanU.ÖzenS.et al. (2012). Metallobeta-lactamase enzymes and antibiotic susceptibilities in strains of Pseudomonas Aeruginosa isolated from intensive care units in Turkey. Turkiye Klinikleri J Med Sci32, 687–693. doi: 10.5336/medsci.2011-24972
104
ÇetinY. S.MollamehmetoğluS. O.DüzenliU.TuranM.BozanN. (2022). Treatment of multi-drug resistant microorganisms in chronic suppurative otitis media. B-ENT18, 44–51. doi: 10.5152/B-ENT.2022.21425
105
ChangF.WangX.HuangX.LiuX.HuangL. (2023). Analysis on bacterial distribution and change of drug resistance rate in ICUs across Southwest China from 2018 to 2022. Infect. Drug Resist., 5685–5696.
106
ChaturvediP.LambaM.SharmaD.MamoriaV. P. (2021). Bloodstream infections and antibiotic sensitivity pattern in intensive care unit. Trop. Dr.51, 44–48. doi: 10.1177/0049475520977043
107
ChaudharyB. R.MallaK. K.PoudelS.JhaB. K. (2020). Study of antibiotic susceptibility among bacterial isolates in neonatal intensive care unit of a tertiary care hospital: a descriptive cross-sectional study. JNMA J. Nepal Med. Assoc.58, 893–899. doi: 10.31729/jnma.5216
108
ChauhanS.KaurN.SainiA. K.AmanS.ChauhanJ.KumarH. (2022). Colistin resistant gram-negative Bacteria isolated from various clinical samples in north Indian tertiary care center.
109
ChawP.HöpnerJ.MikolajczykR. (2018). The knowledge, attitude and practice of health practitioners towards antibiotic prescribing and resistance in developing countries—a systematic review. J. Clin. Pharm. Ther.43, 606–613. doi: 10.1111/jcpt.12730
110
ChenJ.LiangQ.DingS.XuY.HuY.ChenJ.et al. (2023). Ceftazidime/avibactam for the treatment of carbapenem-resistant Pseudomonas aeruginosa infection in lung transplant recipients. Infect. Drug Resist.16, 2237–2246. doi: 10.2147/IDR.S407515
111
ChenQ.LuW.ZhouD.ZhengG.LiuH.QianC.et al. (2020). Characterization of two macrolide resistance-related genes in multidrug-resistant Pseudomonas aeruginosa isolates. Pol. J. Microbiol.69, 349–356. doi: 10.33073/pjm-2020-038
112
ChenH.MaiH.LopesB.WenF.PatilS. (2022). Novel Pseudomonas aeruginosa strains co-Harbouring Bla (NDM-1) Metallo beta-lactamase and mcr-1 isolated from immunocompromised Paediatric patients. Infect Drug Resist.15, 2929–2936. doi: 10.2147/IDR.S368566
113
ChenY.SunM.WangM.LuY.YanZ. (2014). Dissemination of IMP-6-producing Pseudomonas aeruginosa ST244 in multiple cities in China. Eur. J. Clin. Microbiol. Infect. Dis.33, 1181–1187. doi: 10.1007/s10096-014-2063-5
114
ChenH.WangZ.LiH.WangQ.ZhaoC.HeW.et al. (2015). In vitro analysis of activities of 16 antimicrobial agents against gram-negative bacteria from six teaching hospitals in China. Jpn. J. Infect. Dis.68, 263–267. doi: 10.7883/yoken.JJID.2014.202
115
ChenX.XuJ.ZhuQ.RenY.ZhaoL. (2020). Polymyxin B resistance rates in carbapenem-resistant Pseudomonas aeruginosa isolates and a comparison between Etest® and broth microdilution methods of antimicrobial susceptibility testing. Exp. Ther. Med.20, 762–769. doi: 10.3892/etm.2020.8777
116
ChewK. L.OctaviaS.NgO. T.MarimuthuK.VenkatachalamI.ChengB.et al. (2019). Challenge of drug resistance in Pseudomonas aeruginosa: clonal spread of NDM-1-positive ST-308 within a tertiary hospital. J. Antimicrob. Chemother.74, 2220–2224. doi: 10.1093/jac/dkz169
117
ChittawatanaratK.JaipakdeeW.ChotirosniramitN.ChandachamK.JirapongcharoenlapT. (2014). Microbiology, resistance patterns, and risk factors of mortality in ventilator-associated bacterial pneumonia in a northern Thai tertiary-care university based general surgical intensive care unit. Infect. Drug Resist.7, 203–210. doi: 10.2147/IDR.S67267
118
ChokshiA.SifriZ.CennimoD.HorngH. (2019). Global contributors to antibiotic resistance. J. Global Infect. Dis.11, 36–42. doi: 10.4103/jgid.jgid_110_18
119
ChukamnerdA.PomwisedR.ChusriS.SingkhamananK.ChumtongS.JeenkeawpiamK.et al. (2023). Antimicrobial susceptibility and molecular features of colonizing isolates of Pseudomonas aeruginosa and the report of a novel sequence type (ST) 3910 from Thailand. Antibiotics12:165. doi: 10.3390/antibiotics12010165
120
CillónizC.GabarrúsA.FerrerM.de la BellacasaJ. P.RinaudoM.MensaJ.et al. (2016). Community-acquired pneumonia due to multidrug-and non–multidrug-resistant Pseudomonas aeruginosa. Chest150, 415–425. doi: 10.1016/j.chest.2016.03.042
121
CiprianoR.VieiraV. V.FonsecaE. L.RangelK.FreitasF. S.VicenteA. C. P. (2007). Coexistence of epidemic colistin-only-sensitive clones of Pseudomonas aeruginosa, including the Bla SPM clone, spread in hospitals in a Brazilian Amazon city. Microb. Drug Resist.13, 142–146. doi: 10.1089/mdr.2007.708
122
Çopur ÇiçekA.ErtürkA.EjderN.RakiciE.KostakoğluU.Esen Yıldızİ.et al. (2021). Screening of antimicrobial resistance genes and epidemiological features in hospital and community-associated carbapenem-resistant pseudomonas aeruginosa infections. Infect. Drug Resist.14, 1517–1526. doi: 10.2147/IDR.S299742
123
Czekajło-KołodziejU.Giedrys-KalembaS.MedralaD. (2006). Phenotypic and genotypic characteristics of Pseudomonas aeruginosa strains isolated from hospitals in the north-west region of Poland. Pol. J. Microbiol.55, 103–112
124
da Costa JúniorS. D.da SilvaW. R. C.da SilvaA. M. C. M.MacielM. A. V.CavalcantiI. M. F. (2020). Synergistic effect between usnic acid and polymyxin B against resistant clinical isolates of Pseudomonas aeruginosa. Evid. Based Complement. Alternat. Med.2020:9852145. doi: 10.1155/2020/9852145
125
DadgostarP. (2019). Antimicrobial resistance: implications and costs. Infect. Drug Resist.12, 3903–3910. doi: 10.2147/IDR.S234610
126
DadmaneshM.PilehvarzadehM.EramabadiM.EramabadiP.MoghadamM. B.MashayekhiF. (2014). Community acquired Pseudomonas aeroginosa urinary tract infections in children hospitalized in a Baqiatallah hospital, Tehran, Iran: virulence profile and antibiotic resistance properties. Biosci. Biotechnol. Res. Asia11, 417–426. doi: 10.13005/bbra/1290
127
DarjiS. M.PatelN. (2023). Central line associated blood stream infection: microbiological profile and its antimicrobial susceptibility pattern at tertiary care Centre. J. Pure Appl. Microbiol.17, 911–918. doi: 10.22207/JPAM.17.2.18
128
DassnerA. M.SutherlandC.GirottoJ.NicolauD. P. (2017). In vitro activity of ceftolozane/tazobactam alone or with an aminoglycoside against multi-drug-resistant Pseudomonas aeruginosa from pediatric cystic fibrosis patients. Infect. Dis. Ther.6, 129–136. doi: 10.1007/s40121-016-0141-y
129
DatarR.Coello PelegrinA.OrengaS.ChalansonnetV.MirandeC.DombrechtJ.et al. (2021). Phenotypic and genomic variability of serial Peri-Lung transplantation Pseudomonas aeruginosa isolates from cystic fibrosis patients. Front. Microbiol.12:604555. doi: 10.3389/fmicb.2021.604555
130
de BlasioB. F. (2021). Infectious disease threats: Antibiotic resistance, COVID-19, and future pandemics. Meeting the challenges of existential threats through educational innovation. London: Routledge.
131
de DiosC. J.Del CampoR.RoyuelaA.SoléA.MáizL.OlveiraC.et al. (2016). Bronchopulmonary infection-colonization patterns in Spanish cystic fibrosis patients: results from a national multicenter study. J. Cyst. Fibros.15, 357–365. doi: 10.1016/j.jcf.2015.09.004
132
De FrancescoM. A.RavizzolaG.PeroniL.BonfantiC.MancaN. (2013). Prevalence of multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa in an Italian hospital. J. Infect. Public Health6, 179–185. doi: 10.1016/j.jiph.2012.11.006
133
de Oliveira SantosI. C.de AndradeN. F. P.da Conceição NetoO. C.da CostaB. S.de AndradeM. E.Rocha-de-SouzaC. M.et al. (2019). Epidemiology and antibiotic resistance trends in clinical isolates of Pseudomonas aeruginosa from Rio de janeiro-Brazil: importance of mutational mechanisms over the years (1995–2015). Infect. Genet. Evol.73, 411–415. doi: 10.1016/j.meegid.2019.05.015
134
De VecchiE.SitiaS.RomanoC. L.RicciC.MattinaR.DragoL. (2013). Aetiology and antibiotic resistance patterns of urinary tract infections in the elderly: a 6-month study. J. Med. Microbiol.62, 859–863. doi: 10.1099/jmm.0.056945-0
135
DehbashiS.TahmasebiH.ArabestaniM. R. (2018). Association between Beta-lactam antibiotic resistance and virulence factors in AmpC producing clinical strains of P. aeruginosa. Osong. Public Health Res. Perspect.9, 325–333. doi: 10.24171/j.phrp.2018.9.6.06
136
Del Barrio-TofinoE.Lopez-CausapeC.CabotG.RiveraA.BenitoN.SeguraC.et al. (2017). Genomics and susceptibility profiles of extensively drug-resistant Pseudomonas aeruginosa isolates from Spain. Antimicrob. Agents Chemother.61:1589. doi: 10.1128/AAC.01589-17
137
del Barrio-TofiñoE.López-CausapéC.OliverA. (2020). Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update. Int. J. Antimicrob. Agents56:106196. doi: 10.1016/j.ijantimicag.2020.106196
138
Del GiacomoP.RaffaelliF.LositoA. R.FioriB.TumbarelloM. (2022). XDR-Pseudomonas aeruginosa outside the ICU: is there still place for colistin?Antibiotics.11:193. doi: 10.3390/antibiotics11020193
139
Delgado-ValverdeM.ConejoM. D. C.SerranoL.Fernandez-CuencaF.PascualA. (2020). Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia. J. Antimicrob. Chemother.75, 1840–1849. doi: 10.1093/jac/dkaa117
140
DelroshanN.GhandehariF.MirzaeiR.HoveidaL. (2023). Molecular typing of multidrug-resistant Pseudomonas aeruginosa isolates obtained from hospitalized burn patients by rep-PCR. Infect. Epidemiol. Microbiol.9, 99–106. doi: 10.61186/iem.9.2.99
141
DepkaD.MikuckaA.BogielT.Gospodarek-KomkowskaE. (2020). Comparison of the recommended colistin susceptibility testing methods with colistin gradient strips and semi-automated method for antimicrobial-resistant non-fermenting rods. J. Microbiol. Methods172:105905. doi: 10.1016/j.mimet.2020.105905
142
DescoursG.DesmursL.HoangT. L. T.IbranosyanM.BaumeM.RancA.-G.et al. (2018). Evaluation of the accelerate Pheno™ system for rapid identification and antimicrobial susceptibility testing of gram-negative bacteria in bloodstream infections. Eur. J. Clin. Microbiol. Infect. Dis.37, 1573–1583. doi: 10.1007/s10096-018-3287-6
143
DharatiS.AtitS.LataP.JayshriP.UrvashiL.HiralS. (2021). Microbiological profile and Antibiogram of Uropathogens isolated at a tertiary care hospital. J. Krishna Inst. Med. Sci.10.
144
Di CarloP.SerraN.Lo SauroS.CarelliV. M.GiarratanaM.SignorelloJ. C.et al. (2021). Epidemiology and pattern of resistance of gram-negative bacteria isolated from blood samples in hospitalized patients: a single center retrospective analysis from southern Italy. Antibiotics10:1402. doi: 10.3390/antibiotics10111402
145
Di DomenicoE. G.FarullaI.PrignanoG.GalloM. T.VespazianiM.CavalloI.et al. (2017). Biofilm is a major virulence determinant in bacterial colonization of chronic skin ulcers independently from the multidrug resistant phenotype. Int. J. Mol. Sci.18:1077. doi: 10.3390/ijms18051077
146
DiasV. C.ResendeJ. A.BastosA. N.De Andrade BastosL. Q.De Andrade BastosV. Q.BastosR. V.et al. (2017). Epidemiological, physiological, and molecular characteristics of a Brazilian collection of Carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Microb. Drug Resist.23, 852–863. doi: 10.1089/mdr.2016.0219
147
Díaz-CañestroM.PeriañezL.MuletX.Martin-PenaM. L.Fraile-RibotP. A.AyestaránI.et al. (2018). Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands. Eur. J. Clin. Microbiol. Infect. Dis.37, 2191–2200. doi: 10.1007/s10096-018-3361-0
148
DiekemaD. J.HsuehP.-R.MendesR. E.PfallerM. A.RolstonK. V.SaderH. S.et al. (2019). The microbiology of bloodstream infection: 20-year trends from the SENTRY antimicrobial surveillance program. Antimicrob. Agents Chemother.63, 00355–00319. doi: 10.1128/AAC.00355-19
149
DinM.AwanM. A.Ur RahmanS.AliM.AslamM. (2023). Co-existence of blaIMP, blaNDM-1, and blaSHV, genes of Pseudomonas aeruginosa isolated from Quetta: antimicrobial resistance and clinical significance. Pakistan J. Med. Sci.39:1507. doi: 10.12669/pjms.39.5.7188
150
Do TranH.NguyenY. T. B.TranT. T.LeT. T. T.NguyenH. T. T.NguyenC. M.et al. (2022). Community-acquired pneumonia-causing bacteria and antibiotic resistance rate among Vietnamese patients: a cross-sectional study. Medicine101:e30458. doi: 10.1097/MD.0000000000030458
151
DogonchiA. A.GhaemiE. A.ArdebiliA.YazdansetadS.PournajafA. (2018). Metallo-beta-lactamase-mediated resistance among clinical carbapenem-resistant Pseudomonas aeruginosa isolates in northern Iran: a potential threat to clinical therapeutics. Ci Ji Yi Xue Za Zhi.30, 90–96. doi: 10.4103/tcmj.tcmj_101_17
152
DongS.-X.WangJ.-T.ChangS.-C. (2012). Activities of doripenem against nosocomial bacteremic drug-resistant gram-negative bacteria in a medical center in Taiwan. J. Microbiol. Immunol. Infect.45, 459–464. doi: 10.1016/j.jmii.2012.08.022
153
DoumithM.AlhassinahS.AlswajiA.AlzayerM.AlrashidiE.OkdahL.et al. (2022). Genomic characterization of carbapenem-non-susceptible Pseudomonas aeruginosa clinical isolates from Saudi Arabia revealed a global dissemination of GES-5-producing ST235 and VIM-2-producing ST233 sub-lineages. Front. Microbiol.12:765113. doi: 10.3389/fmicb.2021.765113
154
DurduB.KritsotakisE. I.LeeA. C.TorunP.HakyemezI. N.GultepeB.et al. (2018). Temporal trends and patterns in antimicrobial-resistant gram-negative bacteria implicated in intensive care unit-acquired infections: a cohort-based surveillance study in Istanbul, Turkey. J. Global Antimicrob. Resist.14, 190–196. doi: 10.1016/j.jgar.2018.04.015
155
EbadatiA.OshaghiM.SaeediS.ParsaP.MahabadiV. P.KarimiM.et al. (2023). Mechanism and antibacterial synergies of poly(Dabco-BBAC) nanoparticles against multi-drug resistant Pseudomonas aeruginosa isolates from human burns. Bioorg. Chem.140:106718. doi: 10.1016/j.bioorg.2023.106718
156
EceG.SamliogluP.AtalayS.KoseS. (2014). Evaluation of the in vitro colistin susceptibility of Pseudomonas aeruginosa and Acinetobacter baumannii strains at a tertiary care Centre in Western Turkey. Infez. Med.22, 36–40
157
EftekharF.HosseinkhanN.AsgharzadehA.TabatabaeiA. (2009) Genetic profiling of Pseudomonas aeruginosa isolates from Iranian patients with cystic fibrosis using RAPD-PCR and PFGE. Iranian Journal of Basic Medical Sciences.
158
EidD.SayedO. M.HozayenW. G.AzmyA. F. (2020). Battling biofilm forming nosocomial pathogens using chitosan and Pluronic F127. J. Pure Appl. Microbiol.14, 1893–1903. doi: 10.22207/JPAM.14.3.28
159
EjazH. (2022). Molecular characterization and antibiogram of the carbapenemase gene variants in clinical strains of Pseudomonas aeruginosa. Mol. Biol. Rep.49, 10531–10539. doi: 10.1007/s11033-022-07930-z
160
EkkelenkampM. B.CantónR.Díez-AguilarM.TunneyM. M.GilpinD. F.BernardiniF.et al. (2020). Susceptibility of Pseudomonas aeruginosa recovered from cystic fibrosis patients to murepavadin and 13 comparator antibiotics. Antimicrob. Agents Chemother.64, 01541–01519. doi: 10.1128/AAC.01541-19
161
El MekesA.ZahlaneK.Ait SaidL.Tadlaoui OuafiA.BarakateM. (2020). The clinical and epidemiological risk factors of infections due to multi-drug resistant bacteria in an adult intensive care unit of University Hospital Center in Marrakesh-Morocco. J. Infect. Public Health13, 637–643. doi: 10.1016/j.jiph.2019.08.012
162
EladawyM.El-MowafyM.El-SokkaryM. M.BarwaR. (2021). Antimicrobial resistance and virulence characteristics in ERIC-PCR typed biofilm forming isolates of P. aeruginosa. Microb. Pathog.158:105042. doi: 10.1016/j.micpath.2021.105042
163
El-MokhtarM. A.HettaH. F. (2018). Ambulance vehicles as a source of multidrug-resistant infections: a multicenter study in Assiut City, Egypt. Infect. Drug Resist.11, 587–594. doi: 10.2147/IDR.S151783
164
ElshafieS. S.WahabA. A.AlJ. I. (2007). Antimicrobial resistance of bacterial strains isolated from respiratory tract of cystic fibrosis patients with CFTR I1234V mutation. J. Pediatr. Infect. Dis.2, 039–043. doi: 10.1055/s-0035-1557010
165
El-SokkaryR.UysalS.ErdemH.KullarR.PekokA. U.AmerF.et al. (2021). Profiles of multidrug-resistant organisms among patients with bacteremia in intensive care units: An international ID-IRI survey. Eur. J. Clin. Microbiol. Infect. Dis.40, 2323–2334. doi: 10.1007/s10096-021-04288-1
166
EmamiA.KazempourA.PirbonyehN.KeshavarziA.ZardoshtM. (2017). Hospitalization length survey and relation with distribution of LasA protease and type III secretion system encoding-genes in multi-drug resistant Pseudomonas aeruginosa isolates from burn wounds in southwest of Iran. Gene Rep.9, 81–85. doi: 10.1016/j.genrep.2017.09.006
167
EmamiA.KeshavarziA.PirbonyehN.BehbahaniM. R. (2019). Identification of different faces of Pseudomonas aeruginosa isolates in burn patients by genetic fingerprinting. Gene Rep.15:100377. doi: 10.1016/j.genrep.2019.100377
168
EmamiA.PirbonyehN.KeshavarziA.BazarganiA.HassanpourS.JavanmardiF. (2020). Evaluating the saliva of burn ICU patients for resistant Infections Harbor Metallo-beta-lactamase genes. J. Burn Care Res.41, 647–651. doi: 10.1093/jbcr/iraa007
169
ErgulA. B.CetinS.AltintopY. A.BozdemirS. E.OzcanA.AltugU.et al. (2017a). Evaluation of microorganisms causing ventilator-associated pneumonia in a pediatric intensive care unit. Eurasian J. Med.49, 87–91. doi: 10.5152/eurasianjmed.2017.16262
170
ErgulA. B.IsikH.AltintopY. A.TorunY. A. (2017b). A retrospective evaluation of blood cultures in a pediatric intensive care unit: a three year evaluation. Turk Pediatri Ars.52, 154–161. doi: 10.5152/TurkPediatriArs.2017.5451
171
Escolà-VergéL.PigrauC.Los-ArcosI.ArévaloÁ.ViñadoB.CampanyD.et al. (2018). Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections. Infection46, 461–468. doi: 10.1007/s15010-018-1133-5
172
EvansS. R.TranT. T. T.HujerA. M.HillC. B.HujerK. M.MediavillaJ. R.et al. (2019). Rapid molecular diagnostics to Inform empiric use of ceftazidime/avibactam and Ceftolozane/Tazobactam against Pseudomonas aeruginosa: PRIMERS IV. Clin. Infect. Dis.68, 1823–1830. doi: 10.1093/cid/ciy801
173
FakhkhariP.TajeddinE.AzimiradM.Salmanzadeh-AhrabiS.Abdi-AliA.NikmaneshB.et al. (2022). Involvement of Pseudomonas aeruginosa in the occurrence of community and hospital acquired diarrhea, and its virulence diversity among the stool and the environmental samples. Int. J. Environ. Health Res.32, 61–71. doi: 10.1080/09603123.2020.1726300
174
FalagasM. E.SkalidisT.VardakasK. Z.LegakisN. J.Hellenic Cefiderocol Study G (2017). Activity of cefiderocol (S-649266) against carbapenem-resistant gram-negative bacteria collected from inpatients in Greek hospitals. J. Antimicrob. Chemother.72, 1704–1708. doi: 10.1093/jac/dkx049
175
FangY.WangN.WuZ.ZhuY.MaY.LiY.et al. (2023). An XDR pseudomonas aeruginosa ST463 strain with an IncP-2 plasmid containing a novel transposon Tn 6485f encoding Bla IMP-45 and bla AFM-1 and a second plasmid with two copies of Bla KPC-2. Microbiol. Spectr.11, e04462–e04422. doi: 10.1128/spectrum.04462-22
176
FaragA. M.TawfickM. M.AbozeedM. Y.ShabanE. A.Abo-ShadiM. A. (2020). Microbiological profile of ventilator-associated pneumonia among intensive care unit patients in tertiary Egyptian hospitals. J. Infect. Dev. Ctries.14, 153–161. doi: 10.3855/jidc.12012
177
FarhanS. M.IbrahimR. A.MahranK. M.HettaH. F.Abd El-BakyR. M. (2019). Antimicrobial resistance pattern and molecular genetic distribution of metallo-β-lactamases producing Pseudomonas aeruginosa isolated from hospitals in Minia, Egypt. Infect. Drug Resist.12, 2125–2133. doi: 10.2147/IDR.S198373
178
FarrellD. J.FlammR. K.SaderH. S.JonesR. N. (2013). Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011-2012). Antimicrob. Agents Chemother.57, 6305–6310. doi: 10.1128/AAC.01802-13
179
FarrellD. J.FlammR. K.SaderH. S.JonesR. N. (2014a). Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010. Antimicrob. Agents Chemother.58, 3882–3888. doi: 10.1128/AAC.02465-14
180
FarrellD. J.SaderH. S.FlammR. K.JonesR. N. (2014b). Ceftolozane/tazobactam activity tested against gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int. J. Antimicrob. Agents43, 533–539. doi: 10.1016/j.ijantimicag.2014.01.032
181
FarzanaR.ShamsuzzamanS.MamunK. Z. (2013). Isolation and molecular characterization of New Delhi metallo-beta-lactamase-1 producing superbug in Bangladesh. J. Infect. Dev. Countries7, 161–168. doi: 10.3855/jidc.2493
182
Fekri KohanS.AsadpourL.HoushmandE. (2020). The study of frequency of SIM and AmpC genes in clinical isolates of Pseudomonas aeruginosa in Gilan, Iran. Infect. Epidemiol. Microbiol6, 117–125. doi: 10.29252/iem.6.2.117
183
FeretzakisG.LoupelisE.SakagianniA.SkarmoutsouN.MichelidouS.VelentzaA.et al. (2019). A 2-year single-Centre audit on antibiotic resistance of Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae strains from an intensive care unit and other wards in a general public hospital in Greece. Antibiotics8:62. doi: 10.3390/antibiotics8020062
184
FerjaniS.MaamarE.FerjaniA.KanzariL.BoubakerI. B. B. (2022). Evaluation of three carbapenemase-phenotypic detection methods and emergence of diverse VIM and GES variants among Pseudomonas aeruginosa isolates in Tunisia. Antibiotics11:858. doi: 10.3390/antibiotics11070858
185
Fernández-OlmosA.García-CastilloM.AlbaJ. M.MorosiniM. I.LamasA.RomeroB.et al. (2013). Population structure and antimicrobial susceptibility of both nonpersistent and persistent Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients. J. Clin. Microbiol.51, 2761–2765. doi: 10.1128/JCM.00802-13
186
FlammR. K.FarrellD. J.SaderH. S.JonesR. N. (2014). Ceftazidime/avibactam activity tested against gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012). J. Antimicrob. Chemother.69, 1589–1598. doi: 10.1093/jac/dku025
187
Flores-ParedesW.LuqueN.AlbornozR.RojasN.EspinozaM.PonsM. J.et al. (2021). Evolution of antimicrobial resistance levels of ESKAPE microorganisms in a Peruvian IV-level hospital. Infect Chemother.53, 449–462. doi: 10.3947/ic.2021.0015
188
FlugeG.OjeniyiB.HøibyN.DigranesA.CiofuO.HunstadE.et al. (2001). Typing of Pseudomonas aeruginosa strains in Norwegian cystic fibrosis patients. Clin. Microbiol. Infect.7, 238–243. doi: 10.1046/j.1469-0691.2001.00247.x
189
FordM. B.MendeK.KaiserS. J.BeckiusM. L.LuD.StamJ.et al. (2022). Clinical characteristics and resistance patterns of Pseudomonas aeruginosa isolated from combat casualties. Mil. Med.187, 426–434. doi: 10.1093/milmed/usab259
190
FournierD.CarriereR.BourM.GrisotE.TriponneyP.MullerC.et al. (2021). Mechanisms of resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: results of the GERPA multicenter study. Antimicrob. Agents Chemother.65:20. doi: 10.1128/AAC.01117-20
191
FournierD.RichardotC.MüllerE.Robert-NicoudM.LlanesC.PlésiatP.et al. (2013). Complexity of resistance mechanisms to imipenem in intensive care unit strains of Pseudomonas aeruginosa. J. Antimicrob. Chemother.68, 1772–1780. doi: 10.1093/jac/dkt098
192
FraenkelC. J.StarlanderG.TanoE.SutterlinS.MelhusA. (2023). The first Swedish outbreak with VIM-2-producing Pseudomonas aeruginosa, occurring between 2006 and 2007, was probably due to contaminated hospital sinks. Microorganisms11:974. doi: 10.3390/microorganisms11040974
193
FrancoM. R. G.Caiaffa-FilhoH. H.BurattiniM. N.RossiF. (2010). Metallo-beta-lactamases among imipenem-resistant Pseudomonas aeruginosa in a Brazilian university hospital. Clinics65, 825–829. doi: 10.1590/S1807-59322010000900002
194
FrancoR.de Oliveira SantosI. C.MoraM. F. M.LópezP. V. A.AlvarezV. E. T.ArceF. H. O.et al. (2023). Genotypic characterization and clonal relatedness of metallo-β-lactamase-producing non-fermentative gram negative bacteria in the first 5 years of their circulation in Paraguay (2011-2015). Braz. J. Microbiol.54, 179–190. doi: 10.1007/s42770-022-00888-x
195
GaberS. N.HemedaE. E. M.ElsayehH.-A. S.WahedW. Y. A.KhalilM. A. F.IbrahimE. G. (2020). Propolis extract: a possible antiseptic Oral care against multidrug-resistant non-fermenting Bacteria isolated from non-ventilator hospital-acquired pneumonia. J. Pure Appl. Microbiol.14, 123–131. doi: 10.22207/JPAM.14.1.13
196
GahlotT.KasanaD. (2021). A cross-sectional study of etiological and sensitivity profiling of meningitis in under-five children. Int J Mycobacteriol.10, 149–154. doi: 10.4103/ijmy.ijmy_61_21
197
GajdácsM.BarathZ.KarpatiK.SzaboD.UsaiD.ZanettiS.et al. (2021a). No correlation between biofilm formation, virulence factors, and antibiotic resistance in Pseudomonas aeruginosa: results from a laboratory-based in vitro study. Antibiotics (Basel)10:1134. doi: 10.3390/antibiotics10091134
198
GajdácsM.BuriánK.TerhesG. (2019). Resistance levels and epidemiology of non-fermenting gram-negative bacteria in urinary tract infections of inpatients and outpatients (RENFUTI): a 10-year epidemiological snapshot. Antibiotics8:143. doi: 10.3390/antibiotics8030143
199
GajdácsM.KárpátiK.StájerA.ZanettiS.DonaduM. G. (2021b). Insights on carbapenem-resistant Pseudomonas aeruginosa. Acta Biologica Szegediensis.65, 105–112. doi: 10.14232/abs.2021.1.105-112
200
GalaniI.KontopidouF.SouliM.RekatsinaP.-D.KoratzanisE.DeliolanisJ.et al. (2008). Colistin susceptibility testing by Etest and disk diffusion methods. Int. J. Antimicrob. Agents31, 434–439. doi: 10.1016/j.ijantimicag.2008.01.011
201
GalaniI.PapoutsakiV.KarantaniI.KaraiskosI.GalaniL.AdamouP.et al. (2020). In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece. J. Antimicrob. Chemother.75, 2164–2172. doi: 10.1093/jac/dkaa160
202
GalesA. C.CastanheiraM.JonesR. N.SaderH. S. (2012). Antimicrobial resistance among gram-negative bacilli isolated from Latin America: results from SENTRY antimicrobial surveillance program (Latin America, 2008–2010). Diagn. Microbiol. Infect. Dis.73, 354–360. doi: 10.1016/j.diagmicrobio.2012.04.007
203
GalesA. C.JonesR. N.SaderH. S. (2011). Contemporary activity of colistin and polymyxin B against a worldwide collection of gram-negative pathogens: results from the SENTRY antimicrobial surveillance program (2006–09). J. Antimicrob. Chemother.66, 2070–2074. doi: 10.1093/jac/dkr239
204
GalesA. C.MenezesL. C.SilbertS.SaderH. S. (2003). Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-β-lactamase. J. Antimicrob. Chemother.52, 699–702. doi: 10.1093/jac/dkg416
205
Galindo-MendezM.Navarrete-SalazarH.Pacheco-VasquezR.Quintas-de la PazD.Baltazar-JimenezI.Santiago-LunaJ. D.et al. (2023). Detection of plasmid-mediated resistance against Colistin in multi-drug-resistant gram-negative Bacilli isolated from a tertiary hospital. Microorganisms11:1996. doi: 10.3390/microorganisms11081996
206
GangwarN.SiddapurG.SharmaS. (2021). Clinical implications of culture and sensitivity data in chronic otitis media. Indian J. Otol.27, 101–105. doi: 10.4103/indianjotol.indianjotol_8_21
207
GantV.HussainA.BainM.LongshawC.HenriksenA. S. (2021). In vitro activity of cefiderocol and comparators against gram-negative bacterial isolates from a series of surveillance studies in England: 2014–2018. J. Global Antimicrob. Resist.27, 1–11. doi: 10.1016/j.jgar.2021.07.014
208
García-CastilloM.Del CampoR.MorosiniM. I.RieraE.CabotG.WillemsR.et al. (2011). Wide dispersion of ST175 clone despite high genetic diversity of carbapenem-nonsusceptible Pseudomonas aeruginosa clinical strains in 16 Spanish hospitals. J. Clin. Microbiol.49, 2905–2910. doi: 10.1128/JCM.00753-11
209
Garcia-FernandezS.Garcia-CastilloM.BouG.CalvoJ.CercenadoE.DelgadoM.et al. (2019). Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: the SUPERIOR multicentre study. Int. J. Antimicrob. Agents53, 682–688. doi: 10.1016/j.ijantimicag.2019.02.004
210
GargA.GargJ.KumarS.BhattacharyaA.AgarwalS.UpadhyayG. (2019). Molecular epidemiology & therapeutic options of carbapenem-resistant gram-negative bacteria. Indian J. Med. Res.149, 285–289. doi: 10.4103/ijmr.IJMR_36_18
211
GauderetoJ. J.NetoL. V. P.LeiteG. C.EspinozaE. P. S.MartinsR. C. R.Villas Boa PradoG.et al. (2020). Comparison of methods for the detection of in vitro synergy in multidrug-resistant gram-negative bacteria. BMC Microbiol.20, 1–7. doi: 10.1186/s12866-020-01756-0
212
GhanemS. M.GadG. F.El-BakyA.MahmoudR.WalyN. G. (2023). Association between antibiotic resistance, biofilm formation and LASB gene in Pseudomonas Aeruginosa isolated from different clinical specimens. Bull. Pharm. Sci. Assiut Univ.46, 421–431. doi: 10.21608/bfsa.2023.301132
213
GhasemianS.Karami-ZarandiM.HeidariH.KhoshnoodS.KouhsariE.GhafourianS.et al. (2023). Molecular characterizations of antibiotic resistance, biofilm formation, and virulence determinants of Pseudomonas aeruginosa isolated from burn wound infection. J. Clin. Lab. Anal.37:e24850. doi: 10.1002/jcla.24850
214
GhasemshahiS.AhmadporM.BooskabadiA.RezaeiH.PoopakB.Hakemi-ValaM. (2022). A six-month survey of the frequency of extensively drug-resistant gram-negative bacteria by VITEK 2 system in 2020. Iranian J. Med. Microbiol.16, 134–140. doi: 10.30699/ijmm.16.2.134
215
GherardiG.LinardosG.PompilioA.FiscarelliE.Di BonaventuraG. (2019). Evaluation of in vitro activity of ceftolozane-tazobactam compared to other antimicrobial agents against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagn. Microbiol. Infect. Dis.94, 297–303. doi: 10.1016/j.diagmicrobio.2019.01.012
216
GhoshS.BornmanC.ZaferM. M. (2021). Antimicrobial resistance threats in the emerging COVID-19 pandemic: where do we stand?J. Infect. Public Health14, 555–560. doi: 10.1016/j.jiph.2021.02.011
217
GianiT.ArenaF.PolliniS.Di PilatoV.D’AndreaM. M.Henrici De AngelisL.et al. (2018). Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers. J. Antimicrob. Chemother.73, 664–671. doi: 10.1093/jac/dkx453
218
GilaniM.MunirT.LatifM.RehmanS.AnsariM.HafeezA.et al. (2015). In vitro efficacy of Doripenem against Pseudomonas aeruginosa and Acinetobacter baumannii by E-test. J. Coll. Physicians Surg. Pak.25, 726–729. doi: 10.2015/JCPSP.726729
219
GoliH. R.NahaeiM. R.RezaeeM. A.HasaniA.KafilH. S.AghazadehM.et al. (2017). Prevalence and molecular characterization of class 1 integrons among clinical isolates of Pseudomonas aeruginosa in northwest of Iran. Mol. Genet. Microbiol. Virol.32, 109–115. doi: 10.3103/S0891416817020057
220
GoliH. R.NahaeiM. R.RezaeeM. A.HasaniA.Samadi KafilH.AghazadehM.et al. (2016). Contribution of mexAB-oprM and mexXY (−oprA) efflux operons in antibiotic resistance of clinical Pseudomonas aeruginosa isolates in Tabriz, Iran. Infect. Genet. Evol.45, 75–82. doi: 10.1016/j.meegid.2016.08.022
221
GolliA. L.CristeaO. M.ZlatianO.GlodeanuA. D.BalasoiuA. T.IonescuM.et al. (2022). Prevalence of multidrug-resistant pathogens causing bloodstream infections in an intensive care unit. Infect. Drug Resist.15, 5981–5992. doi: 10.2147/IDR.S383285
222
GomezA. C.OrtizT.ValenzuelaA.Egoávil-EspejoR.Huerto-HuanucoR.PintoJ. A.et al. (2023). Super-infection by multiple microorganisms in COVID-19 patients. Front. Mol. Biosci.10:1113969. doi: 10.3389/fmolb.2023.1113969
223
Gómez-GarcésJ.AracilB.GilY.BurilloA. (2009). Susceptibility of 228 non-fermenting gram-negative rods to tigecycline and six other antimicrobial drugs. J. Chemother.21, 267–271. doi: 10.1179/joc.2009.21.3.267
224
GomilaM.del CarmenG. M.Fernández-BacaV.ParejaA.PascualM.Díaz-AntolínP.et al. (2013). Genetic diversity of clinical Pseudomonas aeruginosa isolates in a public hospital in Spain. BMC Microbiol.13, 138–110. doi: 10.1186/1471-2180-13-138
225
GunalanA.SarumathiD.SastryA. S.RamanathanV.RajaaS.SistlaS. (2021). Effect of combined colistin and meropenem against meropenem resistant Acinetobacter baumannii and Pseudomonas aeruginosa by checkerboard method: a cross sectional analytical study. Indian J. Pharmacol.53, 207–212. doi: 10.4103/ijp.ijp_1013_20
226
GuoH.SongQ.MeiS.XueZ.LiJ.NingT. (2023). Distribution of multidrug-resistant bacterial infections in diabetic foot ulcers and risk factors for drug resistance: a retrospective analysis. PeerJ.11:e16162. doi: 10.7717/peerj.16162
227
Gutierrez-SantanaJ. C.Geronimo-GallegosA.Martinez-CoronaM. B.Lopez-LopezM.Toscano-GaribayJ. D.Cuevas-SchachtF.et al. (2022). High rates of extensively drug-resistant Pseudomonas aeruginosa in children with cystic fibrosis. Curr. Microbiol.79:353. doi: 10.1007/s00284-022-03048-4
228
GuzekA.KorzeniewskiK.TomaszewskiD.RybickiZ.ZwolinskaE. (2017). Bacteriological assessment of pneumonia caused by gram-negative Bacteria in patients hospitalized in intensive care unit. Adv. Exp. Med. Biol.955, 39–46. doi: 10.1007/5584_2016_163
229
GuzekA.RybickiZ.KorzeniewskiK.MackiewiczK.SaksE.ChciałowskiA.et al. (2015). Etiological factors causing lower respiratory tract infections isolated from hospitalized patients. Adv. Exp. Med. Biol.835, 37–44. doi: 10.1007/5584_2014_23
230
GüzelÇ. B.GerçekerA. A. (2008). In vitro activities of various antibiotics, alone and in combination with colistin methanesulfonate, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Chemotherapy54, 147–151. doi: 10.1159/000119741
231
HackelM. A.TsujiM.YamanoY.EcholsR.KarlowskyJ. A.SahmD. F. (2018). In Vitro activity of the Siderophore cephalosporin, Cefiderocol, against Carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative Bacilli collected worldwide in 2014 to 2016. Antimicrob. Agents Chemother.62:e01968. doi: 10.1128/AAC.01968-17
232
HakeamH. A.AskarG.Al SulaimanK.MansourR.Al QahtaniM. M.AbbaraD.et al. (2022). Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: a multicenter retrospective study. J. Infect. Public Health15, 1081–1088. doi: 10.1016/j.jiph.2022.08.020
233
HallitS.AdaimeA.HajjA. (2020). Lebanese Observatory of Pathogenic Agents (Lopa-study): a 2 year-surveillance prospective study. Lebanese Med. J.68, 126–133. doi: 10.12816/0060171
234
HansenC.PresslerT.HøibyN. (2008). Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J. Cyst. Fibros.7, 523–530. doi: 10.1016/j.jcf.2008.06.009
235
HaoL.YangX.ChenH.WeiS.XuB.ZhaoZ. (2023). Distribution and drug resistance of bacterial infection in hospitalized patients at the respiratory department before and after the COVID-19 pandemic in Guangzhou, China. Microorganisms11:2542. doi: 10.3390/microorganisms11102542
236
HasmanH.HammerumA. M.HansenF.HendriksenR. S.OlesenB.AgersøY.et al. (2015). Detection of mcr-1 encoding plasmid-mediated colistin-resistant Escherichia coli isolates from human bloodstream infection and imported chicken meat, Denmark 2015. Eur. Secur.20:30085. doi: 10.2807/1560-7917.ES.2015.20.49.30085
237
HassenB.HammamiS.HassenA.AbbassiM. (2022). Molecular mechanisms and clonal lineages of colistin-resistant bacteria across the African continent: a scoping review. Lett. Appl. Microbiol.75, 1390–1422. doi: 10.1111/lam.13818
238
HawserS.KothariN.JemmelyN.RedderN. (2021). Surveillance of ceftobiprole against gram-positive and gram-negative clinical isolates from 2018 from different European territories. J. Glob. Antimicrob. Resist.26, 326–329. doi: 10.1016/j.jgar.2021.07.012
239
HeidariR.Farajzadeh SheikhA.HashemzadehM.FarshadzadehZ.SalmanzadehS.SakiM. (2022). Antibiotic resistance, biofilm production ability and genetic diversity of carbapenem-resistant Pseudomonas aeruginosa strains isolated from nosocomial infections in southwestern Iran. Mol. Biol. Rep.49, 3811–3822. doi: 10.1007/s11033-022-07225-3
240
HendersonA.TanE.McCarthyK.PatersonD. (2018). Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia. Pathology50, 748–752. doi: 10.1016/j.pathol.2018.08.009
241
Herrera-EspejoS.Cebrero-CangueiroT.Labrador-HerreraG.PachónJ.Pachón-IbáñezM. E.Álvarez-MarínR. (2020). In vitro activity of pentamidine alone and in combination with antibiotics against multidrug-resistant clinical Pseudomonas aeruginosa strains. Antibiotics9:885. doi: 10.3390/antibiotics9120885
242
HindlerJ. A.HumphriesR. M. (2013). Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant gram-negative bacilli. J. Clin. Microbiol.51, 1678–1684. doi: 10.1128/JCM.03385-12
243
HishinumaT.TadaT.Kuwahara-AraiK.YamamotoN.ShimojimaM.KirikaeT. (2018). Spread of GES-5 carbapenemase-producing Pseudomonas aeruginosa clinical isolates in Japan due to clonal expansion of ST235. PLoS One13:e0207134. doi: 10.1371/journal.pone.0207134
244
HishinumaT.UchidaH.TohyaM.ShimojimaM.TadaT.KirikaeT. (2020). Emergence and spread of VIM-type metallo-β-lactamase-producing Pseudomonas aeruginosa clinical isolates in Japan. J. Global Antimicrob. Resist.23, 265–268. doi: 10.1016/j.jgar.2020.09.010
245
HolgerD. J.El GhaliA.BhutaniN.LevK. L.StamperK.KebriaeiR.et al. (2023). Phage-antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa in in vitro static and dynamic biofilm models. Antimicrob. Agents Chemother.67:e0057823. doi: 10.1128/aac.00578-23
246
HolgerD. J.LevK. L.KebriaeiR.MorrisetteT.ShahR.AlexanderJ.et al. (2022b). Bacteriophage-antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa: in vitro synergy testing. J. Appl. Microbiol.133, 1636–1649. doi: 10.1111/jam.15647
247
HolgerD. J.ReboldN. S.AlosaimyS.MorrisetteT.LagnfA.BelzaA. C.et al. (2022a). Impact of ceftolozane–tazobactam vs. best alternative therapy on clinical outcomes in patients with multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa lower respiratory tract infections. Infect. Dis. Ther.11, 1965–1980. doi: 10.1007/s40121-022-00687-9
248
HongJ. S.KimJ. O.LeeH.BaeI. K.JeongS. H.LeeK. (2015). Characteristics of Metallo-β-lactamase-producing Pseudomonas aeruginosa in Korea. Infect. Chemother.47, 33–40. doi: 10.3947/ic.2015.47.1.33
249
HoşbulT.AydoganC. N.KayaS.BedirO.ÖzcanH.GümralR. (2022). In vitro activity of ceftazidime-avibactam and colistin against carbapenem-resistant Pseudomonas aeruginosa clinical isolates. J. Istanbul Faculty Med.85, 355–361. doi: 10.26650/IUITFD.1092556
250
Hosseininassab NodoushanS. A.YadegariS.MoghimS.IsfahaniB. N.FazeliH.PoursinaF.et al. (2017). Distribution of the strains of multidrug-resistant, extensively drug-resistant, and Pandrug-resistant Pseudomonas aeruginosa isolates from burn patients. Adv. Biomed. Res.6:74. doi: 10.4103/abr.abr_239_16
251
Howard-AndersonJ.DavisM.PageA. M.BowerC. W.SmithG.JacobJ. T.et al. (2022). Prevalence of colistin heteroresistance in carbapenem-resistant Pseudomonas aeruginosa and association with clinical outcomes in patients: an observational study. J. Antimicrob. Chemother.77, 793–798. doi: 10.1093/jac/dkab461
252
HrbacekJ.CermakP.ZachovalR. (2020). Current antibiotic resistance trends of uropathogens in Central Europe: survey from a tertiary hospital urology department 2011–2019. Antibiotics9:630. doi: 10.3390/antibiotics9090630
253
HsuehS. C.LeeY. J.HuangY. T.LiaoC. H.TsujiM.HsuehP. R. (2019). In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan. J. Antimicrob. Chemother.74, 380–386. doi: 10.1093/jac/dky425
254
HuY.ChenJ.HuangL.LiuC.ZhouH.ZhangR. (2023). Antimicrobial susceptibility study and molecular epidemiology of ceftazidime/avibactam against Pseudomonas aeruginosa collected from clinical patients in PR China (2004–2021). J. Med. Microbiol.72:001656. doi: 10.1099/jmm.0.001656
255
HuY.LiuC.WangQ.ZengY.SunQ.ShuL.et al. (2021a). Emergence and expansion of a Carbapenem-resistant Pseudomonas aeruginosa clone are associated with plasmid-borne Bla (KPC-2) and virulence-related genes. mSystems6:154. doi: 10.1128/mSystems.00154-21
256
HuY.PengW.WuY.LiH.WangQ.YiH.et al. (2021b). A potential high-risk clone of Pseudomonas aeruginosa ST463. Front. Microbiol.12:670202. doi: 10.3389/fmicb.2021.670202
257
HuX.SunL.NieT.YangY.WangX.PangJ.et al. (2022). Evaluation of agar dilution method in susceptibility testing of Polymyxins for Enterobacteriaceae and non-fermentative rods: advantages compared to broth microdilution and broth macrodilution. Antibiotics11:1392. doi: 10.3390/antibiotics11101392
258
HuangY.-S.WangJ.-T.TaiH.-M.ChangP.-C.HuangH.-C.YangP.-C. (2022). Metal nanoparticles and nanoparticle composites are effective against Haemophilus influenzae, Streptococcus pneumoniae, and multidrug-resistant bacteria. J. Microbiol. Immunol. Infect.55, 708–715. doi: 10.1016/j.jmii.2022.05.003
259
HubandM. D.CastanheiraM.FlammR. K.FarrellD. J.JonesR. N.SaderH. S. (2016). In vitro activity of ceftazidime-avibactam against contemporary Pseudomonas aeruginosa isolates from U.S. medical centers by census region, 2014. Antimicrob. Agents Chemother.60, 2537–2541. doi: 10.1128/AAC.03056-15
260
HubandM. D.LindleyJ. M.MendesR. E.FedlerK. A.BennV. J.ZhangJ.et al. (2020). In vitro activity of KHP-3757 (a novel LpxC inhibitor) and comparator agents against recent and molecularly characterized Pseudomonas aeruginosa isolates from a global surveillance program (2017–2018). Diagn. Microbiol. Infect. Dis.98:115191. doi: 10.1016/j.diagmicrobio.2020.115191
261
HumphriesR. M.JanssenH.Hey-HadaviJ. H.HackelM.SahmD. (2023). Multidrug-resistant gram-negative bacilli recovered from respiratory and blood specimens from adults: the ATLAS surveillance program in European hospitals, 2018–2020. Int. J. Antimicrob. Agents61:106724. doi: 10.1016/j.ijantimicag.2023.106724
262
IbrahimM. E. (2018). High antimicrobial resistant rates among gram-negative pathogens in intensive care units. A retrospective study at a tertiary care hospital in Southwest Saudi Arabia. Saudi Med. J.39, 1035–1043. doi: 10.15537/smj.2018.10.22944
263
IbrahimS.Al-SaryiN.Al-KadmyI.AzizS. N. (2021). Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals. Mol. Biol. Rep.48, 6987–6998. doi: 10.1007/s11033-021-06690-6
264
IoannouP.AlexakisK.MarakiS.KofteridisD. P. (2023). Pseudomonas bacteremia in a tertiary hospital and factors associated with mortality. Antibiotics12:670. doi: 10.3390/antibiotics12040670
265
IsmailS. J.MahmoudS. S. (2018). First detection of New Delhi metallo-β-lactamases variants (NDM-1, NDM-2) among Pseudomonas aeruginosa isolated from Iraqi hospitals. Iran. J. Microbiol.10, 98–103
266
Izadi Pour JahromiS.MardanehJ.SharifiA.PezeshkpourV.Behzad-BehbahaniA.SeyyediN.et al. (2018). Occurrence of a multidrug resistant Pseudomonas aeruginosa strains in hospitalized patients in southwest of Iran: characterization of resistance trends and virulence determinants. J. Microbiol.11:57341. doi: 10.5812/jjm.57341
267
JalaliY.SturdikI.JalaliM.PayerJ. (2021). Isolated carbapenem resistant bacteria, their multidrug resistant profile, percentage of healthcare associated infection and associated mortality, in hospitalized patients in a University Hospital in Bratislava. Clin. Study122, 379–385. doi: 10.4149/10.4149/BLL_2021_063
268
JamalifarH.SamadiN.NowrooziJ.DezfulianM.FazeliM. R. (2019). Down-regulatory effects of green coffee extract on las I and las R virulence-associated genes in Pseudomonas aeruginosa. DARU J. Pharm. Sci.27, 35–42. doi: 10.1007/s40199-018-0234-0
269
JansenG.MahrtN.TueffersL.BarbosaC.HarjesM.AdolphG.et al. (2016). Association between clinical antibiotic resistance and susceptibility of Pseudomonas in the cystic fibrosis lung. Evol. Med. Public Health2016, 182–194. doi: 10.1093/emph/eow016
270
JaponiA.VazinA.DavarpanahM. A.ArdakaniM. A.AlborziA.JaponiS.et al. (2011). Ventilator-associated pneumonia in Iranian intensive care units. J. Infect. Dev. Countries5, 286–293. doi: 10.3855/jidc.1212
271
JauhariS.PalS.GoyalM.PrakashR.JuyalD. (2020). Bacteriological and antimicrobial sensitivity profile of burn wound infections in a tertiary Care Hospital of Uttarakhand. Int. J. Curr. Res. Rev.12, 30–36. doi: 10.31782/IJCRR.2020.12127
272
JayaraniM.JaikumarS.SandhyaR. T. (2020). Microbiological profile and drug resistant Organism's pattern in diabetic foot ulcer patients at tertiary care hospital Puducherry. Int. J. Res. Pharmaceutical Sci.11, 6692–6697. doi: 10.26452/ijrps.v11i4.3592
273
JazaniN. H.ZahediA.GarebagiN. (2012). Phenotypic detection of metallo-β-lactamase producing Pseudomonas aeruginosa isolated from Urmia hospitals. African J. Microbiol. Res.6, 1387–1392. doi: 10.5897/AJMR11.1023
274
JeanS.-S.HsuehP.-R.LeeW.-S.ChangH.-T.ChouM.-Y.ChenS.et al. (2009). Nationwide surveillance of antimicrobial resistance among non-fermentative gram-negative bacteria in intensive care units in Taiwan: SMART programme data 2005. Int. J. Antimicrob. Agents33, 266–271. doi: 10.1016/j.ijantimicag.2008.08.026
275
JeanS. S.LeeY. L.LiuP. Y.LuM. C.KoW. C.HsuehP. R. (2022). Multicenter surveillance of antimicrobial susceptibilities and resistance mechanisms among Enterobacterales species and non-fermenting gram-negative bacteria from different infection sources in Taiwan from 2016 to 2018. J. Microbiol. Immunol. Infect.55, 463–473. doi: 10.1016/j.jmii.2021.07.015
276
JeanS. S.LeeW. S.YuK. W.LiaoC. H.HsuC. W.ChangF. Y.et al. (2016). Rates of susceptibility of carbapenems, ceftobiprole, and colistin against clinically important bacteria collected from intensive care units in 2007: results from the surveillance of multicenter antimicrobial resistance in Taiwan (SMART). J. Microbiol. Immunol. Infect.49, 969–976. doi: 10.1016/j.jmii.2014.12.008
277
JeongS.JeonK.LeeN.ParkM.-J.SongW. (2024). Changing genotypic distribution, antimicrobial susceptibilities, and risk factors of urinary tract infection caused by carbapenemase-producing pseudomonas aeruginosa. Ann. Lab. Med.44, 38–46. doi: 10.3343/alm.2024.44.1.38
278
Jimenez-GuerraG.Heras-CanasV.Gutierrez-SotoM.Del PilarA.-P. M.Exposito-RuizM.Navarro-MariJ. M.et al. (2018). Urinary tract infection by Acinetobacter baumannii and Pseudomonas aeruginosa: evolution of antimicrobial resistance and therapeutic alternatives. J. Med. Microbiol.67, 790–797. doi: 10.1099/jmm.0.000742
279
JonesR. N.CastanheiraM.HuB.NiY.LinS. S.MendesR. E.et al. (2013a). Update of contemporary antimicrobial resistance rates across China: reference testing results for 12 medical centers (2011). Diagn. Microbiol. Infect. Dis.77, 258–266. doi: 10.1016/j.diagmicrobio.2013.07.003
280
JonesR. N.FlontaM.GurlerN.CepparuloM.MendesR. E.CastanheiraM. (2014). Resistance surveillance program report for selected European nations (2011). Diagn. Microbiol. Infect. Dis.78, 429–436. doi: 10.1016/j.diagmicrobio.2013.10.008
281
JonesR. N.Guzman-BlancoM.GalesA. C.GallegosB.CastroA. L. L.MartinoM. D. V.et al. (2013b). Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011). Braz. J. Infect. Dis.17, 672–681. doi: 10.1016/j.bjid.2013.07.002
282
JuhászE.IvánM.PintérE.PongráczJ.KristófK. (2017a). Colistin resistance among blood culture isolates at a tertiary care Centre in Hungary. J. Global Antimicrob. Resist.11, 167–170. doi: 10.1016/j.jgar.2017.08.002
283
JuhászE.KovacsA.PongraczJ.IvanM.KristofK. (2017b). In vitro activity of Colistin and trimethoprim/sulfamethoxazole against consortia of multidrug resistant non-fermenting gram-negative Bacilli isolated from lower respiratory tract. Jundishapur J. Microbiol.10:14034. doi: 10.5812/jjm.14034
284
JungS.ChungE. K.JunM. S.SonE. S.RhieS. J. (2019). Differences in Colistin administration and bacterial and treatment outcomes in critically ill patients. Sci. Rep.9:8781. doi: 10.1038/s41598-019-44965-y
285
KabicJ.FortunatoG.Vaz-MoreiraI.KekicD.JovicevicM.PesovicJ.et al. (2023). Dissemination of metallo-β-lactamase-producing Pseudomonas aeruginosa in Serbian hospital settings: expansion of ST235 and ST654 clones. Int. J. Mol. Sci.24:1519. doi: 10.3390/ijms24021519
286
KakhandkiL.TakpereA. Y.BagaliS.WavareS.KarigoudarR.ShahapurP. R. (2020). Antibiogram of gram negative bacteria isolated from the skin and soft tissue infections a guide for empirical therapy to the clinicians. J. Pure Appl. Microbiol.14, 1353–1358. doi: 10.22207/JPAM.14.2.32
287
KanwarN.HarrisonC. J.PenceM. A.QinX.SelvaranganR. (2023). Comparative in vitro antipseudomonal activity of ceftolozane/tazobactam against Pseudomonas aeruginosa isolates from children with cystic fibrosis. Diagn. Microbiol. Infect. Dis.105:115904. doi: 10.1016/j.diagmicrobio.2023.115904
288
KaramiP.KhalediA.MashoofR. Y.YaghoobiM. H.KaramiM.DastanD.et al. (2020). The correlation between biofilm formation capability and antibiotic resistance pattern in Pseudomonas aeruginosa. Gene Rep.18:100561. doi: 10.1016/j.genrep.2019.100561
289
KarimzadehI.SadeghimaneshN.MirzaeeM.SaghebM. M. (2017). Evaluating the resistance pattern of gram-negative bacteria during three years at the nephrology ward of a referral hospital in southwest of Iran. J. Nephropathol.6, 210–219. doi: 10.15171/jnp.2017.35
290
KarlowskyJ. A.AdamH. J.BaxterM. R.Lagacé-WiensP. R.WalktyA. J.HobanD. J.et al. (2013). In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study. Antimicrob. Agents Chemother.57, 5600–5611. doi: 10.1128/AAC.01485-13
291
KarlowskyJ. A.BouchillonS. K.BenaoudaA.SoraaN.ZeroualiK.MohamedN.et al. (2022). Antimicrobial susceptibility testing of clinical isolates of gram-negative bacilli collected in Morocco by the ATLAS global surveillance program from 2018 to 2020. J. Global Antimicrob. Resist.30, 23–30. doi: 10.1016/j.jgar.2022.04.011
292
KarlowskyJ. A.HackelM. A.TsujiM.YamanoY.EcholsR.SahmD. F. (2019a). In vitro activity of cefiderocol, a siderophore cephalosporin, against gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015. Int. J. Antimicrob. Agents53, 456–466. doi: 10.1016/j.ijantimicag.2018.11.007
293
KarlowskyJ. A.KazmierczakK. M.BouchillonS. K.de JongeB. L. M.StoneG. G.SahmD. F. (2019b). In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Latin American countries: results from the INFORM global surveillance program, 2012 to 2015. Antimicrob. Agents Chemother.63:e01814. doi: 10.1128/AAC.01814-18
294
KarlowskyJ. A.LobS. H.HawserS. P.KothariN.SiddiquiF.AlekseevaI.et al. (2023). Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in central and northern Europe (Belgium, Norway, Sweden, Switzerland)—SMART 2017–21. JAC-Antimicrob. Resist.5:dlad098. doi: 10.1093/jacamr/dlad098
295
KarlowskyJ. A.LobS. H.KazmierczakK. M.YoungK.MotylM. R.SahmD. F. (2018a). In vitro activity of imipenem-Relebactam against clinical isolates of gram-negative Bacilli isolated in Hospital Laboratories in the United States as part of the SMART 2016 program. Antimicrob. Agents Chemother.62:62. doi: 10.1128/AAC.00169-18
296
KarlowskyJ. A.LobS. H.YoungK.MotylM. R.SahmD. F. (2018b). Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015–2016. J. Global Antimicrob. Resist.15, 140–147. doi: 10.1016/j.jgar.2018.07.012
297
KarlowskyJ. A.LobS. H.YoungK.MotylM. R.SahmD. F. (2021). In vitro activity of imipenem/Relebactam against gram-negative Bacilli from pediatric patients-study for monitoring antimicrobial resistance trends (SMART) global surveillance program 2015-2017. J. Pediatric Infect. Dis. Soc.10, 274–281. doi: 10.1093/jpids/piaa056
298
KarruliA.MassaA.BertolinoL.AndiniR.SansoneP.DongiovanniS.et al. (2022). Clinical characteristics and outcome of MDR/XDR bacterial infections in a neuromuscular semi-intensive/sub-intensive care unit. Antibiotics11:1411. doi: 10.3390/antibiotics11101411
299
KashfiM.HashemiA.EslamiG.AminM. S.TarashiS.TakiE. (2017). The prevalence of aminoglycoside-modifying enzyme genes among Pseudomonas aeruginosa strains isolated from burn patients. Arch. Clin. Infect. Dis.12:40896. doi: 10.5812/archcid.40896
300
KatchanovJ.AsarL.KluppE. M.BothA.RotheC.KonigC.et al. (2018). Carbapenem-resistant gram-negative pathogens in a German university medical center: prevalence, clinical implications and the role of novel beta-lactam/beta-lactamase inhibitor combinations. PLoS One13:e0195757. doi: 10.1371/journal.pone.0195757
301
KaurN.ChauhanS.SainiA.ChauhanJ.KumarH. (2022). Assessment of colistin resistance in gram negative bacteria from clinical samples in resource-limited settings. Asian Pac J Trop Med15, 367–373. doi: 10.4103/1995-7645.351764
302
KazmierczakK. M.de JongeB. L. M.StoneG. G.SahmD. F. (2018). In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15. J. Antimicrob. Chemother.73, 2777–2781. doi: 10.1093/jac/dky267
303
KazmierczakK. M.RabineS.HackelM.McLaughlinR. E.BiedenbachD. J.BouchillonS. K.et al. (2016). Multiyear, multinational survey of the incidence and global distribution of Metallo-β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob. Agents Chemother.60, 1067–1078. doi: 10.1128/AAC.02379-15
304
KcR.AdhikariS.BastolaA.DevkotaL.BhandariP.GhimireP.et al. (2019). Opportunistic respiratory infections in HIV patients attending sukraraj tropical and infectious diseases hospital in Kathmandu, Nepal. HIV/AIDS Res. Palliative Care11, 357–367. doi: 10.2147/HIV.S229531
305
KeepersT. R.GomezM.CeleriC.NicholsW. W.KrauseK. M. (2014). Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob. Agents Chemother.58, 5297–5305. doi: 10.1128/AAC.02894-14
306
KhajuriaA.PraharajA. K.KumarM.GroverN. (2013). Emergence of NDM–1 in the clinical isolates of Pseudomonas aeruginosa in India. J. Clin. Diagn. Res.7:1328. doi: 10.7860/JCDR/2013/5509.3137
307
KhanF. Y.Abu-KhattabM.AlmaslamaniE. A.HassanA. A.MohamedS. F.ElbuzdiA. A.et al. (2017). Acute bacterial meningitis in Qatar: a hospital-based study from 2009 to 2013. Biomed. Res. Int.2017, 1–8. doi: 10.1155/2017/2975610
308
KhanJ. Z.IsmailM.UllahR.AliW.AliI. (2023). Increased burden of MDR bacterial infections; reflection from an antibiogram of ICUs of a tertiary care hospital. J. Infect. Dev. Ctries.17, 994–998. doi: 10.3855/jidc.18142
309
KhaterE. (2022). Detection of carbapenem-resistant Pseudomonas aeruginosa in tertiary care hospital in Saudi Arabia. Microbes Infect. Dis.0:1320.
310
KhaterE. S.AlFakiA. A. A. (2022). Detection of carbapenem-resistant Pseudomonas aeruginosa in tertiary care hospital in Saudi Arabia. Microbes Infect. Dis.3, 693–702. doi: 10.21608/mid.2022.142569.1320
311
KhorvashF.YazdaniM.ShabaniS.SoudiA. (2017). Pseudomonas aeruginosa-producing Metallo-beta-lactamases (VIM, IMP, SME, and AIM) in the clinical isolates of intensive care units, a University Hospital in Isfahan. Iran. Adv. Biomed. Res.6:147. doi: 10.4103/2277-9175.219412
312
KhoshnoodS.KhosraviA. D.JomehzadehN.MontazeriE. A.MotaharM.ShahiF.et al. (2019). Distribution of extended-spectrum β-lactamase genes in antibiotic-resistant strains of Pseudomonas aeruginosa obtained from burn patients in Ahvaz, Iran. J. Acute Dis.8, 53–57. doi: 10.4103/2221-6189.254426
313
KhosraviA. D.MotaharM.AbbasiM. E. (2017). The frequency of class1 and 2 integrons in Pseudomonas aeruginosa strains isolated from burn patients in a burn center of Ahvaz, Iran. PLoS One12:e0183061. doi: 10.1371/journal.pone.0183061
314
KhosraviA. D.ShafieF.Abbasi MontazeriE.RostamiS. (2016). The frequency of genes encoding exotoxin a and exoenzyme S in Pseudomonas aeruginosa strains isolated from burn patients. Burns42, 1116–1120. doi: 10.1016/j.burns.2016.02.012
315
KhudairA. N. A.MahmoodS. S. (2021). Detection of the antiseptic resistance gene among Pseudomonas aeruginosa isolates. Iraqi J. Sci., 62, 75–82. doi: 10.24996/ijs.2021.62.1.7
316
KiddT. J.RamsayK. A.HuH.ByeP. T.ElkinsM. R.GrimwoodK.et al. (2009). Low rates of Pseudomonas aeruginosa misidentification in isolates from cystic fibrosis patients. J. Clin. Microbiol.47, 1503–1509. doi: 10.1128/JCM.00014-09
317
KimH. S.ParkB. K.KimS. K.HanS. B.LeeJ. W.LeeD. G.et al. (2017). Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study. BMC Infect. Dis.17:500. doi: 10.1186/s12879-017-2597-0
318
KimD.YoonE.-J.HongJ. S.ChoiM. H.KimH. S.KimY. R.et al. (2022). Major bloodstream infection-causing bacterial pathogens and their antimicrobial resistance in South Korea, 2017–2019: phase i report from kor-glass. Front. Microbiol.12:799084. doi: 10.3389/fmicb.2021.799084
319
KıracS.KeskinD.YararM. (2018). Antimicrobial susceptibility pattern and multidrug resistance ındex in Pseudomonas aeruginosa among clinical isolates in Denizli, Turkey. Tanzan. J. Health Res.20:v20i3. doi: 10.4314/thrb.v20i3.6
320
KiratisinP.KazmierczakK.StoneG. G. (2021). In vitro activity of ceftazidime/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018. J. Global Antimicrob. Resist.27, 132–141. doi: 10.1016/j.jgar.2021.08.010
321
KiratisinP.KempfM.StoneG.UttE. (2023). Ceftazidime-avibactam and comparators against Pseudomonas aeruginosa isolates collected globally and in each geographical region between 2017-2020. J. Glob. Antimicrob. Resist.34, 113–118. doi: 10.1016/j.jgar.2023.06.005
322
KoW.-C.StoneG. G. (2020). In vitro activity of ceftazidime–avibactam and comparators against gram-negative bacterial isolates collected in the Asia–Pacific region as part of the INFORM program (2015–2017). Ann. Clin. Microbiol. Antimicrob.19, 1–12. doi: 10.1186/s12941-020-00355-1
323
KohiraN.HackelM. A.OotaM.TakemuraM.HuF.MizunoH.et al. (2023). In vitro antibacterial activities of cefiderocol against gram-negative clinical strains isolated from China in 2020. J. Global Antimicrob. Resist.32, 181–186. doi: 10.1016/j.jgar.2022.11.017
324
KokkayilP.AgarwalR.MohapatraS.BakshiS.DasB.SoodS.et al. (2018). Bacterial profile and antibiogram of blood stream infections in febrile neutropenic patients with haematological malignancies. J. Infect. Dev. Ctries.12, 442–447. doi: 10.3855/jidc.9725
325
KombadeS. P.KaurN.PatroS. K.NagV. L. (2021). Clinico-bacteriological and antibiotic drug resistance profile of chronic suppurative otitis media at a tertiary care hospital in Western Rajasthan. J. Family Med. Prim. Care10, 2572–2579. doi: 10.4103/jfmpc.jfmpc_2480_20
326
KorzekwaK.KędzioraA.StańczykiewiczB.Bugla-PłoskońskaG.WojniczD. (2021). Benefits of usage of immobilized silver nanoparticles as Pseudomonas aeruginosa antibiofilm factors. Int. J. Mol. Sci.23:284. doi: 10.3390/ijms23010284
327
KothariA.KumarS. K.SinghV.KumarP.KaushalK.PandeyA.et al. (2022). Association of multidrug resistance behavior of clinical Pseudomonas aeruginosa to pigment coloration. Eur. J. Med. Res.27:120. doi: 10.1186/s40001-022-00752-6
328
KovacevicP.ZlojutroB.KovacevicT.BaricG.DragicS.MomcicevicD. (2019). Microorganisms profile and antibiotics sensitivity patterns in the only medical intensive care unit in Bosnia and Herzegovina. Microb. Drug Resist.25, 1176–1181. doi: 10.1089/mdr.2018.0458
329
KraghK. N.GijónD.MaruriA.AntonelliA.CoppiM.KolpenM.et al. (2021). Effective antimicrobial combination in vivo treatment predicted with microcalorimetry screening. J. Antimicrob. Chemother.76, 1001–1009. doi: 10.1093/jac/dkaa543
330
KrauseK. M.HaglundC. M.HebnerC.SerioA. W.LeeG.NietoV.et al. (2019). Potent LpxC inhibitors with in vitro activity against multidrug-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother.63:10.1128/aac, 00977–00919. doi: 10.1128/AAC.00977-19
331
KreskenM.Korber-IrrgangB.Korte-BerwangerM.PfennigwerthN.GatermannS. G.SeifertH.et al. (2020a). Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany. Int. J. Antimicrob. Agents55:105959. doi: 10.1016/j.ijantimicag.2020.105959
332
KreskenM.Korte-BerwangerM.GatermannS. G.PfeiferY.PfennigwerthN.SeifertH.et al. (2020b). In vitro activity of cefiderocol against aerobic gram-negative bacterial pathogens from Germany. Int. J. Antimicrob. Agents56:106128. doi: 10.1016/j.ijantimicag.2020.106128
333
KristofK.AdamkovaV.AdlerA.Gospodarek-KomkowskaE.RafilaA.BillovaS.et al. (2021). In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales and Pseudomonas aeruginosa isolates from Central Europe and Israel, 2014–2017 and 2018. Diagn. Microbiol. Infect. Dis.101:115420. doi: 10.1016/j.diagmicrobio.2021.115420
334
KuoS.-C.WangY.-C.TanM.-C.HuangW.-C.ShiauY.-R.WangH.-Y.et al. (2021). In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible gram-negative bacilli from Taiwan. J. Antimicrob. Chemother.76, 2071–2078. doi: 10.1093/jac/dkab141
335
KuriharaD.MatsumotoS.KishiN.IshiiY.MoriM. (2022). In vitro antibacterial activity of imipenem/relebactam against clinical isolates in Japan. Microbiol. Spectrum.10, e02235–e02221. doi: 10.1128/spectrum.02235-21
336
LaiC.-C.ChenY.-S.LeeN.-Y.TangH.-J.LeeS. S.-J.LinC.-F.et al. (2019). Susceptibility rates of clinically important bacteria collected from intensive care units against colistin, carbapenems, and other comparative agents: results from surveillance of multicenter antimicrobial resistance in Taiwan (SMART). Infect. Drug Resist.12, 627–640. doi: 10.2147/IDR.S194482
337
LaurentiuT. A.NicoletaM.OctavP.GheorgheI.MarcelaP.OtiliaB.et al. (2017). Resistance features of pseudomonas aeruginosa strains isolated from patients with infectious complications of cardiovascular surgery. Biointerface Res. Appl. Chem.7, 2004–2008.
338
LeeS.-C.HuangS.-S.SeeL.-C.TsaiM.-H.ShiehW.-B. (2011). In vitro activities of nine current antibiotics against culprit bacteria in nosocomial infections in an institution in northern Taiwan. Chang Gung Med. J.34, 580–589
339
LeeY. L.KoW. C.HsuehP. R. (2023). In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: data from the antimicrobial testing leadership and surveillance (ATLAS) program, 2012-2021. Int. J. Antimicrob. Agents62:106867. doi: 10.1016/j.ijantimicag.2023.106867
340
LeeJ.-Y.LimM. H.HeoS. T.KoK. S. (2012). Repeated isolation of Pseudomonas aeruginosa isolates resistant to both polymyxins and carbapenems from 1 patient. Diagn. Microbiol. Infect. Dis.72, 267–271. doi: 10.1016/j.diagmicrobio.2011.11.014
341
LeeY.-L.LuM.-C.ShaoP.-L.LuP.-L.ChenY.-H.ChengS.-H.et al. (2019). Nationwide surveillance of antimicrobial resistance among clinically important gram-negative bacteria, with an emphasis on carbapenems and colistin: Results from the surveillance of multicenter antimicrobial resistance in Taiwan (SMART) in 2018. Int. J. Antimicrob. Agents54, 318–328. doi: 10.1016/j.ijantimicag.2019.06.009
342
LeeJ.-Y.SongJ.-H.KoK. S. (2011). Identification of nonclonal Pseudomonas aeruginosa isolates with reduced colistin susceptibility in Korea. Microb. Drug Resist.17, 299–304. doi: 10.1089/mdr.2010.0145
343
LiX. Y.LiuX. G.DongZ. L.ChaiL. T.LiuY. J.QiJ.et al. (2023). The distribution, drug susceptibility, and dynamic trends of Pseudomonas aeruginosa infection in a tertiary Hospital in China during 2016–2022. Infect. Drug Resist.16, 3525–3533. doi: 10.2147/IDR.S408956
344
LiQ. Y.LiuB.LiuL. (2021). Successfully controlling the incidence of multidrug-resistant Pseudomonas aeruginosa through antibiotic stewardship and infection control programmes at a Chinese university hospital. J. Clin. Pharm. Ther.46, 1357–1366. doi: 10.1111/jcpt.13446
345
LiX.-F.ShiH.-Q.LiangY.LiJ.JiangB.SongG.-B. (2022). Interaction of biofilm and efflux pump in clinical isolates of carbapenem resistant P. aeruginosa. European Rev. Med. Pharmacol. Sci.26.
346
LicataF.QuirinoA.PepeD.MateraG.BiancoA.Group C (2020). Antimicrobial resistance in pathogens isolated from blood cultures: a two-year multicenter hospital surveillance study in Italy. Antibiotics10:10. doi: 10.3390/antibiotics10010010
347
LinK.-Y.LauderdaleT.-L.WangJ.-T.ChangS.-C. (2016). Carbapenem-resistant Pseudomonas aeruginosa in Taiwan: prevalence, risk factors, and impact on outcome of infections. J. Microbiol. Immunol. Infect.49, 52–59. doi: 10.1016/j.jmii.2014.01.005
348
LinJ.XuC.FangR.CaoJ.ZhangX.ZhaoY.et al. (2019). Resistance and heteroresistance to colistin in Pseudomonas aeruginosa isolates from Wenzhou, China. Antimicrob. Agents Chemother.63, 00556–00519. doi: 10.1128/AAC.00556-19
349
LinZ.ZhaoX.HuangJ.LiuW.ZhengY.YangX.et al. (2019). Rapid screening of colistin-resistant Escherichia coli, Acinetobacter baumannii and Pseudomonas aeruginosa by the use of Raman spectroscopy and hierarchical cluster analysis. Analyst144, 2803–2810. doi: 10.1039/C8AN02220H
350
LiuP. Y.LeeY. L.LuM. C.ShaoP. L.LuP. L.ChenY. H.et al. (2020). National surveillance of antimicrobial susceptibility of Bacteremic gram-negative Bacteria with emphasis on community-acquired resistant isolates: report from the 2019 surveillance of multicenter antimicrobial resistance in Taiwan (SMART). Antimicrob. Agents Chemother.64:64. doi: 10.1128/AAC.01089-20
351
LiuL.LiuB.LiY.ZhangW. (2018). Successful control of resistance in Pseudomonas aeruginosa using antibiotic stewardship and infection control programs at a Chinese university hospital: a 6-year prospective study. Infect. Drug Resist.11, 637–646. doi: 10.2147/IDR.S163853
352
LiuY.-Y.WangY.WalshT. R.YiL.-X.ZhangR.SpencerJ.et al. (2016). Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect. Dis.16, 161–168. doi: 10.1016/S1473-3099(15)00424-7
353
LivermoreD. M.MushtaqS.MeunierD.HopkinsK. L.HillR.AdkinR.et al. (2017). Activity of ceftolozane/tazobactam against surveillance and ‘problem’Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles. J. Antimicrob. Chemother.72, 2278–2289. doi: 10.1093/jac/dkx136
354
LlanesC.PourcelC.RichardotC.PlésiatP.FichantG.CavalloJ. D.et al. (2013). Diversity of β-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study. J. Antimicrob. Chemother.68, 1763–1771. doi: 10.1093/jac/dkt115
355
LobS. H.HawserS. P.SiddiquiF.AlekseevaI.DeRykeC. A.YoungK.et al. (2023). Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland—SMART 2017–2020. Eur. J. Clin. Microbiol. Infect. Dis.42, 365–370. doi: 10.1007/s10096-023-04549-1
356
LockwoodW.LawsonL. A. (1973). Studies on the susceptibility of 150 consecutive clinical isolates of Pseudomonas aeruginosa to tobramycin, gentamicin, colistin, carbenicillin, and five other antimicrobials. Antimicrob. Agents Chemother.4, 281–284. doi: 10.1128/AAC.4.3.281
357
LongshawC.ManisseroD.TsujiM.EcholsR.YamanoY. (2020). In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible gram-negative bacteria from Europe. JAC Antimicrob. Resist.2:60. doi: 10.1093/jacamr/dlaa060
358
López MontesinosI.Gómez-ZorrillaS.Palacios-BaenaZ. R.PrimN.Echeverria-EsnalD.GraciaM. P.et al. (2022). Aminoglycoside or Polymyxin monotherapy for treating complicated urinary tract infections caused by extensively drug-resistant Pseudomonas aeruginosa: a propensity score-adjusted and matched cohort study. Infect. Dis. Ther.11, 335–350. doi: 10.1007/s40121-021-00570-z
359
Lopez-CausapeC.de Dios-CaballeroJ.CoboM.EscribanoA.AsensioO.OliverA.et al. (2017). Antibiotic resistance and population structure of cystic fibrosis Pseudomonas aeruginosa isolates from a Spanish multi-Centre study. Int. J. Antimicrob. Agents50, 334–341. doi: 10.1016/j.ijantimicag.2017.03.034
360
Lopez-CausapeC.Rojo-MolineroE.MuletX.CabotG.MoyaB.FiguerolaJ.et al. (2013). Clonal dissemination, emergence of mutator lineages and antibiotic resistance evolution in Pseudomonas aeruginosa cystic fibrosis chronic lung infection. PLoS One8:e71001. doi: 10.1371/journal.pone.0071001
361
LyN. S.BulittaJ. B.RaoG. G.LandersdorferC. B.HoldenP. N.ForrestA.et al. (2015). Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance. J. Antimicrob. Chemother.70, 1434–1442. doi: 10.1093/jac/dku567
362
MacinS.AkyonY. (2017). Phenotypic and genotypic virulence factors in Pseudomonas aeruginosa strains according to pigment presence. Acta Medica Mediterranea.33, 1033–1038. doi: 10.19193/0393-6384_2017_6_163
363
MacKenzieF.SmithS. V.MilneK.GriffithsK.LeggeJ.GouldI. M. (2004). Antibiograms of resistant gram-negative bacteria from Scottish CF patients. J. Cyst. Fibros.3, 151–157. doi: 10.1016/j.jcf.2004.03.009
364
MaharU.AnwarN.FatimaN.HassanJ.ShamsiT. (2020). Emerging anti-microbial resistance in febrile neutropenia: is it high time to evaluate quality control measures?Pak J Med Sci.36, 1246–1251. doi: 10.12669/pjms.36.6.2138
365
MahdyM. (2022). Isolation and characterization of bacteriophages active against Pseudomonas aeruginosa strains isolated from diabetic foot infections. Archives of Razi Institute.77:2187. doi: 10.22092/ARI.2022.359032.2357
366
MahmoudH.ZakariaS.KishkR.Al-AmirA. (2021). Effect of Meropenem-Colistin and Meropenem-amikacin combinations against Carbapenem-resistant Pseudomonas aeruginosa isolates in Suez Canal university hospitals. Microbes and Infectious Diseases.0:1096. doi: 10.21608/mid.2021.53173.1096
367
MaIM.MaG.-C.LozaE.MaP.-V.BaqueroF.CantónR. (2005). Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips. J. Clin. Microbiol.43, 4480–4485. doi: 10.1128/JCM.43.9.4480-4485.2005
368
MainaJ. W.OnyambuF. G.KibetP. S.MusyokiA. M. (2023). Multidrug-resistant gram-negative bacterial infections and associated factors in a Kenyan intensive care unit: a cross-sectional study. Ann. Clin. Microbiol. Antimicrob.22:85. doi: 10.1186/s12941-023-00636-5
369
MakharitaR. R.El-KholyI.HettaH. F.AbdelazizM. H.HagagyF. I.AhmedA. A.et al. (2020). Antibiogram and genetic characterization of Carbapenem-resistant gram-negative pathogens incriminated in healthcare-associated infections. Infect Drug Resist.13, 3991–4002. doi: 10.2147/IDR.S276975
370
MalekzadeganY.AbdiA.HeidariH.MoradiM.RastegarE.SedighE.-S. H. (2019). In vitro activities of colistin, imipenem and ceftazidime against drug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii isolates in the south of Iran. BMC. Res. Notes12:301. doi: 10.1186/s13104-019-4344-7
371
MallikarjunaP. V.DhanashreeB. (2023). Phenotypic and genotypic characterization of clinical Pseudomonas aeruginosa. J. Taibah Univ. Med. Sci.18, 480–487. doi: 10.1016/j.jtumed.2022.10.012
372
MannoG.CrucianiM.RomanoL.ScapolanS.MentastiM.LoriniR.et al. (2005). Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis Centre. Int. J. Antimicrob. Agents25, 193–197. doi: 10.1016/j.ijantimicag.2004.11.009
373
MansourS. A.EldalyO.Jiman-FataniA.MohamedM. L.IbrahimE. M. (2013). Epidemiological characterization of P. aeruginosa isolates of intensive care units in Egypt and Saudi Arabia. East Mediterr. Health J.19, 71–80. doi: 10.26719/2013.19.1.71
374
MarakiS.MantadakisE.NiotiE.SamonisG. (2015). Susceptibility of 2,252 Pseudomonas aeruginosa clinical isolates over 4 years to 9 antimicrobials in a tertiary Greek hospital. Chemotherapy60, 334–341. doi: 10.1159/000437252
375
MarakiS.MavrosM. N.KofteridisD. P.SamonisG.FalagasM. E. (2012). Epidemiology and antimicrobial sensitivities of 536 multi-drug-resistant gram-negative bacilli isolated from patients treated on surgical wards. Surg. Infect.13, 326–331. doi: 10.1089/sur.2011.115
376
Marteva-ProevskaY.VelinovT.MarkovskaR.DobrikovaD.PavlovI.BoyanovaL.et al. (2021). High level of colistin resistant gram-negative bacteria in a university hospital in Bulgaria. Comptes Rendus de L Academie Bulgare des Sci.74, 899–905. doi: 10.7546/CRABS.2021.06.12
377
MartínezT.VazquezG.AquinoE.GoeringR. V.RobledoI. (2012). Two novel class I integron arrays containing IMP-18 metallo-β-lactamase gene in Pseudomonas aeruginosa clinical isolates from Puerto Rico. Antimicrob. Agents Chemother.56, 2119–2121. doi: 10.1128/AAC.05758-11
378
Mataraci KaraE.YilmazM.Istanbullu TosunA.OzbekC. B. (2020). Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of Pseudomonas aeruginosa. Infect Dis.52, 616–624. doi: 10.1080/23744235.2020.1767803
379
MatuschekE.ÅhmanJ.WebsterC.KahlmeterG. (2018). Antimicrobial susceptibility testing of colistin – evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp. Clin. Microbiol. Infect.24, 865–870. doi: 10.1016/j.cmi.2017.11.020
380
McCrackenM. G.AdamH. J.BlondeauJ. M.WalktyA. J.KarlowskyJ. A.HobanD. J.et al. (2019). Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007–16 study. J. Antimicrob. Chemother.74, iv32–iv38. doi: 10.1093/jac/dkz285
381
MedellM.HartM.DuquesneA.EspinosaF.ValdésR. (2013). Nosocomial ventilator-associated pneumonia in Cuban intensive care units: bacterial species and antibiotic resistance. MEDICC Rev.15, 26–29. doi: 10.37757/MR2013V15.N2.6
382
MedellM.HartM.MarreroO.EspinosaF.OcaZ. M.ValdésR. (2012). Clinical and microbiological characterization of pneumonia in mechanically ventilated patients. Braz. J. Infect. Dis.16, 442–447. doi: 10.1016/j.bjid.2012.08.005
383
MellouliA.ChebbiY.El FatmiR.RaddaouiA.LakhalA.TorjmaneL.et al. (2021). Multidrug resistant bacteremia in hematopoietic stem cell transplant recipients. La Tunisie Medicale99, 269–276
384
MemarM. Y.PormehraliR.AlizadehN.GhotaslouR.BannazadehB. H. (2016). Colistin, an option for treatment of multiple drug resistant Pseudomonas aeruginosa. Physiol Pharmacol.
385
MendesR. E.MendozaM.Banga SinghK. K.CastanheiraM.BellJ. M.TurnidgeJ. D.et al. (2013). Regional resistance surveillance program results for 12 Asia-Pacific nations (2011). Antimicrob. Agents Chemother.57, 5721–5726. doi: 10.1128/AAC.01121-13
386
MeradjiS.BarguiguaA.BentakoukM.NaymeK.ZeroualiK.MazouzD.et al. (2016). Epidemiology and virulence of VIM-4 metallo-beta-lactamase-producing Pseudomonas aeruginosa isolated from burn patients in eastern Algeria. Burns42, 906–918. doi: 10.1016/j.burns.2016.02.023
387
MeradjiS.BarguiguaA.ZeroualiK.MazouzD.ChettibiH.ElmdaghriN.et al. (2015). Epidemiology of carbapenem non-susceptible Pseudomonas aeruginosa isolates in eastern Algeria. Antimicrob. Resist. Infect. Control4:27. doi: 10.1186/s13756-015-0067-2
388
MeschiariM.OrlandoG.KaleciS.BiancoV.SartiM.VenturelliC.et al. (2021). Combined resistance to Ceftolozane-Tazobactam and ceftazidime-avibactam in extensively drug-resistant (XDR) and multidrug-resistant (MDR) Pseudomonas aeruginosa: resistance predictors and impact on clinical outcomes besides implications for antimicrobial stewardship programs. Antibiotics10:1224. doi: 10.3390/antibiotics10101224
389
MickymarayS. (2019). One-step synthesis of Silver nanoparticles using Saudi Arabian Desert seasonal plant Sisymbrium irio and antibacterial activity against multidrug-resistant bacterial strains. Biomol. Ther.9:662. doi: 10.3390/biom9110662
390
MikucionyteG.ZamoranoL.VitkauskieneA.López-CausapéC.JuanC.MuletX.et al. (2016). Nosocomial dissemination of VIM-2-producing ST235 Pseudomonas aeruginosa in Lithuania. Eur. J. Clin. Microbiol. Infect. Dis.35, 195–200. doi: 10.1007/s10096-015-2529-0
391
MilczewskaJ.WolkowiczT.ZacharczukK.MierzejewskaE.KwiatkowskaM.Walicka-SerzyskoK.et al. (2020). Clinical outcomes for cystic fibrosis patients with Pseudomonas aeruginosa cross-infections. Pediatr. Pulmonol.55, 161–168. doi: 10.1002/ppul.24535
392
MilojkovićM.NenadovićŽ.StankovićS.BožićD. D.NedeljkovićN. S.ĆirkovićI.et al. (2020). Phenotypic and genetic properties of susceptible and multidrug-resistant Pseudomonas aeruginosa isolates in southern Serbia. Arh. Hig. Rada Toksikol.71, 231–250. doi: 10.2478/aiht-2020-71-3418
393
MirbagheriS. Z.MeshkatZ.NaderinasabM.RostamiS.NabaviniaM. S.RahmatiM. (2015). Study on imipenem resistance and prevalence of blaVIM1 and blaVIM2 metallo-beta lactamases among clinical isolates of Pseudomonas aeruginosa from Mashhad, northeast of Iran. Iran J. Microbiol.7, 72–78
394
MishraD. R.ShahD. S.ShahN.PrasadJ. N.GuptaP. P.AgrawaalK. K. (2020). Study of microbiological and antibiotic sensitivity pattern of ventilator associated pneumonia (VAP) in ICU of a tertiary care hospital in Nepal. J. Family Med. Prim. Care9, 6171–6176. doi: 10.4103/jfmpc.jfmpc_1430_20
395
MobarakiS.AghazadehM.Soroush BarhaghiM. H.Yousef MemarM.GoliH. R.GholizadehP.et al. (2018). Prevalence of integrons 1, 2, 3 associated with antibiotic resistance in Pseudomonas aeruginosa isolates from northwest of Iran. Biomedicine8:2. doi: 10.1051/bmdcn/2018080102
396
MohamedA. H.MohamudH. A.ArslanE. (2021). Epidemiological characteristics and predisposing factors for surgical site infections caused by bacterial pathogens exhibiting multidrug-resistant patterns. Antibiotics10:622. doi: 10.3390/antibiotics10060622
397
MohamedA. H.Sheikh OmarN. M.OsmanM. M.MohamudH. A.EraslanA.GurM. (2022). Antimicrobial resistance and predisposing factors associated with catheter-associated UTI caused by uropathogens exhibiting multidrug-resistant patterns: a 3-year retrospective study at a tertiary hospital in Mogadishu, Somalia. Trop. Med. Infect. Dis.7:42. doi: 10.3390/tropicalmed7030042
398
MohamedN. M.YoussefA. A. (2011). In vitro activity of tigecycline and comparators against gram-negative bacteria isolated from a tertiary hospital in Alexandria, Egypt. Microb. Drug Resist.17, 489–495. doi: 10.1089/mdr.2010.0195
399
Mohammadi BarzelighiH.BakhshiB.DaraeiB.FazeliH.NasrE. B. (2020). Global sequence analysis and expression of Azurin gene in different clinical specimens of burn patients with Pseudomonas aeruginosa infection. Infect Drug Resist.13, 2261–2275. doi: 10.2147/IDR.S248043
400
MohammadzadehA.MardanehJ.AhmadiR.AdabiJ. (2017). Evaluation of the virulence features and antibiotic resistance patterns of pathogenic Pseudomonas aeruginosa strains isolated from hospitalized patients in Gonabad, Iran. Arch. Pediatric Infect. Dis.In press. doi: 10.5812/pedinfect.41267
401
MohammadzamaniZ.KhorshidiA.KhalediA.ShakerimoghaddamA.MoosaviG. A.PiroozmandA. (2020). Inhibitory effects of Cinnamaldehyde, Carvacrol, and honey on the expression of exoS and ampC genes in multidrug-resistant Pseudomonas aeruginosa isolated from burn wound infections. Microb. Pathog.140:103946. doi: 10.1016/j.micpath.2019.103946
402
MohantyS.MauryaV.GaindR.DebM. (2013). Phenotypic characterization and colistin susceptibilities of carbapenem-resistant of Pseudomonas aeruginosa and Acinetobacter spp. J. Infect. Dev. Ctries.7, 880–887. doi: 10.3855/jidc.2924
403
MoherD.LiberatiA.TetzlaffJ.AltmanD. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med.6, e1000097–e1000096. doi: 10.1371/journal.pmed.1000097
404
MomenahA. M.BakriR. A.JalalN. A.AshgarS. S.FelembanR. F.BantunF.et al. (2023). Antimicrobial resistance pattern of Pseudomonas aeruginosa: An 11-year experience in a tertiary care hospital in Makkah, Saudi Arabia. Infect. Drug Resist.16, 4113–4122. doi: 10.2147/IDR.S409726
405
MonogueM. L.NicolauD. P. (2018). Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa. J. Antimicrob. Chemother.73, 942–952. doi: 10.1093/jac/dkx483
406
MonteroM. M.Domene OchoaS.López-CausapéC.VanScoyB.LuqueS.SorlíL.et al. (2019). Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones. J Glob Antimicrob Resist.18, 37–44. doi: 10.1016/j.jgar.2019.04.012
407
MonteroM.Domene OchoaS.Lopez-CausapeC.VanScoyB.LuqueS.SorliL.et al. (2020). Efficacy of Ceftolozane-Tazobactam in combination with Colistin against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones, in an in vitro Pharmacodynamic model. Antimicrob. Agents Chemother.64:e02542. doi: 10.1128/AAC.02542-19
408
MonteroM. M.López MontesinosI.KnobelH.MolasE.SorlíL.Siverio-ParésA.et al. (2020). Risk factors for mortality among patients with Pseudomonas aeruginosa bloodstream infections: what is the influence of XDR phenotype on outcomes?J. Clin. Med.9:514. doi: 10.3390/jcm9020514
409
MoradiN.KazemiN.GhaemiM.MirzaeiB. (2021). Frequency and antimicrobial resistance pattern of bacterial isolates from patients with COVID-19 in two hospitals of Zanjan. Iranian J. Microbiol.13, 769–778. doi: 10.18502/ijm.v13i6.8078
410
MorataL.Cobos-TriguerosN.MartínezJ. A.SorianoÁ.AlmelaM.MarcoF.et al. (2012). Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother.56, 4833–4837. doi: 10.1128/AAC.00750-12
411
MordiR. M.ErahP. O. (2006). Susceptibility of common urinary isolates to the commonly used antibiotics in a tertiary hospital in southern Nigeria. Afr. J. Biotechnol.5.
412
MorrowB. J.PillarC. M.DeaneJ.SahmD. F.LynchA. S.FlammR. K.et al. (2013). Activities of carbapenem and comparator agents against contemporary US Pseudomonas aeruginosa isolates from the CAPITAL surveillance program. Diagn. Microbiol. Infect. Dis.75, 412–416. doi: 10.1016/j.diagmicrobio.2012.12.012
413
MortezaM.RoyaS.HamedH.AmirZ.AbolfazlA. (2019). Synthesis and evaluation of polymeric micelle containing piperacillin/tazobactam for enhanced antibacterial activity. Drug Deliv.26, 1292–1299. doi: 10.1080/10717544.2019.1693708
414
MostafaS. H.SalehS. E.HamedS. M.AboshanabK. M. (2022). Febrile illness of bacterial etiology in a public fever hospital in Egypt: high burden of multidrug resistance and WHO priority gram negative pathogens. Germs12, 75–85. doi: 10.18683/germs.2022.1308
415
MoubareckC. A.HalatD. H.AkkawiC.NabiA.AlSharhanM. A.AlDeesiZ. O.et al. (2019). Role of outer membrane permeability, efflux mechanism, and carbapenemases in carbapenem-nonsusceptible Pseudomonas aeruginosa from Dubai hospitals: results of the first cross-sectional survey. Int. J. Infect. Dis.84, 143–150. doi: 10.1016/j.ijid.2019.04.027
416
MuletX.Fernandez-EsguevaM.NorteC.ZamoranoL.Del Barrio-TofinoE.OliverA.et al. (2021). Validation of MALDI-TOF for the early detection of the ST175 high-risk clone of Pseudomonas aeruginosa in clinical isolates belonging to a Spanish nationwide multicenter study. Enferm Infect. Microbiol. Clin.39, 279–282. doi: 10.1016/j.eimc.2020.05.022
417
MunnZ.MoolaS.RiitanoD.LisyK. (2014). The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int. J. Health Policy Manag.3, 123–128. doi: 10.15171/ijhpm.2014.71
418
MustafaM. H.ChalhoubH.DenisO.DeplanoA.VergisonA.Rodriguez-VillalobosH.et al. (2016). Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients in northern Europe. Antimicrob. Agents Chemother.60, 6735–6741. doi: 10.1128/AAC.01046-16
419
NaasT.LinaG.Santerre HenriksenA.LongshawC.JehlF. (2021). In vitro activity of cefiderocol and comparators against isolates of gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in France. JAC Antimicrob. Resist.3:dlab081. doi: 10.1093/jacamr/dlab081
420
NairA.PerryA.PerryJ. D.GouldF. K.SamuelJ. (2020). In vitro effects of combined iron chelation, antibiotics and matrix disruption on clinical isolates of Pseudomonas aeruginosa. J. Antimicrob. Chemother.75, 586–592. doi: 10.1093/jac/dkz505
421
NajafiK.KafilH. S.ShokrianS.AzimiS.AsgharzadehM.YousefiM.et al. (2015). Virulence genes and antibiotic resistance profile of Pseudomonas aeruginosa isolates in northwest of Iran. J. Pure Appl. Microbiol.9, 383–389.
422
NarimisaN.GoodarziF.BavariS. (2022). Prevalence of colistin resistance of Klebsiella pneumoniae isolates in Iran: a systematic review and meta-analysis. Ann. Clin. Microbiol. Antimicrob.21:29. doi: 10.1186/s12941-022-00520-8
423
NedeljkovićN. S.TiodorovićB.KocićB.CirićV.MilojkovićM.WaisiH. (2015). Pseudomonas aeruginosa serotypes and resistance to antibiotics from wound swabs. Vojnosanit. Pregl.72, 996–1003. doi: 10.2298/VSP131224108S
424
NegmE. M.ElgharabawyE. S.BadranS. G.RaafatA. O.SolimanS. T.MahmoudH. M.et al. (2023). Analysis of cumulative antibiogram reports in intensive care units at an Egyptian university hospital. J. Infect. Public Health16, 1220–1229. doi: 10.1016/j.jiph.2023.05.032
425
NegmE. M.MowafyS. M.MohammedA. A.AmerM. G.TawfikA. E.IbrahimA. E.et al. (2021). Antibiograms of intensive care units at an Egyptian tertiary care hospital. Egyptian J. Bronchol.15, 1–15. doi: 10.1186/s43168-021-00059-w
426
NelsonR. G.RosowskyA. (2002). Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations. Antimicrob. Agents Chemother.46:940. doi: 10.1128/AAC.46.3.940-940.2002
427
NguyenV. T. K.MontakantikulP.TragulpiankitP.HoungsaitongJ.ShuibM. F. (2021). Colistin dosing regimens against Pseudomonas aeruginosa in critically ill patients: An application of Monte Carlo simulation. Antibiotics10:595. doi: 10.3390/antibiotics10050595
428
NicholsW. W.de JongeB. L.KazmierczakK. M.KarlowskyJ. A.SahmD. F. (2016). In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014). Antimicrob. Agents Chemother.60, 4743–4749. doi: 10.1128/AAC.00220-16
429
NitescuB.PitigoiD.TalapanD.NitescuM.AramaS. S.PavelB.et al. (2023). Etiology and multi-drug resistant profile of bacterial infections in severe burn patients, Romania 2018-2022. Medicina (Kaunas)59:1143. doi: 10.3390/medicina59061143
430
NitzF.de MeloB. O.da SilvaL. C. N.de SouzaM. A.MarquesS. G.Monteiro-NetoV.et al. (2021). Molecular detection of drug-resistance genes of Bla OXA-23-Bla OXA-51 and mcr-1 in clinical isolates of Pseudomonas aeruginosa. Microorganisms9:786. doi: 10.3390/microorganisms9040786
431
NojookambariN. Y.EslamiG.HashemiA.SadredinaminM.TarashiS.RoshaniM.et al. (2019). In vitro antimicrobial activity of Cinnamomum verum, Allium sativum, and Zingiber officinale extracts on metallo-β-lactamase-producing Pseudomonas aeruginosa: A potential therapeutic approach. Acta Microbiologica Hellenica.
432
NolanP. J.JainR.CohenL.FinkleaJ. D.SmithT. T. (2021). In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis. Diagn. Microbiol. Infect. Dis.99:115204. doi: 10.1016/j.diagmicrobio.2020.115204
433
NwabuisiC.OlogeF. E. (2002). Pathogenic agents of chronic suppurative otitis media in Ilorin, Nigeria. East African Med. J.79, 202–205. doi: 10.4314/eamj.v79i4.8879
434
O'CarrollM.SyrmisM.WainwrightC.GreerR.MitchellP.CoulterC.et al. (2004). Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units. Eur. Respir. J.24, 101–106. doi: 10.1183/09031936.04.00122903
435
OdumosuB. T.AdeniyiB. A.Dada-AdegbolaHannahR. C. (2012). Multidrug resistant Pseudomonas aeruginosa from Southwest Nigeria hospitals. Blood3:5.
436
Olowo-okereA.IbrahimY. K. E.EhinmiduJ. O.MohammedY.NabtiL. Z.OlayinkaB. O. (2020). Emergence of VIM metallo-β-lactamase among carbapenem-resistant Pseudomonas species in Northwest Nigeria. Gene Rep.21:100877. doi: 10.1016/j.genrep.2020.100877
437
ÖncülO.ÖksüzS.AcarA.ÜlkürE.TurhanV.UygurF.et al. (2014). Nosocomial infection characteristics in a burn intensive care unit: analysis of an eleven-year active surveillance. Burns40, 835–841. doi: 10.1016/j.burns.2013.11.003
438
OuzzaniM.HammadyH.FedorowiczZ.ElmagarmidA. (2016). Rayyan—a web and mobile app for systematic reviews. Syst. Rev.5, 1–10. doi: 10.1186/s13643-016-0384-4
439
ÖzhakB.ÖğünçD.YıldızE.ÇolakD.GünserenF.ÖngütG. (2019). Evaluation of the BD phoenix100 system and colistin broth disk elution method for antimicrobial susceptibility testing of colistin against gram-negative bacteria. Mikrobiyoloji Bulteni53, 254–261. doi: 10.5578/mb.68066
440
OzsurekciY.AykacK.CengizA. B.BayhanC.SancakB.OncelE. K.et al. (2016). Is colistin effective in the treatment of infections caused by multidrug-resistant (MDR) or extremely drug-resistant (XDR) gram-negative microorganisms in children?Diagn. Microbiol. Infect. Dis.85, 233–238. doi: 10.1016/j.diagmicrobio.2016.02.017
441
OzumbaU. C. (2005). Antimicrobial resistance problems in a university hospital. J. Natl. Med. Assoc.97, 1714–1718
442
PachoriP.GothalwalR.GandhiP. (2019). Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review. Genes Dis.6, 109–119. doi: 10.1016/j.gendis.2019.04.001
443
PancholiP.CarrollK. C.BuchanB. W.ChanR. C.DhimanN.FordB.et al. (2018). Multicenter evaluation of the accelerate PhenoTest BC kit for rapid identification and phenotypic antimicrobial susceptibility testing using morphokinetic cellular analysis. J. Clin. Microbiol.56, e01329–e01317. doi: 10.1128/JCM.01329-17
444
PangZ.RaudonisR.GlickB. R.LinT.-J.ChengZ. (2019). Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol. Adv.37, 177–192. doi: 10.1016/j.biotechadv.2018.11.013
445
PaniA.LuciniV.DugnaniS.SchianchiA.ScaglioneF. (2022). Effects of levofloxacin, Aztreonam, and Colistin on enzyme synthesis by P. aeruginosa isolated from cystic fibrosis patients. Antibiotics11:1114. doi: 10.3390/antibiotics11081114
446
PapagiannitsisC. C.MedveckyM.ChudejovaK.SkalovaA.RotovaV.SpanelovaP.et al. (2017). Molecular characterization of carbapenemase-producing Pseudomonas aeruginosa of Czech origin and evidence for clonal spread of extensively resistant sequence type 357 expressing IMP-7 metallo-β-lactamase. Antimicrob. Agents Chemother.61, 01811–01817. doi: 10.1128/AAC.01811-17
447
PaprockaP.DurnasB.MankowskaA.SklodowskiK.KrolG.ZakrzewskaM.et al. (2021). New beta-lactam antibiotics and Ceragenins – a study to assess their potential in treatment of infections caused by multidrug-resistant strains of Pseudomonas aeruginosa. Infect. Drug Resist.14, 5681–5698. doi: 10.2147/IDR.S338827
448
ParkM. H.KimS. Y.RohE. Y.LeeH. S. (2017). Difference of type 3 secretion system (T3SS) effector gene genotypes (exoU and exoS) and its implication to antibiotics resistances in isolates of Pseudomonas aeruginosa from chronic otitis media. Auris Nasus Larynx44, 258–265. doi: 10.1016/j.anl.2016.07.005
449
ParsaP.AmirmozafariN.NowruziB.BaharM. A. (2020). Molecular characterization of polymorphisms among Pseudomonas aeruginosa strains isolated from burn patients' wounds. Heliyon.6:e05041. doi: 10.1016/j.heliyon.2020.e05041
450
PascaM. R.Dalla ValleC.De Jesus Lopes RibeiroA. L.BuroniS.PapaleoM. C.BazziniS.et al. (2012). Evaluation of fluoroquinolone resistance mechanisms in Pseudomonas aeruginosa multidrug resistance clinical isolates. Microb. Drug Resist.18, 23–32. doi: 10.1089/mdr.2011.0019
451
PatersonD. L.HarrisP. N. (2016). Colistin resistance: a major breach in our last line of defence. Lancet Infect. Dis.16, 132–133. doi: 10.1016/S1473-3099(15)00463-6
452
PechorskyA.NitzanY.LazarovitchT. (2009). Identification of pathogenic bacteria in blood cultures: comparison between conventional and PCR methods. J. Microbiol. Methods78, 325–330. doi: 10.1016/j.mimet.2009.07.008
453
PeñaC.Gómez-ZorrillaS.SuarezC.DominguezM.TubauF.ArchO.et al. (2012). Extensively drug-resistant Pseudomonas aeruginosa: risk of bloodstream infection in hospitalized patients. Eur. J. Clin. Microbiol. Infect. Dis.31, 2791–2797. doi: 10.1007/s10096-012-1629-3
454
PérezA.GatoE.Pérez-LlarenaJ.Fernández-CuencaF.GudeM. J.OviañoM.et al. (2019). High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. J. Antimicrob. Chemother.74, 1244–1252. doi: 10.1093/jac/dkz030
455
PerezF.HujerA. M.MarshallS. H.RayA. J.RatherP. N.SuwantaratN.et al. (2014). Extensively drug-resistant pseudomonas aeruginosa isolates containing blaVIM-2 and elements of Salmonella genomic island 2: a new genetic resistance determinant in Northeast Ohio. Antimicrob. Agents Chemother.58, 5929–5935. doi: 10.1128/AAC.02372-14
456
Pérez-VázquezM.Sola-CampoyP. J.ZuritaÁ. M.ÁvilaA.Gómez-BertomeuF.SolísS.et al. (2020). Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2. Int. J. Antimicrob. Agents56:106026. doi: 10.1016/j.ijantimicag.2020.106026
457
PerovicO.Singh-MoodleyA.LoweM. (2023). In vitro activity of ceftolozane-tazobactam against Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa obtained from blood cultures from sentinel public hospitals in South Africa. Antibiotics.12:453. doi: 10.3390/antibiotics12030453
458
PetcaA. (2021). Bacterial pathogens isolated from surgical site infections and their antibiotic susceptibility. Farmacia69, 741–748. doi: 10.31925/farmacia.2021.4.15
459
PetrovaG.StratevaT.MitevaD.LazovaS.PerenovskaP. (2016). Antimicrobial susceptibility of Pseudomonas aeruginosa before and after initiation of inhaled tobramycin in Bulgaria. J. Infect. Dev. Ctries.10, 1265–1267. doi: 10.3855/jidc.7658
460
PeymaniA.FarivarT. N.GhanbarlouM. M.NajafipourR. (2015). Dissemination of Pseudomonas aeruginosa producing blaIMP-1 and blaVIM-1 in Qazvin and Alborz educational hospitals, Iran. Iran J. Microbiol.7, 302–309.
461
PfallerM. A.FlammR. K.DuncanL. R.MendesR. E.JonesR. N.SaderH. S. (2017). Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 gram-negative organisms from Europe and the Asia-Pacific region (2013-2014). Diagn. Microbiol. Infect. Dis.88, 177–183. doi: 10.1016/j.diagmicrobio.2017.02.020
462
PfallerM.ShortridgeD.ChenW.-T.SaderH.CastanheiraM. (2022). Ceftolozane/tazobactam activity against drug-resistant Pseudomonas aeruginosa and enterobacterales causing healthcare-associated infections in eight Asian countries: report from an antimicrobial surveillance program (2016–2018). Infect. Drug Resist.15, 6739–6753. doi: 10.2147/IDR.S387097
463
PfallerM. A.ShortridgeD.SaderH. S.CastanheiraM.FlammR. K. (2018). Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an antimicrobial surveillance Programme (2013-2015). Int. J. Antimicrob. Agents51, 181–189. doi: 10.1016/j.ijantimicag.2017.09.016
464
Picão RenataC.PoirelL.Gales AnaC.NordmannP. (2009). Diversity of β-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil. Antimicrob. Agents Chemother.53, 3908–3913. doi: 10.1128/AAC.00453-09
465
PierardD.StoneG. G. (2021). In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018). BMC Infect. Dis.21:600. doi: 10.1186/s12879-021-06153-0
466
PittT.SparrowM.WarnerM.StefanidouM. (2003). Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax58, 794–796. doi: 10.1136/thorax.58.9.794
467
PourakbariB.YaslianifardS.YaslianifardS.MahmoudiS.Keshavarz-ValianS.MamishiS. (2016). Evaluation of efflux pumps gene expression in resistant Pseudomonas aeruginosa isolates in an Iranian referral hospital. Iran J Microbiol.8, 249–256
468
PragsamA. K.KumarD. T.DossC. G. P.IyaduraiR.SatyendraS.RodriguesC.et al. (2018). In silico and in vitro activity of ceftolozane/tazobactam against pseudomonas aeruginosa collected across Indian hospitals. Indian J. Med. Microbiol.36, 127–130. doi: 10.4103/ijmm.IJMM_17_349
469
Prasanth ManoharP. M.Thamaraiselvan ShanthiniT. S.Ramankannan AyyanarR. A.BozdoganB.Aruni WilsonA. W.TamhankarA.et al. (2017). The distribution of carbapenem-and colistin-resistance in gram-negative bacteria from the Tamil Nadu region in India. J Med Microbiol66, 874–883. doi: 10.1099/jmm.0.000508
470
PriyadarshiK.DhandapaniS.SivaradjyM.ShanmugamL.SastryA. S. (2023). Feasibility of using ceftazidime-avibactam as a therapeutic option for bloodstream infections caused by multidrug-resistant Enterobacterales and Pseudomonas aeruginosa based on its susceptibility profile. Cureus15:37002. doi: 10.7759/cureus.37002
471
PujjiO. J. S.NakarmiK. K.ShresthaB.RaiS. M.JefferyS. L. A. (2019). The bacteriological profile of burn wound infections at a tertiary Burns Center in Nepal. J. Burn Care Res.40, 838–845. doi: 10.1093/jbcr/irz096
472
QadeerA.AkhtarA.AinQ. U.SaadatS.MansoorS.AssadS.et al. (2016). Antibiogram of medical intensive care unit at tertiary care hospital setting of Pakistan. Cureus8:e809. doi: 10.7759/cureus.809
473
RadanM.MoniriR.KhorshidiA.GilasiH.NorouziZ.BeigiF.et al. (2016). Emerging Carbapenem-resistant Pseudomonas aeruginosa isolates carrying Bla(IMP) among burn patients in Isfahan, Iran. Arch Trauma Res.5:e33664. doi: 10.5812/atr.33664
474
RafalskiyV.PushkarD.YakovlevS.EpsteinO.PutilovskiyM.TarasovS.et al. (2020). Distribution and antibiotic resistance profile of key gram-negative bacteria that cause community-onset urinary tract infections in the Russian Federation: RESOURCE multicentre surveillance 2017 study. J Glob Antimicrob Resist.21, 188–194. doi: 10.1016/j.jgar.2019.09.008
475
RahimiE.AsgariA.AzimiT.Soleiman-MeigooniS. (2021). Molecular detection of carbapenemases and extended-spectrum β-lactamases-encoding genes in clinical isolates of pseudomonas aeruginosa in Iran. Jundishapur J. Microbiol.14:115977. doi: 10.5812/jjm.115977
476
RajenderanS.BalajiV.AnandanS.SahniR. D.TansarliG. S.FalagasM. E. (2014). Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study. PLoS One9:e103253. doi: 10.1371/journal.pone.0103253
477
RamadanR. A.GebrielM. G.KadryH. M.MosallemA. (2018). Carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: characterization of carbapenemase genes and E-test evaluation of colistin-based combinations. Infect Drug Resist.11, 1261–1269. doi: 10.2147/IDR.S170233
478
RamanathanB.JindalH. M.LeC. F.GudimellaR.AnwarA.RazaliR.et al. (2017). Next generation sequencing reveals the antibiotic resistant variants in the genome of Pseudomonas aeruginosa. PLoS One12:e0182524. doi: 10.1371/journal.pone.0182524
479
RashidH.ZebM.JamalQ.WaqarM.FarooqiB.MajidA. (2014). Frequency and antimicrobial susceptibility pattern of Pseudomonas aeruginosa in ear swabs. World Appl. Sci. J.30, 812–817.
480
RattanaumpawanP.UssavasodhiP.KiratisinP.AswapokeeN. (2013). Epidemiology of bacteremia caused by uncommon non-fermentative gram-negative bacteria. BMC Infect. Dis.13:167. doi: 10.1186/1471-2334-13-167
481
RazaM.DasB.GoyalV.LodhaR.ChaudhryR.SoodS.et al. (2019). Emerging multidrug resistance isolates of hospital-acquired bacterial meningitis in a tertiary care Centre in North India. J. Med. Microbiol.68, 1585–1590. doi: 10.1099/jmm.0.001072
482
ReddyR.PathaniaS.KapilA.BakhshiS. (2014). Review of spectrum and sensitivity of bacterial bloodstream isolates in children with malignancy: a retrospective analysis from a single center. Indian J. Cancer51, 425–427. doi: 10.4103/0019-509X.175363
483
RizekC.FuL.Dos SantosL. C.LeiteG.RamosJ.RossiF.et al. (2014). Characterization of carbapenem-resistant Pseudomonas aeruginosa clinical isolates, carrying multiple genes coding for this antibiotic resistance. Ann. Clin. Microbiol. Antimicrob.13:43. doi: 10.1186/s12941-014-0043-3
484
RodulfoH.ArciaA.HernandezA.MichelliE.MartinezD. D. V.GuzmanM.et al. (2019). Virulence factors and integrons are associated with MDR and XDR phenotypes in nosocomial strains of Pseudomonas aeruginosa in a Venezuelan university hospital. Rev. Inst. Med. Trop.61:e20. doi: 10.1590/s1678-9946201961020
485
RolstonK. V.GergesB.ShelburneS.AitkenS. L.RaadI.PrinceR. A. (2020). Activity of cefiderocol and comparators against isolates from cancer patients. Antimicrob. Agents Chemother.64, 01955–01919. doi: 10.1128/AAC.01955-19
486
Rosales-ReyesR.Rodriguez-AlvaradoM.Lezana-FernandezJ. L.Sanchez-LozanoJ. Y.Gayosso-VazquezC.Jarillo-QuijadaM. D.et al. (2020). Pseudomonas aeruginosa isolates from a cohort of Mexican children with cystic fibrosis show adaptation to a chronic phenotype. Pediatr. Infect. Dis. J.39, 899–906. doi: 10.1097/INF.0000000000002714
487
RossoliniG. M.LuzzaroF.MigliavaccaR.MugnaioliC.PiniB.De LucaF.et al. (2008). First countrywide survey of acquired metallo-β-lactamases in gram-negative pathogens in Italy. Antimicrob. Agents Chemother.52, 4023–4029. doi: 10.1128/AAC.00707-08
488
RoutB.DashS. K.Kumar SahuK.BeheraB.PraharajI.OttaS. (2023). Evaluation of different methods for in vitro susceptibility testing of colistin in carbapenem resistant gram-negative Bacilli. Access Microbiol.5:595. doi: 10.1099/acmi.0.000595.v3
489
Roy ChowdhuryP.ScottM.WordenP.HuntingtonP.HudsonB.KaragiannisT.et al. (2016). Genomic islands 1 and 2 play key roles in the evolution of extensively drug-resistant ST235 isolates of Pseudomonas aeruginosa. Open Biol.6:150175. doi: 10.1098/rsob.150175
490
RuekitS.SrijanA.SerichantalergsO.MargulieuxK. R.Mc GannP.MillsE. G.et al. (2022). Molecular characterization of multidrug-resistant ESKAPEE pathogens from clinical samples in Chonburi, Thailand (2017–2018). BMC Infect. Dis.22:695. doi: 10.1186/s12879-022-07678-8
491
RuhE.GaziU.GüvenirM.SüerK.ÇakırN. (2016). Antibiotic resistance rates of Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae isolated from a university-affiliated hospital in North Cyprus. Turk Hij Den Biyol Derg.73, 333–344. doi: 10.5505/TurkHijyen.2016.82653
492
Ruiz-RoldanL.BellesA.BuenoJ.Azcona-GutierrezJ. M.Rojo-BezaresB.TorresC.et al. (2018). Pseudomonas aeruginosa isolates from Spanish children: occurrence in Faecal samples, antimicrobial resistance, virulence, and molecular typing. Biomed. Res. Int.2018, 1–8. doi: 10.1155/2018/8060178
493
SachaP.MichalskaA.OjdanaD.WieczorekP.HauschildT.MajewskiP.et al. (2015). Identification of plasmid OXA and other β-lactamase genes among carbapenem-resistant isolates of Pseudomonas aeruginosa from the clinical university hospital in northeastern Poland. New Microbiol.38, 271–275
494
SaderH. S.CarvalhaesC. G.DuncanL. R.FlammR. K.ShortridgeD. (2020a). Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European gram-negative bacterial surveillance isolates collected during 2012-18. J. Antimicrob. Chemother.75, 2907–2913. doi: 10.1093/jac/dkaa278
495
SaderH. S.CarvalhaesC. G.StreitJ. M.CastanheiraM.FlammR. K. (2020b). Antimicrobial activity of cefoperazone-sulbactam tested against gram-negative organisms from Europe, Asia-Pacific, and Latin America. Int. J. Infect. Dis.91, 32–37. doi: 10.1016/j.ijid.2019.11.006
496
SaderH. S.CastanheiraM.ArendsS. J. R.GoossensH.FlammR. K. (2019). Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY antimicrobial surveillance program (1997-2016). J. Antimicrob. Chemother.74, 1595–1606. doi: 10.1093/jac/dkz074
497
SaderH. S.CastanheiraM.DuncanL. R.FlammR. K. (2018a). Antimicrobial susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers stratified by infection type: results from the international network for optimal resistance monitoring (INFORM) surveillance program, 2015-2016. Diagn. Microbiol. Infect. Dis.92, 69–74. doi: 10.1016/j.diagmicrobio.2018.04.012
498
SaderH. S.CastanheiraM.FarrellD. J.FlammR. K.JonesR. N. (2015a). Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from unites states medical centers (2011-2014). Diagn. Microbiol. Infect. Dis.83, 389–394. doi: 10.1016/j.diagmicrobio.2015.06.008
499
SaderH. S.CastanheiraM.FlammR. K. (2017a). Antimicrobial activity of ceftazidime-avibactam against gram-negative Bacteria isolated from patients hospitalized with pneumonia in U.S. medical centers, 2011 to 2015. Antimicrob. Agents Chemother.61:e02083. doi: 10.1128/AAC.02083-16
500
SaderH. S.CastanheiraM.FlammR. K.JonesR. N. (2016). Antimicrobial activities of ceftazidime-avibactam and comparator agents against gram-negative organisms isolated from patients with urinary tract infections in U.S. medical centers, 2012 to 2014. Antimicrob. Agents Chemother.60, 4355–4360. doi: 10.1128/AAC.00405-16
501
SaderH. S.CastanheiraM.HubandM.JonesR. N.FlammR. K. (2017b). WCK 5222 (Cefepime-Zidebactam) antimicrobial activity against clinical isolates of gram-negative Bacteria collected worldwide in 2015. Antimicrob. Agents Chemother.61:e00072. doi: 10.1128/AAC.00072-17
502
SaderH. S.CastanheiraM.JonesR. N.FlammR. K. (2017c). Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014). Diagn. Microbiol. Infect. Dis.87, 261–265. doi: 10.1016/j.diagmicrobio.2016.11.019
503
SaderH. S.CastanheiraM.MendesR. E.FlammR. K. (2018b). Frequency and antimicrobial susceptibility of gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17). J. Antimicrob. Chemother.73, 3053–3059. doi: 10.1093/jac/dky279
504
SaderH. S.CastanheiraM.ShortridgeD.MendesR. E.FlammR. K. (2017d). Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from U.S. medical centers, 2013 to 2016. Antimicrob. Agents Chemother.61:e01045. doi: 10.1128/AAC.01045-17
505
SaderH. S.DuncanL. R.DoyleT. B.CastanheiraM. (2021a). Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients. JAC Antimicrob. Resist.3. doi: 10.1093/jacamr/dlab126
506
SaderH. S.FarrellD. J.CastanheiraM.FlammR. K.JonesR. N. (2014a). Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). J. Antimicrob. Chemother.69, 2713–2722. doi: 10.1093/jac/dku184
507
SaderH. S.FarrellD. J.FlammR. K.JonesR. N. (2014b). Antimicrobial susceptibility of gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagn. Microbiol. Infect. Dis.78, 443–448. doi: 10.1016/j.diagmicrobio.2013.11.025
508
SaderH. S.FarrellD. J.FlammR. K.JonesR. N. (2014c). Ceftolozane/tazobactam activity tested against aerobic gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). J. Infect.69, 266–277. doi: 10.1016/j.jinf.2014.04.004
509
SaderH. S.FlammR. K.CarvalhaesC. G.CastanheiraM. (2018c). Antimicrobial susceptibility of Pseudomonas aeruginosa to ceftazidime-avibactam, Ceftolozane-Tazobactam, piperacillin-Tazobactam, and Meropenem stratified by U.S. Census divisions: results from the 2017 INFORM program. Antimicrob. Agents Chemother.62:62. doi: 10.1128/AAC.01587-18
510
SaderH. S.FlammR. K.DaleG. E.RhombergP. R.CastanheiraM. (2018d). Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa. J. Antimicrob. Chemother.73, 2400–2404. doi: 10.1093/jac/dky227
511
SaderH. S.FlammR. K.PfallerM. A.CastanheiraM. (2018e). 1004. Frequency of occurrence and antimicrobial susceptibility of Bacteria isolated from patients hospitalized with bloodstream infections in United States medical centers (2015–2017). Open forum infectious diseases. Oxford: Oxford University Press.
512
SaderH. S.HubandM. D.CastanheiraM.FlammR. K. (2017e). Pseudomonas aeruginosa antimicrobial susceptibility results from four years (2012 to 2015) of the international network for optimal resistance monitoring program in the United States. Antimicrob. Agents Chemother.61:514. doi: 10.1128/AAC.02252-16
513
SaderH. S.RhombergP. R.FarrellD. J.JonesR. N. (2015b). Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia. Antimicrob. Agents Chemother.59, 3263–3270. doi: 10.1128/AAC.04839-14
514
SaderH. S.StreitJ. M.CarvalhaesC. G.HubandM. D.ShortridgeD.MendesR. E.et al. (2021b). Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from respiratory samples of patients hospitalized with pneumonia in Western Europe, Eastern Europe and the USA: results from the SENTRY antimicrobial surveillance program (2016–19). JAC-Antimicrob. Resist.3:dlab117. doi: 10.1093/jacamr/dlab117
515
SaderiH.OwliaP.Detection of Multidrug Resistant (MDR) and Extremely Drug Resistant (XDR) P (2015). aeruginosa isolated from patients in Tehran, Iran. Iran J Pathol.10, 265–271
516
SadikotR. T.BlackwellT. S.ChristmanJ. W.PrinceA. S. (2005). Pathogen–host interactions in Pseudomonas aeruginosa pneumonia. Am. J. Respir. Crit. Care Med.171, 1209–1223. doi: 10.1164/rccm.200408-1044SO
517
SaffariM.KaramiS.FiroozehF.SehatM. (2017). Evaluation of biofilm-specific antimicrobial resistance genes in Pseudomonas aeruginosa isolates in Farabi hospital. J. Med. Microbiol.66, 905–909. doi: 10.1099/jmm.0.000521
518
SaleemS.BokhariH. (2020). Resistance profile of genetically distinct clinical Pseudomonas aeruginosa isolates from public hospitals in Central Pakistan. J. Infect. Public Health13, 598–605. doi: 10.1016/j.jiph.2019.08.019
519
SaleemZ.HaseebA.AbuhussainS. S. A.MooreC. E.KamranS. H.QamarM. U.et al. (2023). Antibiotic susceptibility surveillance in the Punjab Province of Pakistan: findings and implications. Medicina (Kaunas)59:1215. doi: 10.3390/medicina59071215
520
SaleemM.Syed KhajaA. S.HossainA.AlenaziF.SaidK. B.MoursiS. A.et al. (2023). Pathogen burden among ICU patients in a tertiary care hospital in hail Saudi Arabia with particular reference to β-lactamases profile. Infect. Drug Resist.16, 769–778. doi: 10.2147/IDR.S394777
521
SaleemM.Syed KhajaA. S.HossainA.AlenaziF.SaidK. B.MoursiS. A.et al. (2022). Catheter-associated urinary tract infection in intensive care unit patients at a tertiary care hospital, hail, kingdom of Saudi Arabia. Diagnostics.12:1695. doi: 10.3390/diagnostics12071695
522
SalimizandH.LotfiG.AfrasiabianS.HajibagheriK.BabahajianA.MohammadiS. (2023). Mortality and outcomes of patients infected with extensively drug-resistant Bacteria admitted to intensive care units. Arch. Clin. Infect. Dis.18:e132030. doi: 10.5812/archcid-132030
523
SamonisG.MarakiS.KarageorgopoulosD.VouloumanouE.FalagasM. (2012). Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur. J. Clin. Microbiol. Infect. Dis.31, 695–701. doi: 10.1007/s10096-011-1360-5
524
SamonisG.MarakiS.RafailidisP. I.KapaskelisA.KastorisA. C.FalagasM. E. (2010). Antimicrobial susceptibility of gram-negative nonurinary bacteria to fosfomycin and other antimicrobials. Future Microbiol.5, 961–970. doi: 10.2217/fmb.10.47
525
SamonisG.MarakiS.VouloumanouE.GeorgantziG.KofteridisD.FalagasM. (2012). Antimicrobial susceptibility of non-fermenting gram-negative isolates to isepamicin in a region with high antibiotic resistance. Eur. J. Clin. Microbiol. Infect. Dis.31, 3191–3198. doi: 10.1007/s10096-012-1684-9
526
Sanchez-LopezJ.Cortes-CuevasJ. L.Diez-AguilarM.Lopez-CausapeC.CantonR.MorosiniM. I. (2021). Evaluation of rapid Polymyxin Pseudomonas test in clinical Pseudomonas aeruginosa isolates with various degrees of multidrug resistance. JAC Antimicrob. Resist.3:dlab104. doi: 10.1093/jacamr/dlab104
527
SantellaB.SerretielloE.De FilippisA.VeronicaF.IervolinoD.Dell'AnnunziataF.et al. (2021). Lower respiratory tract pathogens and their antimicrobial susceptibility pattern: a 5-year study. Antibiotics10:851. doi: 10.3390/antibiotics10070851
528
SantimaleeworagunW.ThunyaharnS.JuntanawiwatP.ThongnoyN.HarindhanavudhiS.NakeesathitS.et al. (2020). The prevalence of colistin-resistant gram-negative bacteria isolated from hospitalized patients with bacteremia. J. Appl. Pharmaceutical Sci.10, 56–59. doi: 10.7324/JAPS.2020.102009
529
SarwatT.YousufM.KhanA. S.KakruD. K.DuttaR. (2021). Prevalence and antibiogram of non-fermenting gram-negative bacilli in blood stream infections: study in a tertiary care Centre, Western Uttar Pradesh, India. Trop Doct.51, 322–325. doi: 10.1177/0049475520979298
530
SchaumburgF.Vas NunesJ.MönninkG.FalamaA.-M.BanguraJ.MathéronH.et al. (2022). Chronic wounds in Sierra Leone: pathogen spectrum and antimicrobial susceptibility. Infection50, 907–914. doi: 10.1007/s15010-022-01762-6
531
SchechnerV.GottesmanT.SchwartzO.KoremM.MaorY.RahavG.et al. (2011). Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy. Diagn. Microbiol. Infect. Dis.71, 38–45. doi: 10.1016/j.diagmicrobio.2011.05.010
532
SchülinT. (2002). In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J. Antimicrob. Chemother.49, 403–406. doi: 10.1093/jac/49.2.403
533
SealeT. W.ThirkillH.TarpayM.FluxM.RennertO. M. (1979). Serotypes and antibiotic susceptibilities of Pseudomonas aeruginosa isolates from single sputa of cystic fibrosis patients. J. Clin. Microbiol.9, 72–78. doi: 10.1128/jcm.9.1.72-78.1979
534
SefraouiI.BerrazegM.DrissiM.RolainJ. M. (2014). Molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa clinical strains isolated from western Algeria between 2009 and 2012. Microb. Drug Resist.20, 156–161. doi: 10.1089/mdr.2013.0161
535
SeifertH.Körber-IrrgangB.KreskenM. (2018). In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany. Int. J. Antimicrob. Agents51, 227–234. doi: 10.1016/j.ijantimicag.2017.06.024
536
ŞenS.CesurS.YilmazN. (2016). In vitro synergistic efficacy of various antibiotic combinations against multi-drug-resistant Pseudomonas aeruginosa isolates obtained from patients in intensive care units. Acta Med. Austriaca32:1041.
537
SendraE.López MontesinosI.Rodriguez-AlarcónA.DuJ.Siverio-ParésA.Arenas-MirasM.et al. (2022). Comparative analysis of complicated urinary tract infections caused by extensively drug-resistant pseudomonas aeruginosa and extended-spectrum β-lactamase-producing klebsiella pneumoniae. Antibiotics11:1511. doi: 10.3390/antibiotics11111511
538
ShahriF. N.IzanlooA.GoharriziM. A. S. B.JamaliA.BagheriH.HjimohammadiA.et al. (2022). Antimicrobial resistance, virulence factors, and genotypes of Pseudomonas aeruginosa clinical isolates from Gorgan, northern Iran. Int. Microbiol.25, 709–721. doi: 10.1007/s10123-022-00256-7
539
SharanH.KatareN.PandeyA.BhatambareG. S.BajpaiT. (2016). Emergence of hospital acquired Carbapenem resistant non-fermenters in teaching institute. J. Clin. Diagn. Res.10, Dc20–dc3. doi: 10.7860/JCDR/2016/22607.9020
540
ShariatiA.AzimiT.ArdebiliA.ChiraniA.BahramianA.PormohammadA.et al. (2018). Insertional inactivation of oprD in carbapenem-resistant Pseudomonas aeruginosa strains isolated from burn patients in Tehran, Iran. New Microbes New Infect.21, 75–80. doi: 10.1016/j.nmni.2017.10.013
541
SharifiH.PouladfarG.ShakibaieM. R.PourabbasB.MardanehJ.MansouriS. (2019). Prevalence of beta-lactamase genes, class 1 integrons, major virulence factors and clonal relationships of multidrug-resistant Pseudomonas aeruginosa isolated from hospitalized patients in southeast of Iran. Iran. J. Basic Med. Sci.22, 806–812. doi: 10.22038/ijbms.2019.35063.8340
542
SharmaS.DevkotaM. D.PokhrelB. M.BanjaraM. R. (2023). Detection of Bla(NDM-1,)mcr-1 and MexB in multidrug resistant Pseudomonas aeruginosa isolated from clinical specimens in a tertiary care hospital of Nepal. BMC Microbiol.23:153. doi: 10.1186/s12866-023-02906-w
543
SharmaJ.SharmaD.SinghA.SunitaK. (2022). Colistin resistance and management of drug resistant infections. Can. J. Infect. Dis. Med. Microbiol.2022, 1–10. doi: 10.1155/2022/4315030
544
SherchanJ. B.DongolA.HumagainS.JoshiA.MagarS. R.BhandariS. (2022). Antibiotic susceptibility pattern of Bacteria causing urinary tract infection. Nepal Health Research Council.
545
SherchanJ. B.HumagainS. (2020). Antimicrobial susceptibility pattern of gram-negative bacteria causing lower respiratory tract infections in Kathmandu university hospital. J Nepal Health Res Counc18, 661–666. doi: 10.33314/jnhrc.v18i4.2566
546
ShethK. V.PatelT. K.MalekS. S.TripathiC. (2012a). Antibiotic sensitivity pattern of bacterial isolates from the intensive care unit of a tertiary care hospital in India. Trop. J. Pharm. Res.11, 991–999.
547
ShethK. V.PatelT. K.TripathiC. (2012b). Antibiotic sensitivity pattern in neonatal intensive care unit of a tertiary care hospital of India. Asian J. Pharm. Clin. Res.5, 46–50.
548
ShiralizadehS.KeramatF.HashemiS. H.MajzoobiM. M.AzimzadehM.AlikhaniM. S.et al. (2023). Investigation of antimicrobial resistance patterns and molecular typing of Pseudomonas aeruginosa isolates among coronavirus disease-19 patients. BMC Microbiol.23:84. doi: 10.1186/s12866-023-02825-w
549
ShivshettyN.KelmaniC.PatilS. (2020). Imipenem resistance mechanisms in multidrug resistant Pseudomonas aeruginosa clinical isolates from South India. Res. J. Biotechnol.15, 80–85.
550
ShortridgeD.CarvalhaesC.DeshpandeL.CastanheiraM. (2021a). Activity of meropenem/vaborbactam and comparators against gram-negative isolates from eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014–19). J. Antimicrob. Chemother.76, 2600–2605. doi: 10.1093/jac/dkab252
551
ShortridgeD.CarvalhaesC. G.StreitJ. M.FlammR. K. (2021b). Susceptibility trends of ceftolozane/tazobactam and comparators when tested against U.S. gram-negative bacterial surveillance isolates (2012-2018). Diagn. Microbiol. Infect. Dis.100:115302. doi: 10.1016/j.diagmicrobio.2020.115302
552
ShortridgeD.CastanheiraM.PfallerM. A.FlammR. K. (2017). Ceftolozane-tazobactam activity against Pseudomonas aeruginosa clinical isolates from US hospitals: report from the PACTS antimicrobial surveillance program, 2012 to 2015. Antimicrob. Agents Chemother.61, 00465–00417. doi: 10.1128/AAC.00465-17
553
ShortridgeD.DuncanL. R.PfallerM. A.FlammR. K. (2019a). Activity of ceftolozane-tazobactam and comparators when tested against gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme. Int. J. Antimicrob. Agents53, 637–643. doi: 10.1016/j.ijantimicag.2019.01.015
554
ShortridgeD.GalesA. C.StreitJ. M.HubandM. D.TsakrisA.JonesR. N. (2019b). Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa over 20 years from the SENTRY antimicrobial surveillance program, 1997-2016. Open Forum Infect. Dis.6, S63–S68. doi: 10.1093/ofid/ofy343
555
ShortridgeD.PfallerM. A.ArendsS. J. R.RaddatzJ.DePestelD. D.FlammR. K. (2019c). Comparison of the in vitro susceptibility of Ceftolozane-Tazobactam with the cumulative susceptibility rates of standard antibiotic combinations when tested against Pseudomonas aeruginosa from ICU patients with bloodstream infections or pneumonia. Open Forum Infect. Dis.6:ofz240. doi: 10.1093/ofid/ofz240
556
ShortridgeD.PfallerM. A.CastanheiraM.FlammR. K. (2018). Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013-2015) as part of the program to assess Ceftolozane-Tazobactam susceptibility (PACTS) surveillance program. Diagn. Microbiol. Infect. Dis.92, 158–163. doi: 10.1016/j.diagmicrobio.2018.05.011
557
ShortridgeD.PfallerM. A.StreitJ. M.FlammR. K. (2020). Antimicrobial activity of ceftolozane/tazobactam tested against contemporary (2015-2017) Pseudomonas aeruginosa isolates from a global surveillance programme. J. Glob. Antimicrob. Resist.21, 60–64. doi: 10.1016/j.jgar.2019.10.009
558
ShortridgeD.StreitJ. M.MendesR.CastanheiraM. (2022). In vitro activity of cefiderocol against US and European gram-negative clinical isolates collected in 2020 as part of the SENTRY antimicrobial surveillance program. Microbiol. Spectrum10, e02712–e02721. doi: 10.1128/spectrum.02712-21
559
ShravaniV.SelviG. A. S.MantravadiH. (2023). Detection of quorum sensing virulence factor genes and its consanguinity to antibiotic sensitivity profile in the clinical isolates of Pseudomonas aeruginosa. Iran. J. Basic Med. Sci.26, 899–905. doi: 10.22038/IJBMS.2023.67981.14992
560
Sid AhmedM. A.Abdel HadiH.Abu JarirS.Al KhalA. L.Al-MaslamaniM. A.JassJ.et al. (2020). Impact of an antimicrobial stewardship programme on antimicrobial utilization and the prevalence of MDR Pseudomonas aeruginosa in an acute care hospital in Qatar. JAC Antimicrob. Resist.2:dlaa050. doi: 10.1093/jacamr/dlaa050
561
Sid AhmedM. A.Abdel HadiH.HassanA. A. I.Abu JarirS.Al-MaslamaniM. A.EltaiN. O.et al. (2019). Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar. J. Antimicrob. Chemother.74, 3497–3504. doi: 10.1093/jac/dkz379
562
Sid AhmedM. A.HamidJ. M.HusainA. A.HadiH. A.SkariahS.SultanA. A.et al. (2021). Clinical outcomes, molecular epidemiology and resistance mechanisms of multidrug-resistant Pseudomonas aeruginosa isolated from bloodstream infections from Qatar. Ann. Med.53, 2345–2353. doi: 10.1080/07853890.2021.2012588
563
Sid AhmedM. A.PetkarH. M.SalehT. M.AlbirairM.ArisgadoL. A.EltayebF. K.et al. (2023). The epidemiology and microbiological characteristics of infections caused by gram-negative bacteria in Qatar: national surveillance from the study for monitoring of antimicrobial resistance trends (SMART): 2017 to 2019. JAC Antimicrob. Resist.5:dlad086. doi: 10.1093/jacamr/dlad086
564
SimarS.SibleyD.AshcraftD.PankeyG. (2017). Colistin and polymyxin B minimal inhibitory concentrations determined by Etest found unreliable for gram-negative bacilli. Ochsner J.17, 239–242
565
SinghalT.ShahS.ThakkarP.NaikR. (2019). The incidence, aetiology and antimicrobial susceptibility of central line-associated bloodstream infections in intensive care unit patients at a private tertiary care hospital in Mumbai, India. Indian J Med Microbiol.37, 521–526. doi: 10.4103/ijmm.IJMM_20_3
566
Singh-MoodleyA.DuseA.NaickerP.KularatneR.NanaT.LekalakalaR.et al. (2018). Laboratory based antimicrobial resistance surveillance for Pseudomonas aeruginosa blood isolates from South Africa. J. Infect. Dev. Ctries.12, 616–624. doi: 10.3855/jidc.9539
567
SleimanA.AbdelkhalekP.DoumatG.AtallahF.HamadehL.MoussaP.et al. (2023). The under investigated facet of the COVID-19 pandemic: molecular analysis of secondary bacterial infections at a COVID dedicated intensive care unit within a tertiary care center in Lebanon. Front. Med.10:1001476. doi: 10.3389/fmed.2023.1001476
568
SolimanA. M.ZaradH. O.NariyaH.ShimamotoT.ShimamotoT. (2020). Genetic analysis of carbapenemase-producing gram-negative bacteria isolated from a university teaching hospital in Egypt. Infect. Genet. Evol.77:104065. doi: 10.1016/j.meegid.2019.104065
569
SoniM.KapoorG.PerumalN.ChaurasiaD. (2023). Emergence of multidrug-resistant non-fermenting gram-negative Bacilli in a tertiary care teaching Hospital of Central India: is Colistin resistance still a distant threat?Cureus15:e39243. doi: 10.7759/cureus.39243
570
StoneG. G.Ponce-de-LeonA. (2020). In vitro activity of ceftazidime/avibactam and comparators against gram-negative bacterial isolates collected from Latin American centres between 2015 and 2017. J. Antimicrob. Chemother.75, 1859–1873. doi: 10.1093/jac/dkaa089
571
StoneG. G.SmayevskyJ.KazmierczakK. (2020). Longitudinal analysis of the in vitro activity of ceftazidime-avibactam vs. Pseudomonas aeruginosa, 2012-2016. Diagn. Microbiol. Infect. Dis.96:114835. doi: 10.1016/j.diagmicrobio.2019.05.007
572
StracquadanioS.TortiE.LongshawC.HenriksenA. S.StefaniS. (2021). In vitro activity of cefiderocol and comparators against isolates of gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in Italy. J. Glob. Antimicrob. Resist.25, 390–398. doi: 10.1016/j.jgar.2021.04.019
573
TacconelliE.CarraraE.SavoldiA.HarbarthS.MendelsonM.MonnetD. L.et al. (2018). Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis.18, 318–327. doi: 10.1016/S1473-3099(17)30753-3
574
TadaT.HishinumaT.WatanabeS.UchidaH.TohyaM.Kuwahara-AraiK.et al. (2019). Molecular characterization of multidrug-resistant Pseudomonas aeruginosa isolates in hospitals in Myanmar. Antimicrob. Agents Chemother.63, 02397–02318. doi: 10.1128/AAC.02397-18
575
TadaT.Miyoshi-AkiyamaT.KatoY.OhmagariN.TakeshitaN.HungN. V.et al. (2013). Emergence of 16S rRNA methylase-producing Acinetobacter baumannii and Pseudomonas aeruginosa isolates in hospitals in Vietnam. BMC Infect. Dis.13:251. doi: 10.1186/1471-2334-13-251
576
TahmasebiH.DehbashiS.AlikhaniM. Y.PorbaranM.ArabestaniM. R. (2020a). Prevalence and molecular typing of Metallo-β-lactamase-producing Pseudomonas aeruginosa with adhesion factors: a descriptive analysis of burn wounds isolates from Iran. Gene Reports21:100853. doi: 10.1016/j.genrep.2020.100853
577
TahmasebiH.DehbashiS.ArabestaniM. R. (2020b). Prevalence and molecular typing of Colistin-resistant Pseudomonas aeruginosa (CRPA) among beta-lactamase-producing isolates: a study based on high-resolution melting curve analysis method. Infect Drug Resist.13, 2943–2955. doi: 10.2147/IDR.S264796
578
TahmasebiH.DehbashiS.ArabestaniM. R. (2020c). Co-harboring of mcr-1 and β-lactamase genes in Pseudomonas aeruginosa by high-resolution melting curve analysis (HRMA): molecular typing of superbug strains in bloodstream infections (BSI). Infect. Genet. Evol.85:104518. doi: 10.1016/j.meegid.2020.104518
579
TakahashiT.TadaT.ShresthaS.HishinumaT.SherchanJ. B.TohyaM.et al. (2021). Molecular characterisation of carbapenem-resistant Pseudomonas aeruginosa clinical isolates in Nepal. J Glob Antimicrob Resist.26, 279–284. doi: 10.1016/j.jgar.2021.07.003
580
TalebM. H.ElmanamaA. A.TalebA. H.TawfickM. M. (2023). Pre-and post-COVID-19 antimicrobial resistance profile of bacterial pathogens, a comparative study in a tertiary hospital. J. Infect. Dev. Ctries.17, 597–609. doi: 10.3855/jidc.17791
581
Talebi Bezmin AbadiA.RizvanovA. A.HaertléT.BlattN. L. (2019). World health organization report: current crisis of antibiotic resistance. BioNanoScience9, 778–788. doi: 10.1007/s12668-019-00658-4
582
TalebiG.Hakemi-ValaM. (2019). Survey on some carbapenems and colistin resistance genes among Pseudomonas aeruginosa isolates from burn and cystic fibrosis patients, Tehran, Iran. Archives of. Clin. Infect. Dis.14:e93651. doi: 10.5812/archcid.93651
583
TanT. Y.NgL. S. Y. (2006). Comparison of three standardized disc susceptibility testing methods for colistin. J. Antimicrob. Chemother.58, 864–867. doi: 10.1093/jac/dkl330
584
TantisiriwatW.BuppanharunJ.EkpanyaskulC.OnruangK.YungyuenT.KiratisinP.et al. (2022). In vitro activity of ceftolozane-tazobactam and other antibiotics against Pseudomonas aeruginosa infection-isolates from an academic medical center in Thailand. Antibiotics.11:732. doi: 10.3390/antibiotics11060732
585
TarashiS.GoudarziH.ErfanimaneshS.PormohammadA.HashemiA. (2016). Phenotypic and molecular detection of metallo-beta-lactamase genes among imipenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii strains isolated from patients with burn injuries. Archives of. Clin. Infect. Dis.11:e39036. doi: 10.5812/archcid.39036
586
TaylorE.BalA. M.BalakrishnanI.BrownN. M.BurnsP.ClarkM.et al. (2021). A prospective surveillance study to determine the prevalence of 16S rRNA methyltransferase-producing gram-negative bacteria in the UK. J. Antimicrob. Chemother.76, 2428–2436. doi: 10.1093/jac/dkab186
587
Tchakal-MesbahiA.MetrefM.SinghV. K.AlmpaniM.RahmeL. G. (2021). Characterization of antibiotic resistance profiles in Pseudomonas aeruginosa isolates from burn patients. Burns47, 1833–1843. doi: 10.1016/j.burns.2021.03.005
588
TekinR.DalT.PirincciogluH.OygucuS. E. (2013). A 4-year surveillance of device-associated nosocomial infections in a neonatal intensive care unit. Pediatr. Neonatol.54, 303–308. doi: 10.1016/j.pedneo.2013.03.011
589
TenoverF. C.NicolauD. P.GillC. M. (2022). Carbapenemase-producing Pseudomonas aeruginosa-an emerging challenge. Emerg. Microbes Infect.11, 811–814. doi: 10.1080/22221751.2022.2048972
590
ThabetA.AhmedS.EsmatM. (2022). Emergence of Colistin-resistant Pseudomonas aeruginasa in Sohag University hospitals, Egypt. Microbes and Infectious Diseases.0, 958–971. doi: 10.21608/mid.2022.150919.1352
591
ThapaT. B.PokhrelS.LamichhaneA.SinghV. K.ShresthaO.SapkotaM.et al. (2023). Prevalence and antibiogram of bacteria causing urinary tract infection among patients with chronic kidney disease. Open Med.18:20230824. doi: 10.1515/med-2023-0824
592
ThelenP.HenriksenA. S.LongshawC.YamanoY.CaldwellB.HamprechtA. (2022). In vitro activity of cefiderocol against gram-negative bacterial pathogens in Germany. J. Global Antimicrob. Resist.28, 12–17. doi: 10.1016/j.jgar.2021.10.029
593
TiengrimS.MootsikapunP.WonglakornL.ChangpradubD.ThunyaharnS.TantisiriwatW.et al. (2017). Comparative in vitro activity of Sitafloxacin against Bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections in 2016. J. Med. Assoc. Thail.100.
594
TohamyS. T.AboshanabK. M.El-MahallawyH. A.El-AnsaryM. R.AfifiS. S. (2018). Prevalence of multidrug-resistant gram-negative pathogens isolated from febrile neutropenic cancer patients with bloodstream infections in Egypt and new synergistic antibiotic combinations. Infect. Drug Resist.11, 791–803. doi: 10.2147/IDR.S163293
595
TsitsopoulosP. P.IosifidisE.AntachopoulosC.AnestisD. M.KarantaniE.KaryotiA.et al. (2016). Nosocomial bloodstream infections in neurosurgery: a 10-year analysis in a center with high antimicrobial drug-resistance prevalence. Acta Neurochir.158, 1647–1654. doi: 10.1007/s00701-016-2890-5
596
TumbarelloM.De PascaleG.TrecarichiE. M.SpanuT.AntonicelliF.MavigliaR.et al. (2013). Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med.39, 682–692. doi: 10.1007/s00134-013-2828-9
597
TumbarelloM.RepettoE.TrecarichiE. M.BernardiniC.De PascaleG.ParisiniA.et al. (2011). Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Epidemiol. Infect.139, 1740–1749. doi: 10.1017/S0950268810003055
598
TuonF. F.CieslinskiJ.RodriguesS. D. S.SerraF. B.PaulaM. D. (2020). Evaluation of in vitro activity of ceftolozane-tazobactam against recent clinical bacterial isolates from Brazil – the EM200 study. Braz. J. Infect. Dis.24, 96–103. doi: 10.1016/j.bjid.2020.04.004
599
UllahR.AmirM.AnjumS.Ur RehmanM.Noorul HasanT.Sajjad NaqviS.et al. (2023). Presence of T3SS (exoS, exoT, exoU and exoY), susceptibility pattern and MIC of MDR-Pseudomonas aeruginosa from burn wounds. J. Infect. Dev. Ctries.17, 1130–1137. doi: 10.3855/jidc.17580
600
UllahN.GulerE.GuvenirM.ArikanA.SuerK. (2019). Isolation, identification, and antibiotic susceptibility patterns of Pseudomonas aeruginosa strains from various clinical samples in a University Hospital in Northern Cyprus. Cyprus J. Med. Sci.4, 225–228. doi: 10.5152/cjms.2019.931
601
Uskudar GucluA.Altay KocakA.Akcil OkM.TutluogluB.BasustaogluA. C.Respiratory Study G (2021). Antibacterial resistance in lower respiratory tract bacterial pathogens: a multicenter analysis from Turkey. J. Infect. Dev. Ctries.15, 254–262. doi: 10.3855/jidc.12599
602
UzunB.GüngörS.SezakN.Afşarİ.Şerifhan İlgünM.DemirciM. (2014). Changes in resistance percentage to antibiotics in Pseudomonas aeruginosa and Acinetobacter baumannii strains isolated from blood cultures of intensive care unit patients. Turk Hij Den Biyol Derg.71, 1–8. doi: 10.5505/TurkHijyen.2014.68916
603
ValenzaG.RadikeK.SchoenC.HornS.OesterleinA.FroschM.et al. (2010). Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment. Scand. J. Infect. Dis.42, 885–889. doi: 10.3109/00365548.2010.509333
604
ValenzaG.TappeD.TurnwaldD.FroschM.KönigC.HebestreitH.et al. (2008). Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J. Cyst. Fibros.7, 123–127. doi: 10.1016/j.jcf.2007.06.006
605
ValenzaG.TuschakC.NickelS.KrupaE.Lehner-ReindlV.HöllerC. (2015). Prevalence, antimicrobial susceptibility, and genetic diversity of Pseudomonas aeruginosa as intestinal colonizer in the community. Infect Dis.47, 654–657. doi: 10.3109/23744235.2015.1031171
606
VamsiK. S.RamavathU. R.ReddyB.GandhariM.ReddyY. (2023). Efficacy of Colistin with Carbapenems combination by checkerboard assay against Carbapenem resistant non lactose fermenting gram negative Bacteria. Journal of Pure & Applied. Microbiology17, 2104–2110. doi: 10.22207/JPAM.17.4.06
607
Van AnN.HoangL. H.LeH. H. L.Thai SonN.HongL. T.VietT. T.et al. (2023). Distribution and antibiotic resistance characteristics of bacteria isolated from blood culture in a teaching hospital in Vietnam during 2014–2021. Infect. Drug Resist.16, 1677–1692. doi: 10.2147/IDR.S402278
608
van BurghS.MaghdidD. M.GanjoA. R.MansoorI. Y.KokD. J.FatahM. H.et al. (2019). PME and other ESBL-positive multiresistant Pseudomonas aeruginosa isolated from hospitalized patients in the region of Kurdistan, Iraq. Microbial Drug Resist.25, 32–38. doi: 10.1089/mdr.2018.0036
609
van der HeijdenI. M.LevinA. S.De PedriE. H.FungL.RossiF.DubocG.et al. (2007). Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins. Ann. Clin. Microbiol. Antimicrob.6, 1–7. doi: 10.1186/1476-0711-6-8
610
VasudevaN.NirwanP. S.ShrivastavaP. (2016). Bloodstream infections and antimicrobial sensitivity patterns in a tertiary care hospital of India. Therap. Adv. Infect. Dis.3, 119–127. doi: 10.1177/2049936116666983
611
VataA.PrunaR.RosuF.MiftodeE.NastaseE.Gina VataL.et al. (2018). Pseudomonas Aeruginosa infections in the “Sfânta Parascheva” infectious diseases hospital of Iasi city. Romanian J. Infect. Dis.21, 115–120. doi: 10.37897/RJID.2018.3.4
612
VeeraraghavanB.JesudasonM. R.PrakasahJ. A. J.AnandanS.SahniR. D.PragasamA. K.et al. (2018). Antimicrobial susceptibility profiles of gram-negative bacteria causing infections collected across India during 2014-2016: study for monitoring antimicrobial resistance trend report. Indian J. Med. Microbiol.36, 32–36. doi: 10.4103/ijmm.IJMM_17_415
613
ViasusD.Puerta-AlcaldeP.CardozoC.Suarez-LledoM.Rodriguez-NunezO.MorataL.et al. (2020). Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection. Clin. Microbiol. Infect.26, 345–350. doi: 10.1016/j.cmi.2019.07.002
614
ViedmaE.JuanC.VillaJ.BarradoL.OrellanaM. Á.SanzF.et al. (2012). VIM-2–producing multidrug-resistant Pseudomonas aeruginosa ST175 clone, Spain. Emerg. Infect. Dis.18, 1235–1241. doi: 10.3201/eid1808.111234
615
VosahlikovaS.DrevinekP.CinekO.PohunekP.MaixnerovaM.UrbaskovaP.et al. (2007). High genotypic diversity of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis in the Czech Republic. Res. Microbiol.158, 324–329. doi: 10.1016/j.resmic.2007.02.003
616
WadhwaR.SharmaY.UpadhyayR. P.BalaK. (2016). Nosocomial infection by non-fermenting gram negative bacilli in tertiary care hospital: screening and cure. Int J Pharm Pharm Sci8, 274–277.
617
WaitesK. B.BadeD. J.BébéarC.BrownS. D.DavidsonM. K.DuffyL. B.et al. (2011). Methods for antimicrobial susceptibility testing for human mycoplasmas; approved guideline. Europe PMC.
618
WalktyA.BaxterM.AdamH.KarlowskyJ. A.Lagacé-WiensP.HobanD. J.et al. (2012). Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals: CANWARD 2008–2011. Diagn. Microbiol. Infect. Dis.73, 361–364. doi: 10.1016/j.diagmicrobio.2012.05.007
619
WalktyA.DeCorbyM.Lagacé-WiensP.KarlowskyJ.HobanD.ZhanelG. (2011). In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob. Agents Chemother.55, 2992–2994. doi: 10.1128/AAC.01696-10
620
WalktyA.DeCorbyM.NicholK.KarlowskyJ.HobanD.ZhanelG. (2009). In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008. Antimicrob. Agents Chemother.53, 4924–4926. doi: 10.1128/AAC.00786-09
621
WalktyA.KarlowskyJ. A.AdamH.BaxterM.Lagacé-WiensP.HobanD. J.et al. (2013). In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012. Antimicrob. Agents Chemother.57, 5707–5709. doi: 10.1128/AAC.01404-13
622
WalktyA.KarlowskyJ. A.Lagace-WiensP.BaxterM. R.AdamH. J.ZhanelG. G. (2022). Antimicrobial resistance patterns of bacterial pathogens recovered from the urine of patients at Canadian hospitals from 2009 to 2020. JAC-Antimicrob. Resist.4:dlac122. doi: 10.1093/jacamr/dlac122
623
WalktyA.Lagace-WiensP.AdamH.BaxterM.KarlowskyJ.MulveyM. R.et al. (2017). Antimicrobial susceptibility of 2906 Pseudomonasaeruginosa clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: results of the Canadian Ward surveillance study (CANWARD), 2008-2015. Diagn. Microbiol. Infect. Dis.87, 60–63. doi: 10.1016/j.diagmicrobio.2016.10.003
624
WaltersM. S.GrassJ. E.BulensS. N.HancockE. B.PhippsE. C.MuletaD.et al. (2019). Carbapenem-resistant Pseudomonas aeruginosa at US emerging infections program sites, 2015. Emerg. Infect. Dis.25, 1281–1288. doi: 10.3201/eid2507.181200
625
WangY.KongJ.ZhangX.LiuY.HuangZ.YuanL.et al. (2022). Plumbagin resurrect colistin susceptible against colistin-resistant Pseudomonas aeruginosa in vitro and in vivo. Front. Microbiol.13:1020652. doi: 10.3389/fmicb.2022.1020652
626
WangW.WangX. (2020). Prevalence of metallo-β-lactamase genes among Pseudomonas aeruginosa isolated from various clinical samples in China. J. Lab. Med.44, 197–203. doi: 10.1515/labmed-2019-0162
627
WangQ.WangZ.ZhangF.ZhaoC.YangB.SunZ.et al. (2020). Long-term continuous antimicrobial resistance surveillance among nosocomial gram-negative Bacilli in China from 2010 to 2018 (CMSS). Infect Drug Resist.13, 2617–2629. doi: 10.2147/IDR.S253104
628
WattalC.GoelN.OberoiJ. K.DattaS.RaveendranR. (2019). Performance of three commercial assays for colistin susceptibility in clinical isolates and mcr-1 carrying reference strain. Indian J. Med. Microbiol.37, 488–495. doi: 10.4103/ijmm.IJMM_20_92
629
WattalC.RaveendranR.GoelN.OberoiJ. K.RaoB. K. (2014). Ecology of blood stream infection and antibiotic resistance in intensive care unit at a tertiary care hospital in North India. Braz. J. Infect. Dis.18, 245–251. doi: 10.1016/j.bjid.2013.07.010
630
WemambuS.JoshiK. (1983). Prevalence and antimicrobial sensitivity of Localpseudomonas aeruginosa at a teaching hospital. Public Health97, 89–94. doi: 10.1016/S0033-3506(83)80004-3
631
WendelA. F.MaleckiM.MattnerF.XanthopoulouK.WilleJ.SeifertH.et al. (2022). Genomic-based transmission analysis of carbapenem-resistant Pseudomonas aeruginosa at a tertiary care Centre in Cologne (Germany) from 2015 to 2020. JAC-Antimicrob. Resist.4:dlac057. doi: 10.1093/jacamr/dlac057
632
WiY. M.ChoiJ.-Y.LeeJ.-Y.KangC.-I.ChungD. R.PeckK. R.et al. (2017). Emergence of colistin resistance in Pseudomonas aeruginosa ST235 clone in South Korea. Int. J. Antimicrob. Agents49, 767–769. doi: 10.1016/j.ijantimicag.2017.01.023
633
WiY. M.Greenwood-QuaintanceK. E.SchuetzA. N.KoK. S.PeckK. R.SongJ.-H.et al. (2018). Activity of ceftolozane-tazobactam against carbapenem-resistant, non-carbapenemase-producing Pseudomonas aeruginosa and associated resistance mechanisms. Antimicrob. Agents Chemother.62, 01970–01917. doi: 10.1128/AAC.01970-17
634
WillmannM.BezdanD.ZapataL.SusakH.VogelW.SchröppelK.et al. (2015). Analysis of a long-term outbreak of XDR Pseudomonas aeruginosa: a molecular epidemiological study. J. Antimicrob. Chemother.70, 1322–1330. doi: 10.1093/jac/dku546
635
WillmannM.KuebartI.MarschalM.SchröppelK.VogelW.FleschI.et al. (2013). Effect of metallo-β-lactamase production and multidrug resistance on clinical outcomes in patients with Pseudomonas aeruginosa bloodstream infection: a retrospective cohort study. BMC Infect. Dis.13, 1–9. doi: 10.1186/1471-2334-13-515
636
WiseM. G.KarlowskyJ. A.HackelM. A.HartiM. A.NtsholeB. M.NjaguaE. N.et al. (2023a). In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from sub-Saharan Africa: ATLAS global surveillance program 2017–2021. J. Global Antimicrobial Resist.35, 93–100. doi: 10.1016/j.jgar.2023.08.022
637
WiseM. G.KarlowskyJ. A.Lemos-LuengasE. V.ValdezR. R.SahmD. F. (2023b). Epidemiology and in vitro activity of ceftazidime-avibactam and comparator agents against multidrug-resistant isolates of Enterobacterales and Pseudomonas aeruginosa collected in Latin America as part of the ATLAS surveillance program in 2015–2020. Braz. J. Infect. Dis.27:102759. doi: 10.1016/j.bjid.2023.102759
638
WuS.YinD.ZhiP.GuoY.YangY.ZhuD.et al. (2022). In vitro activity of MRX-8 and comparators against clinical isolated gram-negative bacilli in China. Front. Cell. Infect. Microbiol.12:829592. doi: 10.3389/fcimb.2022.829592
639
XiJ.JiaP.ZhuY.YuW.ZhangJ.GaoH.et al. (2022). Antimicrobial susceptibility to polymyxin B and other comparators against gram-negative bacteria isolated from bloodstream infections in China: results from CARVIS-NET program. Front. Microbiol.13:1017488. doi: 10.3389/fmicb.2022.1017488
640
YadavS. K.BhujelR.MishraS. K.SharmaS.SherchandJ. B. (2020). Emergence of multidrug-resistant non-fermentative gram negative bacterial infection in hospitalized patients in a tertiary care center of Nepal. BMC. Res. Notes13:319. doi: 10.1186/s13104-020-05163-6
641
YassinM. T.MostafaA. A.-F.Al-AskarA. A.Al-OtibiF. O. (2022). Synergistic antibacterial activity of green synthesized silver nanomaterials with colistin antibiotic against multidrug-resistant bacterial pathogens. Crystals12:1057. doi: 10.3390/cryst12081057
642
YayanJ.GhebremedhinB.RascheK. (2015). Antibiotic resistance of Pseudomonas aeruginosa in pneumonia at a single University Hospital Center in Germany over a 10-year period. PLoS One10:e0139836. doi: 10.1371/journal.pone.0139836
643
YilmazF. N.ÖksüzL.DemirE. S.DöşlerS.SavageP. B.GüzelÇ. B. (2023). Efficacy of Ceragenins alone and in combinations with antibiotics against multidrug-resistant gram negative pathogens from bloodstream infections. Curr. Microbiol.80:327. doi: 10.1007/s00284-023-03443-5
644
YilmazG.SalyanS.AksoyF.KoksalI. (2017). Individualized antibiotic therapy in patients with ventilator-associated pneumonia. J. Med. Microbiol.66, 78–82. doi: 10.1099/jmm.0.000401
645
YousefiS.NahaeiM. R.FarajniaS.AghazadehM.IversenA.EdquistP.et al. (2013). A multiresistant clone of Pseudomonas aeruginosa sequence type 773 spreading in a burn unit in Orumieh. Iran. Apmis.121, 146–152. doi: 10.1111/j.1600-0463.2012.02948.x
646
ZeroualiK.Ramdani-BouguessaN.BoyeC.HammamiA.ActiveG. (2016). Multicentric study in five African countries of antibiotic susceptibility for three main pathogens: Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa. J. Chemother.28, 266–272. doi: 10.1179/1973947814Y.0000000220
647
ZhanelG. G.AdamH. J.BaxterM. R.FullerJ.NicholK. A.DenisuikA. J.et al. (2019). 42936 pathogens from Canadian hospitals: 10 years of results (2007-16) from the CANWARD surveillance study. J. Antimicrob. Chemother.74, iv5–iv21. doi: 10.1093/jac/dkz283
648
ZhanelG. G.AdamH. J.BaxterM. R.FullerJ.NicholK. A.DenisuikA. J.et al. (2013). Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007–11 study. J. Antimicrob. Chemother.68, i7–i22. doi: 10.1093/jac/dkt022
649
ZhanelG. G.AdamH. J.LowD. E.BlondeauJ.DeCorbyM.KarlowskyJ. A.et al. (2011). Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007–2009 study. Diagn. Microbiol. Infect. Dis.69, 291–306. doi: 10.1016/j.diagmicrobio.2010.10.025
650
ZhanelG. G.DeCorbyM.AdamH.MulveyM. R.McCrackenM.Lagacé-WiensP.et al. (2010). Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward surveillance study (CANWARD 2008). Antimicrob. Agents Chemother.54, 4684–4693. doi: 10.1128/AAC.00469-10
651
ZhangY.LinY.ZhangX.ChenL.XuC.LiuS.et al. (2021). Combining Colistin with Furanone C-30 rescues Colistin resistance of gram-negative Bacteria in vitro and in vivo. Microbiol. Spectr.9:e0123121. doi: 10.1128/Spectrum.01231-21
652
ZhaoY.ChenD.ChenK.XieM.GuoJ.ChanE. W. C.et al. (2023). Epidemiological and genetic characteristics of clinical carbapenem-resistant Pseudomonas aeruginosa strains in Guangdong Province, China. Microbiol. Spectrum11, e04261–e04222. doi: 10.1128/spectrum.04261-22
653
ZhuY.ChenJ.ShenH.ChenZ.YangQ.-w.ZhuJ.et al. (2021). Emergence of ceftazidime-and avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Pseudomonas aeruginosa in China. Msystems6, e00787–e00721. doi: 10.1128/mSystems.00787-21
654
ZhuY.KangY.ZhangH.YuW.ZhangG.ZhangJ.et al. (2023). Emergence of ST463 exoU-positive, imipenem-nonsusceptible Pseudomonas aeruginosa isolates in China. Microbiol. Spectrum.11, e00105–e00123. doi: 10.1128/spectrum.00105-23
655
ZorganiA.AbofayedA.GliaA.AlbarbarA.HanishS. (2015). Prevalence of device-associated nosocomial infections caused by gram-negative bacteria in a trauma intensive care unit in Libya. Oman Med. J.30, 270–275. doi: 10.5001/omj.2015.54
656
ZubairK.IregbuK. (2018). Resistance pattern and detection of metallo-beta-lactamase genes in clinical isolates of Pseudomonas aeruginosa in a Central Nigeria tertiary hospital. Niger. J. Clin. Pract.21, 176–182. doi: 10.4103/njcp.njcp_229_17
Summary
Keywords
Pseudomonas aeruginosa, cystic fibrosis, infection prevention, treatment regimens, public health
Citation
Narimisa N, Keshtkar A, Dadgar-Zankbar L, Bostanghadiri N, Far YR, Shahroodian S, Zahedi Bialvaei A and Razavi S (2024) Prevalence of colistin resistance in clinical isolates of Pseudomonas aeruginosa: a systematic review and meta-analysis. Front. Microbiol. 15:1477836. doi: 10.3389/fmicb.2024.1477836
Received
08 August 2024
Accepted
18 September 2024
Published
09 October 2024
Volume
15 - 2024
Edited by
Asad U. Khan, Aligarh Muslim University, India
Reviewed by
Salome N. Seiffert, Zentrum für Labormedizin (ZLM), Switzerland
Ahmed S. Khairalla, University of Regina, Canada
Updates
Copyright
© 2024 Narimisa, Keshtkar, Dadgar-Zankbar, Bostanghadiri, Far, Shahroodian, Zahedi Bialvaei and Razavi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Shabnam Razavi, razavi.sh@iums.ac.ir; Abed Zahedi Bialvaei, zahedi.ab@iums.ac.ir
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.